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  1. Introduction on MS and the perspective of cell therapy 
1.1 MS pathology and clinical features  
Multiple sclerosis (MS) is a neurodegenerative disease characterized by 
relapsing remitting clinical episodes that induce demyelination and loss of 
oligodendrocytes leading to severe motor- and sensory disability. Whereas the 
precise cause of MS is unknown, possible contributing factors are 
environmental factors (Pugliatti et al., 2006), viral infections (Bagert, 2009) and 
genetic predisposition (Holmoy et al., 2010). MS often starts as a relapsing-
remitting disease that develops into an increasing (secondary) progressive 
type. Sometimes the disease starts from the onset as a (primary) progressive 
type (Lublin and Reingold, 1996). The relapses reflect the progression of 
demyelinating lesions within the central nervous system (CNS). Such lesions 
feature inflammation and myelin destruction. MS lesions are classified as 
reactive, active demyelinating, chronic active demyelinating and chronic 
inactive lesions (Van der Valk and De Groot, 2000; Van der Valk and Amor, 
2009). Whereas reactive lesions contain primarily activated microglia but show 
no demyelination yet, active demyelinating lesions contain CD4
+ and CD8
+ T 
cells, peripheral macrophages and activated microglia and B cells (Hauser et 
al., 1986). Chronic inactive lesions hardly contain infiltrating cells and are 
occupied by gliotic scar tissue. 
Axonal demyelination and oligodendrocyte loss are major pathological 
hallmarks of multiple sclerosis. The demyelinated axons degenerate and 
display impaired action potential propagation, which is a major factor 
contributing to loss of function following demyelination (Dutta and Trapp, 2007). 
Although any CNS region can be affected, lesions mostly occur in spinal cord, 
brain stem, optic nerve and ventricle surrounding tissues. Based on location, 
size and number of the lesions the clinical features include motor weakness, 
paralysis, bladder and bowel dysfunctions, impaired vision and sensory 
disorders (Keegan and Noseworthy, 2002) 
Recovery of this loss of function is to a large extent dependent on 
remyelination of spared or regenerating axons. The mammalian CNS maintains 
an endogenous reservoir of oligodendrocyte precursor cells (OPCs), capable of 
generating new oligodendrocytes. However, this endogenous response is 
insufficient to remyelinate surviving axons. The restricted remyelination in MS 
has been associated with the limited myelinating capacity of endogenous 
oligodendrocyte precursor cells (OPCs) (Chari, 2007; Franklin and Ffrench-
Constant, 2008). As with other regenerative processes, remyelination becomes 
even less efficient with age (Shields et al., 2000). This decline has been 
attributed to impaired OPC recruitment (Sim et al., 2002) and inefficient 
differentiation of OPC in old animals (Woodruff et al., 2004). To promote Chapter 1 
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remyelination in the central nervous system either by endogenous or implanted 
remyelinating cells, it is essential to understand the molecular mechanisms 
underlying oligodendrocyte development and differentiation and to define the 
impact of aging on these processes. It is anticipated that insights in the 
epigenetic regulation of myelin formation and repair will provide novel targets 
for therapeutic intervention. 
 
1.2 Cell based remyelination therapy 
No causal treatment for multiple sclerosis is yet available. Anti-inflammatory 
therapy is currently applied to suppress and slow down the disease process but 
therapy promoting myelin repair is not available. Thus drugs that suppress the 
immune system provide the primary therapy for multiple sclerosis. Whereas 
corticosteroids, such as prednisone or methylprednisolone, were initially widely 
used, their application causes numerous side effects. Currently corticosteroids 
are primarily used to treat severe multiple sclerosis attacks. Other drugs that 
refrain the immune system from attacking myelin include: Interferon-β, 
Glatiramer, Mitoxantrone and Natalizumab.  
Stem cell-derived oligodendrocyte precursor cells (OPCs) may provide a 
suitable route for remyelination therapy. Indeed in animal demyelination models 
progenitor-based interventions have been rather successful (Martino et al., 
2010; Uccelli and Mancardi, 2010). For similar remyelination therapy in 
humans, large amounts of safe autologous cells are required. Autologous 
OPCs can be derived from endoscopically harvested neural stem cells (NSCs) 
from the brain ventrical wall or skin-derived neural crest cells. However, the 
quantity of autologous cells that can be obtained from these sources is too 
limited for cell transplantation-based remyelination therapy. Since 2006, a 
promising novel, ample source for autologous NSCs has come into view, i.e the 
induced pluripotent stem cells or IPS cells. (Takahashi and Yamanaka, 2006). 
Easily accessible somatic cells, like skin fibroblasts or blood lymphocytes can 
be reprogrammed into pluripotent stem cells by transfecting them with genes 
encoding for essential pluripotency-determining factors, Oct4, Sox2, Klf4 and c-
Myc. A number of developments in the past 3 years has drastically improved 
the IPS cell technology and brought it closer to safe clinical application. 
It should be noted that currently three clinical trials with autologous 
mesenchymal stem cells are running, but these studies focus on anti-
inflammatory effects and cell support rather than on active remyelination. 
Mesenchymal stem cell therapy has been put forward for treatment of MS after 
studies in the experimental MS animal model, EAE, suggested that 
mesenchymal stem cells may attenuate the autoimmune response against General introduction 
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  myelin and improve the survival of injured cells. Early indications that they 
could give rise to oligodendrocytes could not be confirmed in later experiments.  
 Obviously, grafting strategies in MS still have to deal with the problem of the 
dissemination of the lesions. MRI-guided strategic targeting to the vicinity of 
prominent/disabling lesions and stimulation of the migratory response towards 
lesion-derived factors of the implanted OPCs may be the way to tackle this 
obstacle. Presently, a number of noninvasive imaging techniques are available 
for small experimental animal research, such as bioluminescence imaging 
(BLI), MRI and positron emission tomography (PET), to follow the fate of 
grafted cells for an extended period (Walczak and Bulte, 2007). The outcome 
of such long-term evaluations in experimental animals should be crucial before 
deciding to proceed with planning clinical application of a stem cell-based 
therapy for MS. 
In any case, neural stem cells (NSCs) are the obvious, natural source for 
generating oligodendrocyte precursor cells and, to be able to induce controlled 
oligodendrocyte differentiation of NSCs, insight in their generation during 
normal embryonic development is essential. 
 
2. Oligodendrogenesis 
2.1 Oligodendrocyte formation during embryogenesis 
The multiple restricted origin of oligodendrogenesis during the development of 
the central nervous system (CNS) was established in 1998 (Spassky et al., 
1998). As far as the spinal cord is concerned, the first OPCs appear around 
embryonic day 12.5, originating in the ventral domain, the so-called pMN region 
in mouse. From this region they migrate into the lateral and dorsal part of the 
developing spinal cord where they mature into myelinating oligodendrocytes. In 
addition to the ventrally arising OPCs, a subset of OPCs evolves later in 
embryonic development (around E16) from radial glia located in the dorsal 
spinal cord (Battiste et al., 2007; Cai et al., 2005; Vallstedt et al., 2005). In the 
developing telencephalon, the origin of the earliest appearing OPCs (around 
E14) is located in the ventral region (the medial ganglionic eminence) from 
where they migrate laterally and dorsally and populate the entire embryonic 
telencephalon, including the developing cerebral cortex (Kessaris et al., 2006; 
Kessaris et al., 2008); the ventral region of the diencephalon generates OPCs 
for the developing thalamus, hypothalamus and cerebellum. In a number of 
elegant Cre-lox fate mapping studies on transgenic mice, it has been shown 
that this first wave of OPC formation in the forebrain is followed by a second 
wave of OPCs from the lateral and/or caudal ganglionic eminences. Finally, a 
third wave of OPCs arises from postnatal cortical progenitors. Interestingly, it 
seems that the redundant OPC populations compete for space in the CNS Chapter 1 
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(Kessaris et al., 2006) in the spinal cord, the ventrally derived OPCs finally 
suppress their dorsal counterparts, whereas in the forebrain the dorsal OPCs 
prevail over the ventral lineage that is eliminated in the postnatal stage 
(Kessaris et al., 2006; Kessaris et al., 2008)  
 
2.2 Oligodendrocyte formation in the adult brain 
In the adult brain, oligodendrocyte turnover, replacement and (re) myelination 
is a continuous process for which the brain possesses a more or less 
homogenously distributed reserve of OPCs with the capacity to proliferate and 
maturate when triggered to do so, particularly under demyelinating conditions. 
In the mature brain, multipotent NSCs that by definition also have the potency 
to produce new OPCs are located in two adult neurogenic regions, that is, the 
dentate gyrus of the hippocampus and the subventricular zone (SVZ). The 
oligodendrogenic capacity of these adult NSCs has been clearly established in 
vitro. However, in vivo adult NSCs in the hippocampus mainly produce neurons 
for the granular zone, whereas those in the adult SVZ, that is, the glial fibrillary 
acidic protein (GFAP)-positive type B cells, mainly produce large numbers of 
neuroblasts that migrate along the rostral migratory stream (RMS) to be 
incorporated as periglomerular or granular interneurons in the olfactory bulb 
circuitry. A study (Menn et al., 2006), however, has documented in detail the 
generation of OPCs in the adult SVZ. At different rostrocaudal levels of the 
adult SVZ, the type B cells do produce OPCs, albeit at very low numbers (less 
than 5% of the total number of cells generated), which migrate into the corpus 
callosum, striatum and fimbria fornix where they maturate into myelinating 
oligodendrocytes (Menn et al., 2006). Importantly, the number of OPCs derived 
from the SVZ NSCs increases after a demyelinating lesion in the corpus 
callosum (Menn et al., 2006; Nait-Oumesmar et al., 2007b; Nait-Oumesmar et 
al., 2007a)  
 
2.3 Extrinsic factors in oligodendrocyte formation 
The generation of OPCs by embryonic, neonatal or adult NSCs (also 
denominated respectively as neuroepithelial, neural progenitor or type B cells) 
is the result of a complicated interaction of local extrinsic induction factors and 
the intrinsic transcription machinery of the NSC. The major inductive 
morphogenetic signal for the appearance of OPCs in the ventral region of the 
spinal cord and the telencephalon is Sonic Hedgehog (Shh) (Nicolay et al., 
2007). In the spinal cord, Shh is secreted from the notochord and floor-plate at 
the ventral mid-line; in the telencephalon, it is secreted by neuroepithelial cells 
in the preoptic area. Experiments with cyclopamine, a hedgehog blocker, and General introduction 
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  analysis of oligodendrogenesis in Shh-/- mice, have shown that OPCs are also 
generated in the spinal cord and forebrain along an Shh-independent route that 
is triggered by basic fibroblast growth factor 2 (FGF2) (Cai et al., 2005; 
Kessaris et al., 2004; Kessaris et al., 2006) The dorsally derived OPCs in the 
spinal cord and the postnatal wave of OPCs derived from cortical progenitors 
are examples of such a Shh independent, FGF2-dependent pathway. In 
addition to FGF2, bone morphogenetic protein (BMP) may be involved. BMP 
antagonizes Shh-induced oligodendrocyte specification and inhibition of BMP 
signalling is sufficient to induce OPC formation both in vivo and in vitro (Mekki-
Dauriac et al., 2002; Vallstedt et al., 2005). Dorsal oligodendrogenesis may be 
enabled when BMP levels gradually reduce. The local induction factors that 
cause OPC formation in adult NSCs in the hippocampus or SVZ are still largely 
unknown. It is as yet unclear whether the adult oligodendrogenic route is Shh-
independent, FGF2-dependent, BMP-regulated or triggered otherwise. Indeed, 
intraperitoneal injection of FGF2 but also platelet-derived growth factor AB 
(PDGFAB) has been shown to vigorously promote the differentiation of the 
adult SVZ NSCs into OPCs (Lachapelle et al., 2002). Hsieh et al. (Hsieh et al., 
2004a)have shown in vitro as well as in vivo that insulin-like growth factor 1 
(IGF1) can instruct the adult neural progenitor cells in the hippocampus to 
become oligodendrocytes by upregulating Noggin, Smad6 and Smad7 and 
antagonists of BMP. IGF1 is produced by local astrocytes and microglia, 
particularly in response to inflammatory, demyelinating conditions (Mason et 
al., 2001). 
 
2.4 Intrinsic factors in oligodendrocyte formation  
Binding of Shh to its receptors on embryonic NSCs initiates intracellular 
signalling cascades that eventually activate or repress transcription factors as 
the ultimate downstream effectors of oligodendrocyte differentiation (Wegner, 
2008) The first transcription factors that occur in differentiating OPCs in spinal 
cord and forebrain (therefore used as markers for early OPCs) are Olig1 and 
Olig2, members of the basic helix–loop–helix (bHLH) factor family (Nicolay et 
al., 2007). In the ventral pMN domain of the early developing spinal cord, Olig2 
cooperates with Ngn2 and is associated with the formation of a motoneuron–
oligodendrocyte lineage; subsequent downregulation of Ngn2 and co-
expression of Olig2 and Nkx2.2 leads to the generation of OPCs. In contrast to 
Olig2, Olig1 in the spinal cord merely seems to be involved in survival and 
maturation of OPCs, whereas it is crucial for the induction of cortical OPCs. 
Analysis of Olig1/2 null embryos, revealing a complete absence of all types of 
OPCs in the CNS, has clearly corroborated the essential role of these 
transcription factors in OPC differentiation. Furthermore, at later stages, Olig1 Chapter 1 
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seems to be involved specifically in the expression of myelin specific genes 
and thus in myelinogenesis and is also essential for repair of demyelinated 
lesions (Xin et al., 2005). As far as adult oligodendrogenesis is concerned, 
Olig2 has also been demonstrated in the OPCs that arise from the SVZ NSCs 
(Hack et al., 2005; Menn et al., 2006). Overexpression of both Olig1 and Olig2 
in combination with blocking BMP has been shown to enhance oligodendrocyte 
differentiation of adult NSCs (Cheng et al., 2007). In addition to Olig1 and 2, 
another bHLH factor, Mash1, induced by Shh, has been implicated in 
oligodendrocyte differentiation and appears crucial for the generation of a 
subset of OPCs arising in the ventral forebrain between E11.5 and E13.5 
(Parras et al., 2007). Interestingly, another group of bHLH factors, Id2 and Id4, 
has been found to inhibit OPC differentiation (Gokhan et al., 2005; Marin-
Husstege et al., 2006). A second group of transcription factors crucially 
involved in OPC differentiation includes members of the Sox family, 
characterized by their so-called high-mobilitygroup (HMG) domain. In 
particular, Sox8, Sox9 and Sox10 are expressed in OPCs directly after the 
induction of oligodendrocyte lineage and, therefore, are also frequently used as 
marker proteins for early OPCs (Wegner and Stolt, 2005). Sox10 is co-
expressed with Sox8 and studies on Sox10 knock-out mice have shown that 
OPCs are still produced but fail to maturate; Sox8 null mutants do not show a 
clear phenotype, suggesting a functional redundancy between Sox10 and 
maybe Sox9 (Wegner and Stolt, 2005).  Sox9 is expressed in OPCs slightly 
prior to Sox8 and Sox10, but in contrast to Sox8 and Sox10 disappears when 
they start to terminally differentiate. Studies with specific conditional ablation of 
Sox9 (Wegner and Stolt, 2005) indicated that Sox9 in combination with Olig2 is 
essential for oligodendrocyte specification, with Sox9 conferring glial identity 
and Olig2 OPC identity. Sox5 and Sox6 seem to be merely involved in the 
progression of OPC differentiation towards the more mature stages (Stolt et al., 
2006). Three members of the homeodomain transcription factor family, Nkx2.2, 
Nkx6.1 and Nkx6.2, are expressed in differentiated OPCs (Nicolay et al., 2007). 
Nkx2.2 is not essential for OPC formation, but is required for the progression of 
oligodendrocyte differentiation and maturation. Nkx6.1 and Nkx6.2 induce the 
expression of Olig2, which indeed is strongly reduced in the spinal cord of 
Nkx6.1 knockout mice (Vallstedt et al., 2005). In the ventral region of the spinal 
cord of Nkx6.1/Nkx6.2 double mutants, therefore, no OPCs (and motoneurons) 
can be formed (Vallstedt et al., 2005; Cai et al., 2005a). However, in the dorsal 
region, Olig2-positive OPCs can still be detected suggesting another 
differentiation pathway of this subset of OPCs, possibly via FGF2. Finally, two 
members of the Zinc-finger superfamily of transcription factors, Myt1 and General introduction 
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  YinYang1 (YY1), seem to play a role in the transition of OPC from cell cycle 
exit to differentiation (He et al., 2007; Nielsen et al., 2004). 
 
2.5. Oligodendrocyte precursor cell survival and multiplication 
Upon OPC formation, it is essential that their niche provides signals for survival 
and proliferation. In addition to FGF2, one of the earliest and best described 
mitogens and survival factors for OPCs is PDGF-AA (Nicolay et al., 2007). The 
PDGF-a receptor is one of the first to be induced upon Olig2 expression and so 
this receptor is used as a marker for early OPCs. PDGF-AA is ubiquitously 
present in the developing CNS and is produced by developing astrocytes and 
neurons (Nicolay et al., 2007). In PDGF-AA null mutants, the number of OPCs 
is dramatically reduced in developing spinal cord, whereas overexpression of 
PDGF-AA results in a dramatic increase. Recently, (Hu et al., 2008) found that 
PDGF-AA, in addition to its proliferation-promoting effect on OPCs, could 
mediate oligodendrocyte lineage differentiation in embryonic NSCs; the effect 
of PDGFAA on OPCs is modulated by other factors such as the chemokine 
CXCL1 and in particular FGF2. Of the family of neurotrophins, brain-derived 
neurotrophic factor (BDNF), but particularly neurotrophin-3 (NT-3), has been 
shown to stimulate OPC proliferation and survival via its receptor trkC 
(Rosenberg et al., 2006). As OPCs arise in highly restricted domains, while 
they are widely distributed in the mature CNS, they must have a considerable 
migratory capacity to reach their final destination where they start myelination. 
The nature of the cellular substrates and the migratory guidance mechanisms 
for OPCs are not fully understood. Cell surface components such as adhesion 
molecules, extracellular matrix (ECM) receptors and chemokine receptors have 
been implicated in regulating OPC migration. Upon arrival at their final 
destination, the induction of maturation and myelinating activity of the OPCs is 
regulated by the environment of the axon, by axon-derived signals [e.g. 
neuregulin 1 (Nrg1), ciliary neurotrophic factor (CNTF)], by axonal activity and 
hormonal influences (e.g. thyroid hormone, estrogens). 
 
2.6. Differentiation of neural stem cells into oligodendrocyte precursor 
cells in vitro: recapitulating the in-vivo process 
Knowing the extrinsic and intrinsic factors that play a crucial role during in-vivo 
oligodendrogenesis, one can use these factors to induce and control the 
predifferentiation as well as the multiplication of NSCs in vitro to get sufficient 
amounts of OPCs for implantation purposes. Various studies (Glaser et al., 
2005; Izrael et al., 2007; Kang et al., 2007) have used differentiation media 
containing (a combination of) induction and growth factors such as Shh, PDGF, 
FGF2, IGF1, and NT-3 or BMP antagonists like noggin. Obviously, the Chapter 1 
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response of NSCs to these factors depends on the presence and expression 
level of the proper receptors. An alternative approach, circumventing receptor-
mediated external triggering, is the forced expression of key oligodendrogenic 
transcription factors via gene transfection. Obvious candidates are the Olig 
transcription factors. Transfection of Olig1 in mouse embryonic NSCs indeed 
can induce the differentiation of OPCs; however, these OPCs appear unable to 
recruit downstream transcription factors such as homeobox protein Nkx-2.2 
(Balasubramaniyan et al., 2004). Olig2 transfection appears to be more 
efficient, as it was shown that Olig2 transfection into mouse embryonic NSCs in 
vitro can promote the formation of OPCs, including their expression of Nkx2.2 
and a full maturation (Copray et al., 2006). Similarly, forced Olig2 expression in 
adult mouse SVZ NSCs could induce OPC generation (Hack et al., 2005). 
Transfection of mouse embryonic stem cell-derived NSCs with Olig2 indeed 
generated significantly more oligodendrocytes than astrocytes or neurons, but 
not exclusively (Du et al., 2006). So, OPC differentiation induction of NSC 
requires an integrated interaction between the transcription factors Olig2, 
Sox9/10 (Liu et al., 2007b), Nkx6.1/6.2, Mash1 and YY1. Present strategies to 
induce optimal differentiation of NSCs into OPCs in vitro include multiple gene 
transfection with these oligodendrogenic genes. Apparently, predifferentiation 
of NSCs in vitro into OPCs for implantation purposes should not proceed 
beyond the OPC stage: at that stage, these cells still have migratory capacity, 
which serves to bring them to the site for remyelination after implantation. For 
their survival, further maturation and proper (re)myelinating functioning, they 
depend on the permissive/instructive conditions at the local environment of the 
lesion site. 
 
3. OPCs at sites of (re) myelination 
  Permissive/instructive conditions for (re)myelinating activity of OPCs at the 
lesion site are determined by the local presence of survival and growth factors, 
by specific axonal signalling factors and by the composition of the ECM. These 
conditions should be similar to the ones existing during normal embryogenesis. 
In addition to these basic conditions, OPCs have to deal with the inflammatory 
environment they are grafted in. 
 
3.1. Survival and growth factors 
In addition to the oligodendrocytic survival and growth factors PDGF and IGF1, 
members of the neurotrophin growth factor family have been shown to be 
important for the survival and myelinating activity of OPCs, in particular BDNF 
and NT-3. BDNF and NT-3 have been shown to act directly on OPCs via the General introduction 
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  TrkB and TrkC receptor to promote their proliferation, survival and maturation 
(Hu et al., 2008). In addition to neurotrophins, leukaemia inhibitory factor (LIF) 
and ciliary neurotrophic factor (CNTF) appear to be essential factors for 
oligodendrocytes to promote their final maturation acting via the gp130 kDa 
receptor (Stankoff et al., 2002). 
 
3.2. Axonal signals 
From the fact that dendrites are not myelinated, one can already deduce that 
axon-derived signals play a major instructive role in myelination. An important 
axon-derived factor is Nrg-1. Although most evidence for its involvement has 
been obtained in the peripheral nervous system and in the interaction between 
Schwann cells and peripheral axons, experiments indicate that also in the CNS 
Nrg-1 regulates myelination; b-secretase null (Bace1-null) mice, which lack the 
final processing of Nrg-1, have shown a prominent reduction in oligodendrocyte 
myelination activity (Hu et al., 2006). Expression of axonal adhesion molecules 
is also thought to affect (re)myelination. Whereas axonal expression of 
polysialylated neural cell adhesion molecules (NCAMs) acts as an inhibitor of 
remyelination, other adhesion molecules such as L1 provide a positive signal 
for remyelination (Coman et al., 2005). Axonal electrical activity also provides a 
potent promyelinating signal that at least in part is due to extra-synaptically 
released adenosine, which upregulates the expression as well as activates 
purinergic receptors in OPCs (Coman et al., 2005). Interestingly, this axon-
derived adenosine has been shown to act on astrocytes stimulating their 
release of CNTF and LIF, promoting oligodendrocyte myelination activity 
(Ishibashi et al., 2006). Indeed, this exemplifies the complex role of astrocytes 
in MS lesions, which appears to be stage-dependent. Under demyelinating 
conditions, astrocytes actively promote oligodendrocyte death and suppress 
OPCs recruitment and differentiation, whereas under remyelinating conditions 
astrocytes attract OPCs and stimulate their differentiation and survival 
(Williams et al., 2007). 
 
3.3. Extracellular matrix 
Laminin-2 is a potent promoter of oligodendrocyte survival and myelination. 
The laminin receptor a6b1 integrin present in resting OPCs detects laminin-2 
and enhances oligodendrocyte differentiation and myelin formation (Olsen and 
ffrench-Constant, 2005). Accordingly, axonal laminin-2 may serve as an 
extracellular myelination-inducing signal. Integrin growth factor interactions play 
an important regulatory role in oligodendroglial proliferation and maturation 
(Baron et al., 2005). 
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3.4. Inflammatory environment and microglia 
OPCs grafted in the demyelination lesion site inevitably will encounter 
inflammatory conditions. Many studies have clearly shown that inflammatory 
activity is actually required for remyelination (Setzu et al., 2006). Macrophage 
depletion, for instance, in experimental animals results in deficient 
remyelination; macrophages appear to be essential for the removal of myelin 
debris, which is a potent inhibitor of OPC differentiation (Kotter et al., 2006). 
The proinflammatory cytokine interleukin IL-1b stimulates the production of the 
oligodendrocyte survival and growth factor IGF1 by local reactive astrocytes 
and microglia (Mason et al., 2001). Studies on MS (Butovsky et al., 2006a; 
Butovsky et al., 2006b) have shown that oligodendrogenesis can be stimulated 
by microglia that have been conditioned by IL-4 and started to produce IGF1. 
This effect has been demonstrated in vitro using NSCs cocultured with IL-4-
treated microglia as well as in vivo after intraventricular injection of IL-4-treated 
microglia in mice subjected to experimental allergic encephalitis (EAE), an 
experimental animal model for MS (Butovsky et al., 2006a; Butovsky et al., 
2006b) 
 
4. Epigenetic factors in oligodendrogenesis 
As in other cell types, the achievement of functional maturity of 
oligodendrocytes is the result of an intricate interplay between extrinsic signals 
and intrinsic, i.e. genetic and epigenetic, factors. While there is a substantial 
amount of information about essential oligodendrogenic transcription factors, 
oligodendrocyte differentiation genes and myelin genes, the regulation of their 
expression and/or silencing at specific stages during oligodendrocyte 
development and maturation by epigenetic factors is now just getting slowly 
unraveled. The identification of these epigenetic regulatory pathways has 
already led to novel ideas about etiopathogenic mechanisms underlying 
demyelinating diseases such as multiple sclerosis and may offer new 
therapeutic targets. Moreover, understanding the pathways leading to a stable 
specific differentiation of stem cells will benefit the production of pure, 
functional oligodendrocytes for cell replacement therapies. 
 
4.1. Chromatin architecture in oligodendrocytes 
The tri-dimensional organization of chromatin within the nucleus is critical for 
the regulation of gene expression, and the resulting nuclear location of a gene 
prominently determines its likelihood to be transcribed. During differentiation, 
positioning of chromosome territories may expose sites to the transcriptional 
machinery, thus facilitating efficient gene expression. Heterochromatin, highly General introduction 
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  condensed chromatin with transcriptionally inactive genes, is generally found in 
the peripheral region of the nucleus of most cell types. Constitutive 
heterochromatin, chromatin that is always condensed, and facultative 
heterochromatin, which may be decondensed in some circumstances or during 
developmental stages, also have a characteristic nuclear distribution pattern. 
Euchromatin, in general, consists of decondensed, gene-rich, transcriptionally 
active chromatin and appears to be associated with nuclear domains enriched 
in splicing factors (Bartova et al., 2008). With the use of genomic in situ 
hybridization (GISH), the localization of a specific gene in a precise region of 
the nucleus has become feasible. As far as oligodendrocytes are concerned, 
GISH has been used to locate the genes encoding for proteolipid protein (PLP) 
and myelin basic protein (MBP) (Nielsen et al., 2002). PLP and MBP are both 
up-regulated during the differentiation of OPCs into mature oligodendrocytes. 
Both in OPCs and in the more mature oligodendrocytes, the PLP gene 
appeared to be consistently located in the nuclear periphery and not to be co-
localized with the MBP gene. Increased transcriptional activity of the PLP gene 
was found to correlate with the local accumulation of splicing factors and of the 
myelin transcription factor 1 (Myt1), which is known to bind to the PLP promotor 
(Nielsen et al., 2002). These data suggest that oligodendrocyte lineage genes 
and nuclear proteins might have specific and separate patterns of nuclear 
distribution and that activation of oligodendrocyte specific genes is established 
by changes in the distribution of local proteins regulating transcription rather 
than changes in clustering of coordinately regulated genes. 
 
4.2. Histone modification in oligodendrocyte differentiation 
4.2.1. Histone Code  
Posttranslational modifications of nucleosomal histones consist of a growing 
listof alterations to amino acid residues on histone tails (figure 1A) that 
modulate gene expression independent of changes in the DNA sequence 
(Ptashne, 2007). These reversible posttranslational modifications of amino 
acids include acetylation/deacetylation, methylation (Shilatifard, 2006), 
phosphorylation (Dyson et al., 2005), sumoylation (Iniguez-Lluhi, 2006), 
ubiquitination (Weake and Workman, 2008), and citrullination (Mastronardi et 
al., 2006). These modifications establish a ‘‘histone code’’ that is cell-type 
specific. A dynamic balance of these modifications dictates the transcriptional 
state of chromatin, as some histone changes confer a more open and 
transcriptionally competent state and others silence gene activation by 
chromatin compaction. Histone acetylation is functionally associated with 
transcriptionally competent chromatin, characterized by dispersed euchromatin. 
In contrast, histone deacetylation is functionally correlated with transcriptionally Chapter 1 
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inactive chromatin (Bartova et al., 2008). Closely associated with the state of 
histone acetylation is histone methylation of lysine residues. However, in this 
case both the position of the amino acid to be methylated and the number of 
methyl groups added determine whether transcriptional capacity is enhanced 
or inhibited. Specifically, trimethylation of lysine 4 on histone H3 is associated 
with transcriptional activation, while trimethylation of lysine 9 or 27 on histone 
H3 is associated with transcriptional silencing (Shilatifard, 2006; Sims, III and 
Reinberg, 2008) (figure 1B, 1C). Repressive histone methylation on K9 is often 
coupled with histone deacetylation and has been associated with chromatin 
condensation and the formation of heterochromatin. Similar to acetyl groups on 
lysine residues, methyl groups can also be enzymatically removed from 
histones, due to the activity of specific demethylases. Besides lysine residues, 
methylation of arginine residues also leads to enhanced transcriptional activity. 
Asymmetric methylation of arginine 3 on histone H4 and of arginine 17 on 
histone H3 result in gene activation, while symmetric methylation of arginine 8 
on histone H3 and of arginine 3 on histone H4 is associated with gene 
repression (Paik et al., 2007; Pal and Sif, 2007). Arginine methylation can be 
reversed by enzymatic conversion of arginine into citrulline residues, thereby 
further enhancing the complexity of the histone code. 
 
4.2.2. Histone Acetyltransferases and Oligodendrocyte Differentiation 
The rate and type of histone modifications in oligodendrocytes are controlled by 
a large group of enzymes and depend on the developmental stage, health, and 
age of the cells. Histone modifications are clearly involved in cell fate decision 
and early stem cell differentiation, and this is also the case for late 
oligodendrocyte differentiation. Acetylation is essentially involved in the 
regulation of gene expression and is catalyzed by a family of histone 
acetyltransferases (HAT) and reversed by histone deacetylase-mediated 
deacetylation. Members of the HAT family include GCN5, CBP and p300, each 
one being associated with transcriptional activation. 
Histone acetylases have been shown to play an important role in neural stem 
cell differentiation. Indeed, HAT p300 is recruited to the lineage specific gene 
glial fibrillary acidic protein (GFAP) during astrogliogenesis, controlling the 
amount of gene expression (Asklund et al., 2004; Song and Ghosh, 2004). In 
addition, removal of histone deacetylase (HDAC) complexes from neurogenic 
marker genes, such as NeuroD, is necessary for neuronal differentiation to 
proceed (Hsieh et al., 2004b). Although the acetylation of histones is necessary 
for transcriptional activation of several neuronal lineages, the role of HATs in 
oligodendrocyte differentiation is less pronounced.  General introduction 
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Figure 1 - Histone modifications A. Model of the basic transcriptional unit, a nucleosome, shows 
the histone core octamer (H2A, H2B, H3, and H4, in blue) and the H1 linker protein, enwrapped 1.5 
times by 150 bp of DNA (red). The histone tails can be modified by enzymes that catalyze 
methylation, acetylation, phosphorylation, citrullination, ubiquitination, or sumoylation of specific 
amino acids. B. The scheme of three nucleosomes depicts a part of the chromatin with promotor 
and gene DNA that is open for transcription. The transcriptional active state is achieved by the 
acetylation or methylation of lysine 9 (K9) or lysine 4 (K4), respectively in the tail of histone 3 (H3). 
C. Transcriptional silencing can be caused by the histone modification resulting from the 
methylation of K9 or trimethylation of K27. 
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In fact, HDACs have been shown to play a more critical role in the progression 
of progenitor cells toward the oligodendrocyte lineage. 
 
4.2.3. Histone Deacetylases (HDACs) and Oligodendrocyte Differentiation 
HDACs remove the acetyl groups from histone lysine residues and render the 
chromatin less accessible to transcription factors. HDACs have been classified 
into four broad classes, based on sequence homology to yeast histone 
deacetylases: Class I (HDAC-1, -2, -3, and -8), Class II (HDAC-4, -5, -6, -7, -9, 
and -10), Class III (SIRT1-7), and Class IV (HDAC11). Each class of HDAC 
has a unique expression pattern and is involved in different patterns of gene 
repression. Class I HDACs are generally localized to the nucleus and 
expressed in a ubiquitous manner in many tissues (Thiagalingam et al., 2003). 
They are often found as part of larger protein complexes that repress gene 
expression. Class II HDACs are generally localized in the cytoplasm and are 
shuttled to the nucleus when needed; the exception is HDAC10, which has 
been shown to be a constitutive nuclear protein. Moreover, Class II HDACs are 
differentially expressed in human tissue, found more prominently in the heart, 
brain, and skeletal muscle (Cress and Seto, 2000; Zhou et al., 2000). Class III 
HDACs are a family of NAD-dependent enzymes, also called ‘‘sirtuins,’’ due to 
their homology to the yeast Sir2 (Imai et al., 2000). They appear to play an 
important role in deacetylating histone H4 lysine 16 (Vaquero et al., 2007). 
However, Sirt1 has been shown to affect several additional proteins, including 
p53 (Cheng et al., 2003; Langley et al., 2002; Luo et al., 2001; Vaziri et al., 
2001), FoxO (Brunet et al., 2004; Motta et al., 2004), p300/CBP (Motta et al., 
2004), NFB (Yeung et al., 2004), and histone H1 (Vaquero et al., 2004). 
HDAC11, the only current member of class IV HDACs, shares properties of 
Class I and Class II. The size of the protein falls in line with Class I HDACs but 
it is differentially expressed in human tissues, a characteristic of Class II 
HDACs (Thiagalingam et al., 2003). Unlike other neuronal lineages, 
oligodendrocyte differentiation of progenitor cells is initiated by a global histone 
deacetylation program (Marin-Husstege et al., 2002). During the early stages of 
oligodendrocyte development, HDACs mediate two critical processes: 
suppressing the choice of alternative lineages and repressing the expression of 
inhibitors of myelin specific genes (figure 2A). At the mature stage of the 
oligodendrocyte, essential stable repression of inhibitors of myelin genes is 
established via the action of histone methyl transferases, HMTs (in particular of 
the Suvar3-9 family) resulting in the methylation of H3K9, followed by the 
binding of HP1 (heterochromatin protein 1) causing compaction of the 
nucleosome figure 2B). The stable silencing of the myelin gene inhibitors General introduction 
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  promotes myelination activity. The remyelination capacity of OPCs in aged 
animals is reduced due to diminished recruitment of HDACs and HMTs, 
resulting in histone acetyl transferase (HAT) activity to prevail causing an 
acetylated, transcriptional activated state of genes blocking proper OPC 
development and maturation and myelination (figure 2C) 
HDACs contribute to oligodendrocyte epigenetic identity by blocking critical 
transcription factors of alternative lineages, in particular Sox2 (Lyssiotis et al., 
2007; Shen and Casaccia-Bonnefil, 2008). The importance of histone 
deacetylation in determining the direction of neural stem cell differentiation has 
been demonstrated in differentiation experiments in vitro with HDAC inhibitors. 
Differentiation of neural stem cells in the presence of HDAC inhibitors results in 
a noticeable reduction in oligodendrocytes on the account of a larger 
population of astrocytes and neurons (He et al., 2007; Liu et al., 2007a; 
Siebzehnrubl et al., 2007). Moreover, to initiate oligodendrocyte differentiation, 
HDAC1 and HDAC2 are recruited to the promoters of inhibitory molecules of 
myelin specific genes (He et al., 2007; Shen and Casaccia-Bonnefil, 2008). 
Transcriptional inhibitors of oligodendrocyte differentiation include Hes5 (Kondo 
and Raff, 2000a; Liu et al., 2006), Sox11 and Tcf4. (He et al., 2007; Kondo and 
Raff, 2000b; Marin-Husstege et al., 2006; Samanta and Kessler, 2004). Yin 
Yang 1 is the transcription factor that facilitates the recruitment of HDAC1 to 
the promoters of some of these transcriptional inhibitors, allowing for 
subsequent expression of myelin specific genes (He et al., 2007). Thus, the 
global deacetylation program initiated by HDACs, especially specific isoforms 
of Class I HDACs, enables expression of an oligodendrocyte transcriptional 
profile. SIRT2, a member of Class III HDACs, is also enriched during 
oligodendrocyte development but it does not target its deacetylase capacity 
toward histones H3 or H4. Rather, SIRT2 targets acetylated a-tubulin, possibly 
effecting morphological differentiation of oligodendrocytes (Tang and Chua, 
2008). 
 
4.2.4. Histone Methylases and Oligodendrocyte Differentiation 
Histone methyltransferases (HMTases) are enzymes that catalyze the addition 
of methyl groups to various histone lysine residues. As noted above, histone 
methylation of specific residues is mediated by distinct enzymes. Methylation of 
lysine 4 on histone H3 (H3K4) is catalyzed by the mixed lineage leukemia 
(MLL) complex. Specifically, the SET domain of MLL is responsible for 
methylation of lysine K4 in the tail of histone H3. A number of HMTases are 
capable of methylating histone H3 at lysine 9 (H3K9), most notably the Su (var) 
3-9 family.  Chapter 1 
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Figure 2 - Histone modification and oligodendrocyte development. A. The differentiation of neural 
stem cells into oligodendrocyte precursor cells (OPCs) requires the recruitment of Class I histone 
deacetylases, HDACs (in particular 1 and 2) at genes encoding transcriptional inhibitors of OPC 
formation (e.g. Hes5, Id2, Id4, Sox11, and Tcf4) and those encoding the fate toward neurons or 
astrocytes. The HDAC activity at lysine 9 (K9) of histone protein 3 (H3) leads to the silencing of the 
expression of these genes, enabling oligodendrocyte formation. Yin Yang 1 and presumably Ezh2 
are thought to facilitate the recruitment of the HDACs at these specific locations. The repression is 
still reversible, since some regulation is required to prevent premature myelination. B. Essential 
stable repression of inhibitors of myelin genes at the mature stage of the oligodendrocyte, is 
established via the action of histone methyl transferases, HMTs (in particular of the Suvar3-9 
family) resulting in the methylation of H3K9, followed by the binding of HP1 (heteroprotein protein 
1) causing compaction of the nucleosome. The stable silencing of the myelin gene inhibitors 
promote myelination activity. C. The remyelination capacity of OPCs in aged animals is reduced 
due to diminished recruitment of HDACs and HMTs, resulting in histone acetyl transferase (HAT) 
activity to prevail causing an acetylated, transcriptional activated state of genes blocking proper 
OPC development and maturation and myelination. General introduction 
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  However, the mechanism and the machinery responsible for methylation is 
dependent on the substrate and status of the cell, as dimethylases play a major 
role in euchromatin and trimethylases play a major role in transcriptionally 
inactive chromatin formation (Shilatifard, 2006). A prominent HMTase involved 
in methylation of lysine 27 on histone H3 (H3K27) is enhancer of zeste 
homologue 2 Ezh2, a member of the so-called Polycomb Group (PcG) proteins 
(see section 4.3). The role of histone H3 methylation by Ezh2 in 
oligodendrocyte differentiation is unknown and forms a major research aim of 
this thesis. 
 
4.2.5. Histone Demethylases and Oligodendrocyte Differentiation  
While it was believed that histone methylation is a permanent modification, the 
discovery of lysine-specific demethylase enzymatic activities has revealed the 
dynamic process of histone methylation. Similar to methylation, demethylation 
is a differential process requiring distinct enzymes. LSD1 is a demethylase 
specific for mono- and dimethyl groups on lysine residues, while Jumonji 
domain-containing enzymes (JmjC) catalyze removal of trimethyl groups from 
lysine residues (Benevolenskaya, 2007; Cheng and Zhang, 2007; Culhane and 
Cole, 2007). These histone demethylases are often coupled into a complex 
with other histone modifiers to enhance their individual activities, such as 
combining H3K4 trimethylation with H3K27 demethylation (Lan et al., 2008). 
While, so far no direct relevance of histone demethylation for oligodendrocyte 
differentiation has been found, involvement of H3K4 demethylase in the 
repression of neuronal genes in non-neuronal tissues has been shown 
(Tahiliani et al., 2007). Although less studied, methylation of arginine residues 
provides another mode of dynamic gene regulation. In mammals, protein 
arginine methyltransferase 1 (PRMT1) and co-activator associated arginine 
methyltransferase 1 (CARM1) work in conjunction to catalyze methylation of 
arginine 3 on histone H4 (H4R3) and of arginines 2 and 17 on histone H3 
(H3R2; H3R17), which results in gene activation.  
Meanwhile, PRMT5 catalyzes the methylation of arginine 8 on histone H3 
(H3R8) and of arginine 3 on histone H4 (H4R3), which is associated with gene 
silencing (Paik et al., 2007; Pal and Sif, 2007). In both cases of arginine 
methylation, removal of the methyl group is not facilitated by any histone 
demethylases, as seen for lysine residues, but rather, the reaction is reversed 
by specific deiminases (Wang et al., 2004). Human peptidylarginine deiminase 
2 (PAD2) and peptidylarginine deiminase 4 (PAD4) both convert arginine into 
citrulline, which removes the methyl group from the residue. Similar to histone 
demethylation, there is currently no direct role for arginine methylation in 
oligodendrocyte development. However, high levels of PAD2 and PAD4 Chapter 1 
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enzyme, as well as subsequently high levels of citrullination, have been 
observed in myelin isolated from patients with multiple sclerosis (Wood et al., 
2008) and experimental models of demyelination (Mastronardi et al., 2006). 
 
4.3. DNA methylation in oligodendrocytes 
DNA methylation is an important epigenetic mechanism for regulating gene 
expression. It takes place at the CpG sequences within the immediate 5’ 
promoter regions of genes. These regions have CpG contents greater than 
60%, compared to 40% for the bulk DNA. Methylation of cytosine in CpG 
sequences turns off promoter activity and thereby decreases gene expression, 
since methylation affects both DNA structure and the binding of transcription 
factors. DNA methylation is regulated by the balance between DNA 
methyltransferases and DNA demethylases. As DNA methylation normally 
provides stable repression of genes, DNA methylation patterns are often cell-
type specific, as seen in adult oligodendrocytes.  
Interestingly, specific alterations in DNA methylation patterns found in brains 
from MS patients, have led to novel ideas about the pathogenesis of MS 
(Casaccia-Bonnefil et al., 2008). An MS brain have a very specific two-fold 
higher DNA demethylase activity in comparison to normal brains and for 
instance brains of Alzheimer’s, Parkinson’s or Huntington’s patients 
(Mastronardi et al., 2007). As a consequence, DNA isolated from the white 
matter of MS brains contained only about 1/3 of the amount of methylated 
cytosine found in DNA from normal subjects or Alzheimer’s, Parkinson’s or 
Huntington’s patients (Mastronardi et al., 2007).  
The consequence of higher DNA demethylase activity in MS brains is that 
specific, normally repressed genes, particularly those with a high CpG content 
in their promoter, are reactivated. One of those genes is PAD2, which is 
involved in the deimination of myelin basic protein (MBP). While in normal 
brains only a very small proportion of MBP is citrullinated, the brains of patients 
with chronic MS are comprised of a larger percentage of citrullinated MBP, 
approximately 40% of the total MBP (Moscarello et al., 1986; Moscarello et al., 
1994). The conversion of the majority of arginines in MBP into citrullines by 
increased levels of PAD2 resulted in aberrant interactions with other myelin 
components (Finch and Moscarello, 1972; Wood and Moscarello, 1989). 
Several studies have indicated the potential importance of abnormal 
citrullination of MBP in the sensitization of T-cells and the subsequent 
enhancement of the auto-immune response underlying MS pathogenesis 
(D'Souza et al., 2005; Musse et al., 2006; Tranquill et al., 2000; Zhou et al., 
1995).  General introduction 
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  4.4. microRNA in oligodendrocytes  
Whereas the previous epigenetic mechanisms regulating gene expression all 
operate at the transcriptional level, microRNAs (miRNA) are involved in mRNA 
translational regulation. miRNAs are endogenous small non-coding RNAs with 
a length of approximately ~22 nucleotides. They are encoded by DNA that 
resides between or within protein-coding genes.  
The long primary miRNA transcripts are processed into precursor miRNA stem-
loops of ~60 nucleotides by the nuclear RNA polymerase type-III Drosha and 
then transported to the cytoplasm by exportin-5. 
After further trimming by Dicer, a cytoplasmic RNA polymerase type-III, they 
obtain their mature, short (~22 nucleotides), single-stranded form, which is 
bound to argonaute proteins. This silencing complex ultimately mediates the 
miRNA suppression of specific target mRNAs by imperfectly base pairing at the 
3’ untranslated region (3’ UTR).  This can either lead to the destabilization and 
degradation of the target mRNA or to its translational repression. In general, 
miRNAs are present at very high copy numbers per cell and they can regulate 
hundreds, thousands or even more mRNA targets, and so their impact on gene 
expression regulation must be considered profound. Apart from involvement of 
miRNAs in various cancers, specific microRNAs have been shown to modulate 
muscle differentiation (Chen et al., 2006), ES cell lineage commitment (Ivey et 
al., 2008; Tay et al., 2008; Krichevsky et al., 2006), haematopoietic lineage 
commitment (Johnnidis et al., 2008; Lu et al., 2008; Koralov et al., 2008), and 
cardiovascular development (Zhao et al., 2007), as well as synaptic 
development (Schratt et al., 2006). In comparison to other organs, human and 
rodent brains contain many more types of miRNAs that are expressed at much 
higher levels, possibly reflecting their importance in the development and 
maintenance of the integrity of this complex organ. 
The expression of miRNAs is not homogenous over all brain regions and it 
alters during brain development. Although most of the functions of miRNAs in 
the brain still have to be discovered, recent studies in various animal models 
have implicated miRNAs as major players in neuroprotection and 
neurodegeneration (see review (Nelson et al., 2008). miRNA expression 
profiles of the separate neural populations, neurons, astrocytes and 
oligodendrocytes, have hardly been addressed and are mainly restricted to 
neurons. However, Lau et al., 2008 published a study in which they identified 
for the first time the miRNA expression profile (microRNAome) of developing 
oligodendrocytes isolated from postnatal (P7) rat brain (Lau et al., 2008). They 
were able to identify 98 miRNAs in developing rat oligodendrocytes, of which 
43 changed their expression levels during the transition from oligodendrocyte 
progenitor cell (A2B5+/GalC-) to premyelinating oligodendrocyte Chapter 1 
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(A2B5+/GalC+). Of the 98 identified miRNAs, 37 displayed a mRNA target 
bias; the expression level of the predicted target of 13 miRNAs appeared to be 
dynamically regulated during oligodendrocyte differentiation. So far, the most 
interesting example of that appeared to be miR-9, which is down-regulated 
during oligodendrocyte differentiation and inversely correlated with the 
expression of its predicted targets. One of these targets is peripheral myelin 
protein (PMP) 22, a protein produced by Schwann cells. PMP22 mRNA, but not 
protein, is present in oligodendrocytes.  Lau et al. demonstrated that miR-9 
interacts with the 3’ untranslated region of PMP22 and down-regulates its 
expression in oligodendrocytes, whereas Schwann cells lack miR-9 (Lau et al., 
2008). These data show that miRNAs play an important role in the expression 
of oligodendrocytic genes, regulating the process of differentiation and 
maturation. 
 
4.5. Polycomb repressing complexes as fate determining factors in stem 
cell differentiation 
Polycomb-group proteins (PcG) are a family of proteins first discovered in fruit 
flies that can remodel chromatin such that epigenetic silencing of genes takes 
place. PcG proteins work in multimeric protein complexes called polycomb 
repressive complexes (PRCs). PRCs play an important role in chromatin 
modification and as such confer transcriptional silencing in higher eukaryotes. 
At present it is generally recognized that PRCs represent a global silencing 
system which is essential in multi-cellular development, stem cell biology and 
cancer (Sparmann and van, 2006; Schwartz and Pirrotta, 2007; Pietersen and 
van, 2008; Simon and Kingston, 2009). Accordingly, large numbers of genes 
are repressed by PRCs, including genes that encode crucial developmental 
regulators. 
The two major PRCs that target gene repression are polycomb repressive 
complex 1 (PRC1) and PRC2 (figure 3). According to the current notion PRC2 
methylates histone H3 on Lys27 (H3K27), which is a central feature of PRC-
silenced chromatin, whereas PRC1 is commonly viewed as a direct executor of 
silencing at target genes. However, much about the basic PcG mechanisms 
remains unresolved. H3K27me3 is distributed over large chromosomal regions 
and its distribution correlates with PRC2 binding, covering up to 20% of gene 
promoters in ES cells (Boyer et al., 2006; Lee et al., 2006). Surprisingly, most 
of these promoters are also marked by the activating histone modification 
H3K4me3 (firure 3) resulting in the identification of so-called ‘bivalent domains’ 
(Bernstein et al., 2006). General introduction 
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  The current hypothesis is that bivalent chromatin states poise genes for 
subsequent activation (Schuettengruber and Cavalli, 2009). 
Interestingly, there are multiple versions of PRC1 and PRC2, suggesting that 
diverse subunit compositions have distinct functions. This is especially relevant 
in mammalian systems, in which many individual subunits are encoded by a 
variety of PcG genes. PRC2 contains four core subunits and its primary activity 
is to methylate H3K27 (Cao et al., 2002; Pietersen and van, 2008; Kuzmichev 
et al., 2002). Trimethylated H3K27 (H3K27me3) is considered the principal 
form of H3K27 involved in PcG silencing (Boyer et al., 2006; Schuettengruber 
and Cavalli, 2009). 
 
 
Figure 3 - Possible mechanism of transcription repression by PcG proteins (PRCs). The PRC2 is 
recruited to chromatin by unknown mechanisms (potentially by involving polycomb response 
elements, transcription factors and ncRNAs). PRC2 catalyzes the tri-methylation of histone H3 at 
lysine 27 (H3K27me2/3). Enhancer of zeste homolog 2 (Ezh2) is the catalytic subunit of PRC2; its 
activity requires binding to the two other core components of PRC2, the suppressor of zeste 12 
(SUZ12) and embryonic ectoderm development (EED). Retinoblastoma-associated protein 46 
(RbAp46) and RbAp48 and the histone deacetylases HDAC1 and HDAC2 are also known subunits 
of PRC2 however, they are not essential for PRC2 histone methyltransferase (HMT) activity. The 
tri-methylation of H3K27 is recognized by the PRC1 which finally catalyzes lysine 119 mono-
ubiquitylation (K119) of histone H2A (H2AUb1), thus hindering the transcription by limiting the 
access of RNA polymerase II to the chromatin. 
 
In addition to H3K27 trimethylation, studies also suggest additional functions of 
PRC2. The active site of PRC2 is constituted by the SET domain of the 
catalytic subunit, enhancer of Zeste (Ezh2). These PcG proteins require 
presence of suppressor of Zeste 12 (Suz12) and extra sex combs (Esc) or 
embryonic ectoderm development (Eed) (Cao and Zhang, 2004; Pasini et al., 
2004). In mammals, two related genes encode Ezh1 and Ezh2. Furthermore, 
four distinct isoforms of Eed are known (Kuzmichev et al., 2002). This variation 
of polycomb group proteins renders a variety of related mammalian PRC2 
complexes. Chapter 1 
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Recent studies reveal prominent differences between PRC2 complexes 
containing either Ezh2 or Ezh1. It seems that Ezh2 is primarily expressed 
during embryogenesis and in proliferating cells and that Ezh1 is mostly found in 
adult tissues and non-dividing cells. Furthermore, PRC2–Ezh1 has much less 
methyltransferase activity than PRC2–Ezh2. Additional variation of the PRC2 
complex is induced by Polycomb-like protein (PCL in flies and PHF1 in 
mammals), which after binding alters the properties of PRC2 (Sarma et al., 
2008; Savla et al., 2008). It has been shown that PCL (or PHF1) stimulates the 
PRC2-mediated conversion of H3K27me2 to H3K27me3 (Sarma et al., 2008). 
It also has been reported that PHF1 enhances PRC2 methyltransferase activity 
(Cao et al., 2008). Furthermore, experiments in D. melanogaster suggest that 
PCL is involved in the recruitment of PRC2 (Savla et al., 2008). Despite the 
general notion that H3K27 methylation  is a crucial event in PcG-mediated 
silencing, its underlying mechanism is still unknown. 
There is currently no conclusive evidence that methylation of H3K27 induces 
silencing by altering nucleosome interactions. Interestingly, the affinity of the 
chromodomain of Polycomb, a PRC1 constituent, for H3K27me3 (Min et al., 
2003) suggests that this methylation of H3K27me3 provides a docking site for 
PRC1, and it has been suggested that  H3K27 methylation supports initial 
recruitment of PRC1  to target genes . In support of this view, disruption  of 
PRC2 leads to loss of PRC1 from chromatin targets in D. melanogaster (Cao et 
al., 2002) and in mammalian cells (Boyer et al., 2006).  
A variety of genetic and biochemical studies suggest that PRC1 family 
complexes are the key element for transcriptional silencing (Levine et al., 2004; 
Schuettengruber et al., 2007). The mechanisms of PRC1 silencing are not yet 
fully understood and might include direct repression of the transcription 
machinery and regulation of chromatin structure. PRC1 complexes contain 
stoichiometric amounts of the PcG proteins Polycomb, Polyhomeotic, Posterior 
sex combs (PsC) and Ring, and a variety of other proteins. Mammalian 
homologues of these four proteins also form a stable, functional complex. 
PRC1 is known to repress transcription, inhibit ATP-dependent chromatin 
remodeling and compact nucleosome arrays (Francis et al., 2004). The human 
PRC1 core proteins PRC1, RING1b and b lymphoma Mo-MLv insertion region 
1 (BMI1) also ubiquitylate histone H2A in cells. This gave rise to the hypothesis 
that H2A ubiquitylation is a key function of PRC1 (Cao et al., 2005), and leads 
to the current view that the PRC1 family has two functional forms: one complex 
(the originally defined PRC1) that can efficiently compact chromatin and 
another complex (called RING-associated factor (Draf) in D. melanogaster and 
bCL6 corepressor (BCor) in mammals) that can efficiently ubiquitylate H2A. General introduction 
  ￿￿￿
C
h a p t e r   1
  The exact mechanism of PRC1-mediated silencing is yet unsolved. However, 
recent studies point to a block of transcriptional elongation as a likely 
mechanism. It has thus been proposed that the ubiquitylation of histone H2A 
might prohibit processes that allow the movement of RNA polymerase, thereby 
causing polymerase pausing, which might be a key mechanism in PcG 
silencing (Zhou et al., 2008).  It is yet unknown how the ubiquitylation of the 
carboxy-terminal tail of H2A obstructs elongation.  It could be that direct 
inhibition of displacement of the nucleosome from the DNA or alterations in 
nucleosome dynamics prevent disassembly of the nucleosome. Alternatively, 
compaction of nucleosomes by PRC1 (Francis et al., 2004) might also block 
their displacement by RNA polymerase. Finally, a compacted nucleosome 
structure might stabilize Histone-DNA interactions so strongly that movement of 
RNA polymerase II cannot occur. 
Several reports show that PcGs are involved in neural stem cell development. 
It is well known that deficiency in the PcG Bmi-1 leads to progressive postnatal 
growth retardation and neurological defects. Indeed Bmi-1 is essential for self-
renewal of neural stem cells but does not affect their survival or differentiation. 
Thus in postnatal Bmi-1-/- neural stem cells, the cyclin-dependent kinase 
inhibitor gene p16Ink4a is up-regulated, reducing the rate of proliferation 
(Molofsky et al., 2003). In addition Bmi-1 is also important for embryonic NSC 
self-renewal, which is mediated by the cell-cycle inhibitor p21 (Fasano et al., 
2007; He et al., 2009). Furthermore, Bmi-1 overexpression in cultured adult 
forebrain NSCs induces a pronounced increase in proliferation of NSCs that 
continue to generate neurons even after multiple passages (Fasano et al., 
2009). It has also been shown that a subpopulation of neuroblastoma I-type 
cells possess self-renewal capacity that requires Bmi-1. Clearly, Bmi-1 
expression levels influence the lineage commitment of neuroblastoma I-type 
cells (Cui et al., 2006). It has been reported that Ezh2-dependent epigenetic 
silencing of BMP receptor 1B (BMPR1B) in glioblastoma tumor inducing cells is 
involved in astroglial differentiation. Indeed forced expression of BMPR1B 
blocks their differentiation capabilities and induces loss of their tumorigenicity 
(Lee et al., 2008). 
Recent studies have indicated that PcG proteins may be involved in cortical 
neurogenesis. Inactivation of PRCs by knockout of Ring1B, Ezh2 or Eed 
appears to prolong the neurogenic phase and delays the onset of the 
astrogenic phase (Hirabayashi and Gotoh, 2010; Hirabayashi et al., 2009). 
 
5. Outline of the thesis 
The studies in this thesis address crucial issues related to the potential clinical 
use of NSC-derived OPCs in demyelinating diseases such as MS:  Firstly, it is Chapter 1 
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essential to differentiate NSCs into stable OPCs that can mature into 
myelinating oligodendrocytes after migrating to the site of demyelinated axons. 
Full functional and stable differentiation can only be established if we 
understand the pivotal epigenetic mechanisms of the transcriptional processes 
underlying this differentiation process. Secondly, the longterm stability, safety 
and functionality of NSC-derived OPCs after intracerebral implantation have to 
be assured.  
So, the work presented in this thesis had two main objectives: 
A)  To investigate the epigenetic mechanisms underlying the specific 
stable differentiation of NSCs towards OPCs. 
B)  To monitor the survival, the migration, functionality and efficacy of 
grafted NSCs and NSC derived OPCs after intracerebral implantation 
in MS animal models using in-vivo imaging with Bioluminescence 
Imaging (BLI).  
 
The first aim of the thesis is addressed in the Chapters 2, 3, and 4. In these 
chapters we specifically focus on the role of the polycomb group protein Ezh2 
in the differentiation of neural stem cells towards an oligodendrocytic cell 
lineage. We elaborate on the finding that this major epigenetic regulatory factor 
remains highly expressed (in-vitro and in-vivo) in oligodendrocytes (in contrast 
to differentiating astrocytes and neurons) up to the stage of myelination. 
Silencing experiments are performed to reveal the indispensability of Ezh2 
repressive activity on gene transcription for proper oligodendrocyte 
differentiation. Using chromatin immunoprecipitation followed by high-
throughput sequencing (Chip-Seq) we assess the specific target genes of Ezh2 
in differentiating oligodendrocytes and compare them with those in neural stem 
cells. Based on these target gene lists and validation experiments, we explore 
the signalling pathways essential for proper and stable oligodendrocyte 
differentiation controlled by Ezh2.  
The second part of the thesis, comprising Chapters 5 and 6, reports on 
transplantation experiments with neural stem cells (NSCs) and neural stem 
cells primed to become oligodendrocyte precursor cells (Olig2-tNSC) in animal 
models for MS. Bioluminescent in-vivo monitoring is used to follow the fate of 
the implanted cells in the life animal. In the cuprizone mouse model we 
demonstrate the longterm remyelination activity of stereotactically implanted 
Olig2-NSCs and compare their behaviour with injected undifferentiatied NSCs. 
The EAE mouse model, mimicing more adequately the inflammatory aspect of 
MS, is used to study the fate, survival and clinical efficacy of NSCs and Olig2-
NSCs after intraventricular injection. General introduction 
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1. ABSTRACT 
The mechanisms underlying the regulation of neural stem cell (NSC) renewal 
and maintenance of their multipotency are still not completely understood. Self-
renewal of stem cells in general implies repression of genes that encode for 
cell lineage differentiation. Enhancer of zeste homolog 2 (Ezh2) is a Polycomb 
group protein (PcG) involved in stem cell renewal and maintenance by inducing 
gene silencing via histone methylation and deacetylation. To establish the role 
of Ezh2 in the maintenance and differentiation of NSCs, we have examined the 
expression of Ezh2 in NSCs isolated from embryonic (E14) mice during 
proliferation and differentiation in-vitro. Our results show that Ezh2 is highly 
expressed in proliferating NSCs. In accordance with its suggested role as 
transcription repressor, the expression of Ezh2 decreased when the NSCs 
differentiated into neurons and was completely suppressed during 
differentiation into astrocytes. Surprisingly, Ezh2 remained highly expressed in 
NSCs that differentiated into an oligodendrocytic cell lineage, starting from 
oligodendrocyte precursor cells (OPCs) up to the immature (premyelinating) 
oligodendrocyte stage. To further establish the role of Ezh2 in NSC 
differentiation, we silenced and induced over-expression of the Ezh2 gene in 
NSCs. High levels of Ezh2 in differentiating NSCs appeared to be associated 
with an increase in oligodendrocytes and a reduction in astrocytes, whereas 
low levels of Ezh2 led to completely opposite effects. The increase in the 
number of oligodendrocytes induced by enhanced expression of Ezh2 could be 
ascribed to stimulation of OPC-proliferation although stimulation of 
oligodendrocyte-differentiation cannot be excluded.  
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2. INTRODUCTION 
Proteins encoded by the polycomb group (PcG) genes are known to play a 
crucial role in the gene expression program which allows stem cells to maintain 
a pluripotent state but also allows for differentiation into more specialized 
phenotypes when signalled to do so (for reviews see (Azuara et al., 2006; 
Rajasekhar and Begemann, 2007; Sparmann and van, 2006)). The PcG 
proteins were first described in Drosophila, where they repress the homeotic 
genes controlling segment identity in the developing embryo (Ringrose and 
Paro, 2004; Ringrose et al., 2004). The PcG proteins form multiple Polycomb 
Repressive Complexes (PRCs), the components of which are conserved from 
Drosophila to humans. Among the known types of PRCs, PRC1 and PRC2 are 
the best described and as yet considered the most important ones. Whereas 
PRC2 is of importance for the initiation of gene repression, PRC1 is involved in 
the maintenance of gene repression. At the site of repression the PRC2 
initiation complex binds to the PcG target genes; one of the components of 
PRC2, enhancer of zeste homologue 2 (Ezh2), then trimethylates lysine 27 of 
histone H3. Subsequently, PRC1 recognizes the trimethylated H3K27 
(H3K27me
3) sites and silences the target genes either by direct inhibition of the 
transcriptional machinery, by ubiquitilation of H2AK119, by chromatin 
compaction and/or by recruitment of DNA methyl-transferases (DNMTs) 
(Rajasekhar and Begemann, 2007; Sparmann and van, 2006), cohorts of 
developmental genes that are silenced by PRC1 and 2 in murine and human 
embryonic stem cells have been identified (Boyer et al., 2006; Bracken et al., 
2006; Lee et al., 2006); removal from the target genes or functional 
modification of the PRCs leads to expression of these genes and to cellular 
differentiation. And so, it has been found that in the transition from an ES cell 
into a neural stem cell, concomitant with a reduction of H3K27me
3, the 
transcript levels of, for instance, Olig1, 2, 3, EGFrec, Nes and Sox 9 increase 
(Boyer et al., 2006). During subsequent cellular differentiation, the composition 
and histone substrates of the PRCs change considerably, altering their mere 
repressive function (Kuzmichev et al., 2005). 
Also in adult stem cells, such as haematopoietic and neural stem cells, the PcG 
proteins have been shown to play an important role in self renewal, 
maintenance of pluripotency and repression of differentiation. The strongest 
evidence for neural stem cells has been provided for the PcG protein Bmi1 
(component of PRC1) (Iwama et al., 2004; Lessard et al., 1999; Leung et al., 
2004; Molofsky et al., 2003; Molofsky et al., 2005); Bmi1-deficient mice exhibit 
aberrant transformations coupled with acute neurological disorders and severe 
proliferation defects during haematopoiesis (van der Lugt et al., 1994). Ezh2 in neural stem cells 
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The involvement of the PRC2-PcG protein Ezh2, in the maintenance and the 
prevention of aging of haematopoietic stem cells has been demonstrated 
(Kamminga et al., 2006). In addition, preliminary indications suggest that Ezh2 
is also expressed in adult neural stem cells in the hippocampus (Gurok et al., 
2007) and subventricular zone (Allen Brain Atlas, http://www.brain-map.org). 
In the present study, we have investigated the expression of Ezh2 in 
undifferentiated neural stem cells and during their differentiation into neurons, 
astrocytes and oligodendrocytes in order to establish its involvement in the 
regulation of maintenance and differentiation of neural stem cells. 
 
3. MATERIAL AND METHODS 
3.1. Animals 
For all experiments C57BL/6 mice, that were housed under standard conditions 
with free access to food and water were used. All animal experiments were 
carried out in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals and regulations of the local Experimental 
Animal Committee.  
3.2. Cell cultures 
Primary murine neural stem cell culture: Neural stem cells (NSCs) were 
isolated from the telencephalon of C57/Bl6 mouse embryos at E14. Briefly, the 
telencephalon was cut into small pieces at room temperature and after 
mechanically triturating in ice-cold phosphate buffer saline the tissue was 
incubated with accutase (Sigma Aldrich, Zwijndrecht, The Netherlands) for 15 
minutes at 37C
o
. After repeated trituration, the cell suspension was passed 
through a cell strainer (70 μm pore size; Falcon, Franklin Lakes, NJ) and 
seeded (1-1.5 million cells) in T25 (Nunc, Roskilde, Denmark) tissue culture 
flasks containing proliferation medium, which consisted of Neurobasal medium 
(Invitrogen, Breda, The Netherlands) supplemented with B27 (2%, Invitrogen), 
human recombinant epidermal growth factor (EGF) (20ng/ml, Invitrogen), basic 
fibroblast growth factor (bFGF) (20ng/ml; Invitrogen), glutamax (1%; GIBCO), 
primocin (100μg/ml) and heparin (5μg/ml; Sigma Aldrich) in a humidified 5% 
CO2/95% air incubator at 37°C. Within 3-5 days the cells grew as free-floating 
neurospheres and were dissociated and passaged with the use of accutase.To 
induce the differentiation of NSCs into the 3 neural cell types, neurospheres 
were exposed to accutase for 5-10 minutes and dissociated by triturating. 
Subsequently, the cells were plated in poly-L-lysine and laminin-coated 
chamber slides (Nunc), at approximately 15.000 cells per well in Neurobasal 
medium supplemented with B27 for 5 days at 5% CO2 and 37°C.  
Primary murine astrocyte culture: Mixed glial cultures were established as 
described previously (Biber et al., 1997). In short, brains from postnatal Chapter 2 
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C57/Bl6 mice were rapidly isolated and after removal of meninges, the cortices 
were dissected in ice-cold medium A (Hank’s Balanced Salt Solution -HBBS- 
supplemented with 1.5% glucose and 1.5% HEPES). Cortices were dissociated 
mechanically by trituration in medium A and subsequently by trypsinisation for 
20 minutes at 37°C in medium A supplemented with 0.25% trypsin and 
1000U/ml DNase I. After inhibition of trypsin with medium A containing 
0.1mg/ml trypsin inhibitor (Sigma-Aldrich), 20% fetal calf serum (FCS) and 
1000U/ml DNAse I, the cells were centrifuged for 10 minutes at 800 rpm. 
Single cell suspensions were seeded in T75cm
2  culture flasks (Greiner) 
containing Dulbeccos’s Modified Eagles’s Medium (DMEM) containing 
10%FCS, 1%glutamine, 1% sodium pyruvate and primocin. After 7-10 days in-
vitro, the mixed glial cultures were placed overnight on a shaker (150rpm) at 
37°C and the following day the non-adherent glial cells were removed. Next, 
astrocytic monolayers were carefully separated from the underlying adherent 
microglia by a mild trypsinisation step and plated in new T75cm
2 tissue culture 
flasks. In the following weeks, the overnight shaking and trypsinisation steps 
were repeated until pure astrocyte cultures (>98%) were obtained. 
Primary murine oligodendrocyte culture: T 75cm
2 flasks containing mixed glial 
culture were shaken overnight and 37°C. Subsequently, the supernatant 
containing detached cells were passed through a cell strainer (70 μm pore size; 
Falcon, Franklin Lakes, NJ). Following centrifugation at 2000rpm, the pellet 
was resuspended in culture medium and plated in uncoated culture dishes for 
30 minutes. Microglia and astrocytes attached to the bottom of the culture dish 
while oligodendrocyte precursor cells (OPCs) remained floating. In consecutive 
turns the floating cells were transferred from one culture dish to another until a 
pure (>95%) OPC culture was obtained. Following centrifugation, the primary 
OPCs were cultured in SATO medium consisting of DMEM with additives: 
glutamax (1%), putrescine (16µg/ml; Sigma), thyroxin (T4, 400ng/ml; Sigma), 
triiodothyroxin (T3, 400ng/ml; Sigma), progesterone (6.2ng/ ml; Sigma), sodium 
selenite (5ng/ml; Sigma), bovine serum albumin (BSA, 100µg/ml; Sigma), 
insulin (5µg/ml; Sigma), transferrin (50µg/ml; Sigma),  B27 (2%) and primocin 
(100μg/ml). During the first 2 days of culture, SATO medium was 
supplemented with Sonic hedgehog (Shh, 100ng/ml; R&D Systems, Abington, 
U.K) and platelet-derived growth factor (PDGF-α, 10ng/ml; R&D Systems). 
During subsequent culturing the OPCs differentiated and maturated along 
standard stages: oligodendroblasts, immature oligodendrocytes and mature 
oligodendrocytes. Thus suspensions of each stage cell type were obtained by 
culturing cells in SATO medium for 24 hours (OPCs), 48 hours 
(oligodendroblasts), one week (immature oligodendrocytes) and 3 weeks Ezh2 in neural stem cells 
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(mature oligodendrocytes), respectively. Medium was refreshed after every 
second day. 
Primary murine cortical neuronal culture:  Cultures of cortical neurons were 
established as described previously(Biber et al., 2001). In brief, cortices of 
C57/Bl6 embryonic day 17 embryos were excised and collected in ice-cold 
HBSS supplemented with 30% glucose. Meninges were removed and brain 
tissue was dissociated by trituration in Neurobasal/B27 medium (supplemented 
with 0.4% glucose, 2 mM L-glutamine, 0.01% penicillin/streptomycin) and 
filtered through a cell strainer. After one washing step, cells were seeded on 
poly-D-lysine (10μg/ml)-coated six well plates and maintained in Neurobasal/ 
B27 medium for 7 days in a humidified atmosphere (5% CO2/95% air) at 37°C. 
Oligodendrocyte cell lines: three oligodendrocyte cell lines were used: Oli-neu, 
N19 and N20.1. N19 and N20.1 (kindly provided by dr. M.J. Leroy, University 
Rene Descartes, Paris, France) were cultured on poly-L-lysin coated tissue 
culture flasks at permissive temperature (34°C) in DMEM:F12 medium, 
supplemented with 10% FCS, 1%glutamine and 1% penicillin/streptomycine. 
The Oli-neu cell line (kindly provided by dr. J. Trotter, Johannes Gutenberg 
University of Mainz, Germany) was also cultured on poly-L-lysine coated cell 
culture flasks in SATO medium with 1% horse serum at 37°C. N19 and N20.1 
differentiation was induced by culturing these cells at non permissive 
temperature (39°C) with 1%FCS; 1mM dibutyryl cyclic AMP (dbcAMP) was 
added for differentiation induction of the Oli-neu cells. 
3.3. Gene transfection of NSCs 
Overexpression of Ezh2 was induced using the Ezh2 expression vector (Ezh2 
in pCMV-SPORT 6, Open Biosystem) and Ezh2 expression was silenced by 
using Ezh2 shRNA plasmid DNA constructs with the following sequence: 
CCGGGCGTATAAAGACACCACCTAACTCGAGTTAGGTGGTGTCTTTATAC
GCTTTTTG. (Sigma MISSION® DNA  NM_007971). All gene transfections 
were performed using an electroporesis based transfection protocol (Amaxa 
GmbH, Cologne, Germany) specifically designed for the transfection of 
embryonic mouse NSCs by Amaxa®. Using accutase, neurospheres were 
dissociated and 3-5x10
6  cells were transfected with 10μg DNA of the 
overexpression vector or 3μg of the shRNA plasmid DNA vector. For control 
transfections, the same vector containing DNA encoding green fluorescent 
protein (eGFP) was used. Following transfection, the NSCs were kept for 24 
hours (shRNA) and 72 hours (pCMV-SPORT 6) in a humidified 5% CO2/95% 
air incubator at 37°C in Neurobasal medium supplemented with B27 and 1% 
FCS. The transfection efficiency of this procedure for mouse NSCs amounted 
to 60-80% and results in the transient expression of the transfected gene 
lasting up to 10-12 days (Balasubramaniyan et al., 2004). Ezh2 expression Chapter 2 
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after transfection was established at RNA level (with RT-PCR) and at protein 
level (with Western Blotting), subsequently, NSCs were plated in poly-L-
lysin/laminin coated chamber slides (Nunc) to study the differentiation pattern. 
3.4. Western Blot analysis 
SDS-PAGE gel electrophoresis and Western Blot analysis was used to detect 
Ezh2 protein expression in undifferentiated NSCs and different neural cell 
types. Following centrifugation cells were re-suspended in Radio Immuno 
Precipitation Assay (RIPA) buffer along with a cocktail of protease inhibitors. 
Re-suspensions were sonicated for 5 seconds and centrifuged for 10 min at 
12000 RPM and 4°C. Pellets were discarded; supernatants were mixed with 
Laemmli Buffer and boiled for 5 minutes. Proteins were separated for 1,5h on a 
10% SDS-polyacrylamide gel electrophoresis apparatus (Biorad). 
Subsequently, proteins were transferred to nitrocellulose membranes using 
semi-dry transfer buffer (25mM Tris, 150mM glycin, 10% (v/v) methanol) and 3 
mA/cm
2 current for 45-50 minutes. Nitrocellulose membranes were blocked 
with 3% milk in TBS-T (0,1% Tween-20) for 1h at room temperature. 
Membranes were probed overnight at 4°C using mouse anti-Ezh2 antibody (BD 
Transduction Lab, Cat. No. 612666) at 1:1000 dilution in blocking solution and 
mouse anti-β-actin (Abcam, ab6276) at 1:5000 dilution. (The housekeeping 
gene  β-actin was used for normalization of Ezh2 expression levels). 
Membranes were washed four times with TBS-T, 10 min each. Primary Ezh2-
antibody and anti-β-actin antibody were detected using horseradish peroxidase 
(HRP)-conjugated anti-mouse IgG (Dako, Code No. P0260). Incubation with 
secondary antibody was performed for 1h at room temperature at 1:10000 
dilutions in blocking solution. After four times washing in TBS-T, protein signals 
were detected by enhanced chemiluminescence detection system (Amersham 
Biosciences). Signals were visualized on X-ray film (Konica Minolta) and 
quantified. The intensities of the protein signals were quantified using Image J 
software. Measured intensities (pixel-counts) of β-actin were used to normalize 
the intensities of the Ezh2 signals. Normalized intensities of Ezh2-samples 
were used to calculate the relative expression level of Ezh2. Statistical analysis 
of the results of 3 experiments was done using Student’s t-test.  
3.5. RT-PCR analysis 
RT-PCR and real time quantitative PCR (qPCR) of Ezh2 expression was 
performed on mRNA collected from pooled undifferentiated NSCs, from pooled 
NSCs after differentiation and from various differentiated neural cell types. For 
RT-PCR the following primer pair for Ezh2 was used: FW 5’-GTC GGT GCA 
AAG CAC AAT GC-3’ BW 5’AGC TCC ACA CGT CAG ACA GAGG-3’. qPCR 
was performed using the primer pair: FW 5’-TGG ACC ACA GTG TTA CCA 
GCA-3’ BW 5’-TGG GCG TTT AGG TGG TGT CT-3’. PCR amplification was Ezh2 in neural stem cells 
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performed using SYBR Green, in 96-well microtiter plates in an iCycler thermal 
cycler (Bio-Rad, Hercules, CA). The ∆CT method by means of three reference 
genes (β-actin, HPRT1 and GAPDH) was used to perform the relative 
quantification among NSCs, different neural cell types and OPC lines. To 
calculate the relative expression, Ezh2 expression was normalized using a 
reference gene in each sample (2
CT(reference – CT(target)).The resulting expression 
values obtained (figure 2f) were indicated in relation to the expression in NSCs 
(=1). 
3.6. Immunocytochemistry 
After culture periods of up to 5 days, NSC cultures were fixated with 4% 
paraformaldehyde and immunostained for markers of various neural cell types 
at various differentiation stages. 
The following antibodies were used to identify neurons: anti-microtubule-
associated protein2 (MAP-2) (1:500, Chemicon, AB5622) and astrocytes: anti-
glial fibrillary acidic protein (GFAP) (1:250, Chemicon, MAB3402). The different 
cell stages of differentiation into oligodendrocytes were identified by: anti-RIP 
(1:250, Chemicon, MAB1580), anti-platelet derived growth factor receptor 
alpha (PDGFR-α) (1:250, Santa Cruz Biotechnology Inc.), anti-NG2 (1:500, 
chondroitin sulfate proteoglycan, Chemicon, AB5320), anti-galactocerebroside 
(Galc) (1:250, Chemicon, MAB 342) and anti-myelin basic protein (MBP) 
(1:500, Chemicon, AB980). Undifferentiated NSCs were identified with anti-
nestin. Expression of Ezh2 in NSCs and neural cell types was analyzed by 
using anti-Ezh2 (1:250, BD Transduction Laboratories, 612666). Freshly 
differentiated astrocytes (astroblasts) were recognized using anti-S100β 
(1:400, ICN, 11420), while young neuroblasts were labeled with anti-PSA-
NCAM (1:300, Chemicon, MAB5324) or anti-doublecortin (DCX) (1:500, 
Chemicon, AB5910). FITC- or Cy3-conjugated secondary antibodies and 
Hoechst nuclear staining were used to identify the labeled and unlabeled cells. 
3.7. Microscopy analysis 
Quantitative analysis of the cell differentiation pattern of NSCs without or after 
Ezh2 expression modulation was performed using a Leica (SP2 AOBS) 
Confocal Laser Scan Microscope or a Zeiss (Axioskope 2) Fluorescent 
Microscope equipped with a Leica DFC300FX camera and the Leica 
microsystem LAS program.  
For differential cell type counting, based on cell type specific immuno (double) 
staining, pictures at 10 x magnifications were made of five randomly selected 
areas in the culture dish. Differential cell count analyses were done using 
Image J software. Statistical analysis of the results of 3 experiments was 
performed using Student’s t-test. 
 Chapter 2 
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4. RESULTS 
4.1. Expression of Ezh2 in mouse embryonic neural stem cells  
Neural stem cells (NSCs) isolated from E14 mice were cultured in EGF- and 
bFGF-supplemented medium to maintain their undifferentiated state and to 
promote their proliferation resulting in cell aggregates, the neurospheres (figure 
1a). 
 
 
 
Figure 1 - Expression of Ezh2 in mouse embryonic neural stem cells (NSCs). (a-a’’’) After 
dissociation of the neurospheres, immunohistochemical staining shows that the individual nestin-
positive NSCs (red fluorescence in cytoplasm) express Ezh2 (green fluorescence in nucleus); 
nuclear staining with Hoechst = blue. (b-b”) The presence of Ezh2 in all NSCs was associated with 
trimethylation of lysine 27 in histone 3, as demonstrated with an antibody directed against 
H3K27me
3. Bars: 50μm 
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To detect Ezh2 expression in individual NSCs, we dissociated the 
neurospheres and fixated them to perform immunohistochemistry. All of the 
nestin-positive NSCs appear to express Ezh2 (figure 1b). Moreover, all NSCs, 
in accordance with the known activity of Ezh2, showed immunostaining for 
trimethylated lysine 27 histone H3 (H3K27me
3) (figure 1c). 
4.2. Expression of Ezh2 during differentiation of mouse embryonic neural 
stem cells  
Plating dissociated mouse E14 NSCs in Neurobasal medium in poly-L-
lysine/laminin coated culture dishes resulted within 5 days in differentiation 
towards neurons, astrocytes and oligodendrocytes.  
 
 
 
Figure 2 - Expression of Ezh2 in mouse embryonic neural stem cells (NSCs) after differentiation. 
(a) NSCs differentiating into (GFAP-positive) astrocytes completely down regulate the expression 
of Ezh2, while (b) those differentiating into (MAP2-positive) neurons show a prominent reduction in 
Ezh2 expression. (c) However, NSCs differentiated into an oligodendrocyte cell lineage (RIP-
positive) maintain about the same level of expression of Ezh2 as undifferentiated NSCs (c’ insert 
shows same cells only stained for Ezh2, arrows). (d-d’) Western Blot analysis and quantification on 
pure populations of primary undifferentiated NSCs, astrocytes (astro), neurons (neuro), and 
(premyelinating) oligodendrocytes (oligo) confirmed the findings observed in the mixed cell cultures 
of differentiated NSCs. (e) RT-PCR on pure suspensions of NSCs, primary astrocytes (astro), 
neurons (neuro), (premyelinating) oligodendrocytes (oligo) and 3 oligodendrocyte cell lines, i.e. 
N19, N20.1 and Oli-neu cells (u=undifferentiated, d=differentiated) revealed the same pattern for 
Ezh2 mRNA as demonstrated at the protein level in Western Blots (f) Bar in a-c: 50μm. 
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Double immunostaining for neural cell types and Ezh2 revealed the cell specific 
expression of Ezh2: differentiation into astrocytes was accompanied by an 
almost complete down regulation of the Ezh2 expression (figure 2a) and also 
during neuronal differentiation Ezh2 expression was significantly reduced 
(figure 2b). However, in NSCs that differentiated into an oligodendrocytic cell 
lineage, Ezh2 expression remained at an almost similar level as in 
undifferentiated NSCs (figure 2c). 
Western Blot analysis and quantification on pure populations of primary 
undifferentiated NSCs, astrocytes, neurons, and (premyelinating) 
oligodendrocytes confirmed the findings observed in the mixed cell cultures of 
differentiated NSCs (figure 2d and e). 
Moreover, analysis at mRNA level, using RT-PCR, on pure suspensions of 
NSCs, primary astrocytes, neurons, and (premyelinating) oligodendrocytes 
revealed the same pattern of Ezh2 expression as demonstrated at the protein 
level (figure 2f); the specific expression of Ezh2 during differentiation into 
oligodendrocyte cell lineage was further confirmed in 3 oligodendrocyte cell 
lines, i.e. N19, N20.1 and Oli-Neu cells (figure 2f). 
4.3. Overexpression of Ezh2 in mouse embryonic neural stem cells  
In order to investigate the involvement of Ezh2 in the differentiation process of 
mouse E14 NSCs, we have induced transient over expression of Ezh2; 
increase in intracellular Ezh2 levels was confirmed using Western Blot analysis 
(figure 3a-a’). Plating Ezh2-overexpressing NSCs for differentiation resulted in 
a significant change of the differentiation pattern in comparison to eGFP-
transfected control NSCs. Besides a slight increase in the number of neurons, 
Ezh2-overexpression in differentiating NSCs resulted in a reduction in the 
number of astrocytes and a significant increase in the number of 
oligodendrocytes (figure 3b-d). 
4.4. Silencing of Ezh2 expression in mouse embryonic neural stem cells 
In addition, we have reduced the intracellular level of Ezh2 in mouse E14 NSCs 
using transfection of short hairpin silencing RNA (shRNA) (figure 4a-a’) and 
studied its effect on NSC proliferation and differentiation. Silencing of Ezh2 in 
undifferentiated NSCs appeared to reduce or slow down their proliferation, 
since the size of neurospheres 24 hours after plating was significantly smaller 
(data not shown). 
Differentiation of NSCs in which the Ezh2 level was reduced by silencing, 
resulted in an inverse differentiation pattern compared to NSCs over 
expressing Ezh2. 
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Figure 3 - Over expression (OE) of Ezh2 in mouse embryonic neural stem cells (NSCs). (a-a’) 
Western blot analysis shows the significant increase in Ezh2 expression due to Ezh2 gene 
transfection. (b-c) Overviews of immunohistochemical stainings for RIP (b,b’) and GFAP (c,c’)   
showing the effect of Ezh2 overexpression (OE) on the in-vitro differentiation of NSCs in 
respectively oligodendrocytes and astrocytes in comparison to controls (b,c) (Bars: 50μm) (d) 
Quantification of the differentiation pattern of NSCs with Ezh2 overexpression (OE) shows a 
significant reduction in astrocyte number and significant increase in the number of 
oligodendrocytes (means of 3 independent experiments ± standard error, ***p< 0.001; *p< 0.05, 
Student T-test). 
 
 
 
 
Figure 4 - Silencing of the Ezh2 expression in mouse embryonic neural stem cells (NSCs). (a-a’) 
Western blot analysis shows the significant decrease in Ezh2 expression in NSCs. (b-c) Overviews 
of immunohistochemical stainings for RIP (b,b’) and GFAP (c,c’) showing the effect of Ezh2 
silencing on the in-vitro differentiation of NSCs in respectively oligodendrocytes and astrocytes in 
comparison to controls (b,c) (Bars: 50μm) (d). Quantification of the differentiation pattern of NSCs 
with reduced Ezh2 expression shows a significant reduction in the number of oligodendrocytes and 
a significant increase in astrocyte differentiation (means of 3 independent experiments ± standard 
error; ***p<0.001; *p< 0.05; Student T-test). 
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Thus silencing Ezh2 in differentiating NSCs significantly reduced the number of 
oligodendrocytes and promoted the generation of astrocytes, whereas the 
number of neurons was slightly decreased (figure 4b-d).  
4.5. Involvement of Ezh2 in oligodendrocyte generation 
The increase in the number of oligodendrocytes differentiating from Ezh2 over 
expressing NSCs may be due to selective survival, selective stimulation of 
OPC proliferation or/and a direct oligodendrocyte differentiation stimulating 
effect. As far as selective survival is concerned, no differences in cell death 
(number of apoptotic cells) was observed between differentiating control NSCs 
and Ezh2-overexpressing or silenced NSCs (data not shown).    In order to 
determine whether the increase in the number of oligodendrocytes after 
differentiation of Ezh2-overexpressing NSCs, could be ascribed to a selective 
Ezh2-mediated stimulation of proliferation of freshly formed OPCs, we 
examined the proliferative activity of the PDGFrec-positive OPCs with the use 
of the mitosis marker KI67 (figure 5). Indeed, Ezh2 overexpression significantly 
doubled the proliferation of OPCs (figure 5a); Ezh2 silencing, in contrast, 
significantly reduced OPC proliferation (figure 5b) 
 
 
 
Figure 5 – Oligodendrocyte precursor cell (OPC) proliferation and Ezh2 expression. (a) 
Overexpression of Ezh2 in freshly differentiated OPCs stimulates their proliferation, while silencing 
of Ezh2 expression (b) results in a decrease of proliferating OPCs. (Means of 3 independent 
experiments ± standard error; ***p< 0.001, Student-T test) 
 
4.6. Ezh2 expression during oligodendrocyte differentiation of mouse 
embryonic neural stem cells 
Apart from a role for Ezh2 in regulating OPC proliferation, its selective 
expression in oligodendrocytic cell lineage may still point to the involvement in 
oligodendrocyte differentiation and maturation. 
We examined the expression of Ezh2 at subsequent stages of oligodendrocyte 
differentiation and maturation (figure 6a) in more detail by performing double 
immunolabeling for Ezh2 and marker proteins of specific oligodendrocyte  Ezh2 in neural stem cells 
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Figure 6 - Expression of Ezh2 during various stages of in-vitro differentiation of mouse embryonic 
neural stem cells (NSCs). (a). Schematic drawings of the stages of oligodendrocyte differentiation 
(appearing after indicated days-in-vitro, D.I.V.)  that are shown in figures b-e, immunostained (red 
fluorescent) for PDGF receptor alpha, NG2, RIP and BMP respectively. Double staining of these 
stages for Ezh2 (green fluorescent, singular Ezh2 staining in b’-e’) shows that Ezh2 is expressed 
during all stages of oligodendrocyte differentiation but not in the mature oligodendrocytes. (f). 
Western blot analysis of Ezh2 expression in the various oligodendrocyte stages confirms the 
immunohistochemical findings. (g-i). Double immunostaining for Ezh2 and DCX (g), PSA-NCAM (h) 
and S100β (i), shows that respectively early neuroblasts (g-h) and freshly formed astroblasts (i) do 
not express Ezh2 (Hoechst staining: blue) (Bar in g for g-i: 50μm) 
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differentiation stages taken at different time-points during oligodendrocyte 
differentiation/maturation.  
Besides the early oligodendrocyte precursor cell (OPC) stage we subsequently 
distinguished the oligodendroblast, the immature and the mature 
oligodendrocyte stage. Cell proliferation could only be detected in the short 
OPC stage. Ezh2 expression was evident from the OPC stage up to the 
immature oligodendrocyte stage, but was down regulated in the mature 
(myelinating) oligodendrocyte characterized by the start of myelin basic protein 
(MBP) production (figure 6b-e). 
Western Blot analysis at different stages of oligodendrocyte differentiation 
confirmed the immunocytochemical findings (figure 6f). The specific expression 
of Ezh2 in differentiating oligodendrocytes may merely reflect a difference in 
the efficiency and speed to differentiate in-vitro in comparison to differentiating 
astrocytes and neurons. Ezh2 expression in undifferentiated NSCs may just 
gradually disappear during differentiation and, consequently, in cell types with 
an extended differentiation pathway (oligodendrocytes) it can be detected 
longer than in cell types (astrocytes, neurons) with a short differentiation 
pathway.  
Therefore, we have tried to detect Ezh2 at the earliest stages of astrocyte and 
neuron differentiation, using specific early markers, such as S100β (for freshly 
formed astrocytes) and doublecortin (DCX) and PSA-NCAM for young 
neuroblasts. In both cases the expression of Ezh2 was not detectable (figure 
6g-i). 
 
5. DISCUSSION 
Our studies show that neural stem cells (NSCs) derived from E14 mouse brain 
express the polycomb group protein (PcG) Ezh2. Whereas Ezh2 expression in 
NSCs is downregulated upon differentiation into neurons and particularly in 
astrocytes, surprisingly, its expression remains at a high level in freshly 
differentiated proliferative oligodendrocyte precursor cells (OPCs), at 
subsequent stages of oligodendrocyte differentiation and only disappears in 
mature oligodendrocytes. Interference with Ezh2 expression in NSCs during 
proliferation and differentiation reveals the involvement of Ezh2 in the 
regulation of NSC and OPC proliferation and presumably in oligodendrocyte 
differentiation and maturation.  
A number of studies have shown that PcG proteins are important for the 
maintenance and self-renewal of embryonic stem cells and various adult stem 
cells, e.g. haematopoietic stem cells, muscle precursor cells, and NSCs 
(Azuara et al., 2006; Boyer et al., 2006; Rajasekhar and Begemann, 2007; 
Sparmann and van, 2006). In general, in line with its function described for the Ezh2 in neural stem cells 
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development of Drosophila, the PcG repressor complexes repress the 
transcription of gene programs encoding differentiation into a specific cell 
lineage and retain stem cells in a proliferative stage. It has been shown, for 
instance, that the proliferation of haematopoietic stem cells is regulated by a 
balance between the PRC2 and PRC1 components Eed and Bmi1 (Iwama et 
al., 2004; Lessard et al., 1999), whereas overexpression of Ezh2 preserves the 
long term repopulating potential of these cells over serial transplantation 
preventing aging and exhaustion (Kamminga et al., 2006). The PcG protein 
Bmi1, a component of PRC1, has been shown to be involved in the 
maintenance and proliferation regulation of adult NSCs (Iwama et al., 2004; 
Lessard et al., 1999; Leung et al., 2004; Molofsky et al., 2003; Molofsky et al., 
2005); besides severe proliferation defects during haematopoiesis, Bmi1-
deficient mice exhibit aberrant transformations coupled with acute neurological 
disorders (van der Lugt et al., 1994). In a laser capture microdissection and 
microarray analysis (Gurok et al., 2007) high Ezh2 expression was detected 
selectively in proliferating adult NSCs in the hippocampus (Gurok et al., 2007). 
Our present findings on the expression of Ezh2 in undifferentiated proliferating 
NSCs in-vitro and its downregulation upon differentiation into astrocytes and 
neurons, seem to be in accordance to a potential role in the regulation in NSC 
self-renewal and maintenance of stemness. 
Unexpectedly, differentiation of NSCs into oligodendrocytes did not result in the 
downregulation of Ezh2 expression. The expression of Ezh2 in OPCs may 
reflect the multipotency ascribed to rat OPCs by Kondo and Raff (Kondo and 
Raff, 2000; Kondo and Raff, 2004). They showed that, with proper extracellular 
stimuli, cultured rat OPCs could be dedifferentiated back towards type 2 
astrocytes, which subsequently could be stimulated to proliferate and to 
behave like NSCs, producing neurons, astrocytes and oligodendrocytes. In 
order to further establish a potential role of Ezh2 in OPC multipotency, it may 
be relevant to correlate Ezh2 downregulation in rat OPCs with loss of 
multipotency (the Kondo/Raff protocol to induce OPC multipotency appeared to 
be ineffective in our cultured mouse OPCs). Ezh2 over expression and 
silencing in differentiating NSCs resulted in an increase and a reduction of the 
number of oligodendrocytes respectively. Since no indications were found for 
differences in selective cell death, the increase in oligodendrocytes 
differentiating from overexpressing Ezh2 must be ascribed to selective 
stimulation of OPC proliferation or/and a direct oligodendrocyte differentiation 
stimulating effect. The observed increase in proliferation of OPCs by Ezh2, 
seems to be in line with the role of Ezh2 in self-renewal and proliferation 
described in other stem cell types, e.g. haematopoietic stem cells. Whether the 
proliferation of OPCs is regulated by a balance between the PRC2 and PRC1 Chapter 2 
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components as in haematopoietic stem cells (Lessard et al., 1999), still has to 
be elucidated but sofar we were unable to detect Bmi1 expression in 
proliferating OPCs (unpublished data). 
Besides high expression in OPCs, Ezh2 remained up regulated during the 
subsequent stages of oligodendrocyte differentiation, i.e. in oligodendroblasts 
up to immature (premyelinating) oligodendrocytes arising in culture around day 
14. Ezh2 expression is only down regulated at the time the oligodendrocyte 
reaches its mature myelination stage. The likely different role of Ezh2 in 
proliferating OPCs and in oligodendrocyte differentiation may point to different 
target genes or to differences in the composition and activity of the PRC 
complexes involved. The process of differentiation into an oligodendrocyte cell 
lineage is prominently associated with gene de-repression, i.e. the silencing of 
oligodendrogenic gene repressors (Shen and Casaccia-Bonnefil, 2008). The 
presence of an Ezh2 PRC2 complex in differentiating oligodendrocytes is in 
line with the findings that this complex has been linked to recruitment of histone 
deacetylase activity (Chopra and Mishra, 2005) and that histone deacetylase 
activity is essential for oligodendrocyte differentiation and maturation (Marin-
Husstege et al., 2002). PRC2 initiates transcriptional repression and in that 
process the Ezh2-mediated H3K27 trimethylation leads to the recruitment of 
PRC1 which is thought to maintain repressive conditions. Indeed, Ezh2-
mediated H3K27 trimethylation could be demonstrated in NSCs and OPCs, but 
the recruitment of PRC1, subsequent continuous gene transcription repression, 
and the genes targeted have yet to be demonstrated. Three studies (Boyer et 
al., 2006; Bracken et al., 2006; Lee et al., 2006) have described that the most 
prominent target gene repressed via the PRC2 complex in embryonic stem 
cells is Olig2. Since Olig2 is a gene crucially involved in oligodendrocyte 
specification (Copray et al., 2006; Du et al., 2006; Zhou et al., 2001), it seems 
unlikely that this gene is repressed via Ezh2 and subsequent PRC1 recruitment 
in the oligodendrocytic cell lineage generated in NSCs. It has been 
demonstrated that the actual recruitment of PRC1 by the PRC2 complex is 
dependent on  the composition of the PRC2 complex and the properties of the 
components involved: a number of Ezh2 PRC2 complexes has been identified, 
which can contain for instance at least four different Eed isoforms (Cao and 
Zhang, 2004; Cao et al., 2005), differently interacting with Ezh2 and leading to 
different recruitment strategies of PRC complexes, besides PRC1, also PRC3 
and 4. The composition of the PRCs, their histone substrate specificity, and so 
the action mediated via Ezh2 is highly dynamic and distinct at different stages 
in cell differentiation (Kuzmichev et al., 2005; Kouzarides, 2007). They may 
differentially regulate the expression of the different transcription factors that Ezh2 in neural stem cells 
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determine the transition from one stage of differentiation into the next during 
OPC maturation (Nicolay et al., 2007) . 
In conclusion, our data show for the first time the involvement of the Polycomb 
group protein Ezh2 in proliferation and differentiation of NSC-derived 
oligodendrocytes. The challenge for further research would be to unravel the 
complex molecular mechanisms underlying the regulation by Ezh2 and other 
PcG proteins during the differentiation and maturation of oligodendrocytes. 
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1. ABSTRACT 
The polycomb group protein Ezh2 is a major epigenetic repressor of gene 
transcription originally found to prevent untimely differentiation of embryonic 
stem cells. Recently we demonstrated that Ezh2 is expressed in neural stem 
cells (NSCs) and downregulated during their differentiation into astrocytes or 
neurons. However, high levels of Ezh2 were still present in differentiating 
oligodendrocytes until the myelinating stage. In this study we show Ezh2 
expression in premyelinating oligodendrocytes (pOLs) during remyelination in 
cuprizone model. To detect the target genes of Ezh2 in NSCs and in pOLs, we 
performed chromatin immunoprecipitation followed by massive parallel high-
throughput sequencing (Chip-Seq). We found 293 and 175 unique Ezh2 target 
genes in NSCs and pOLs, respectively, with only 29 genes shared by both cell 
types. Analysis of these target genes indicate that in NSCs the repressive 
activity of Ezh2 is mainly targeted to genes involved in cell cycle control and 
differentiation while in pOLs Ezh2 mainly represses genes associated with 
committed neuronal and astrocytic cell lineage. Suppression of Ezh2 activity in 
NSCs blocks their proliferation and ultimately results in NSC apoptosis. 
Derepression of cell cycle control genes Cdkn2a and Tcf21, and derepression 
of Gdf6 and Gdf7, activators of TGF-beta signaling, appears to be the 
underlying mechanism for these effects in NSCs. Suppression of Ezh2 activity 
in pOLs resulted in blockage of their differentiation and ultimately in apoptosis. 
Derepression of Wnt7b and Smo, resulting in the activation of Wnt signaling, of 
Ttc21b, resulting in aberrant Shh signaling, and of the NMDA subunits Grin2a 
and 2b, causing glutamate hypersensitivity in the pOLs, seems to be 
responsible for that.  
Our results demonstrate the indispensibility of Ezh2 for NSC maintenace and 
selfrenewal and its role in promoting oligodendrocyte differentiation. Chapter 3 
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2. INTRODUCTION 
Multipotent neural stem cells (NSCs) give rise to neurons, astrocytes and 
oligodendrocytes. Insight in the molecular regulatory mechanisms underlying 
NSC selfrenewal and differentiation into each of these celltypes is of 
fundamental importance for understanding proper brain development, for 
explaining brain tumor formation and for application of NSCs in regenerative 
therapies for various neurodegenerative disorders. 
The differentiation of NSCs into a specific neural cell type is ultimately 
determined by interplay between extrinsic and intrinsic factors. Several 
signaling pathways are intricately involved in triggering a distinct set of 
transcription factors, which in turn set off the transcription of genes that 
determine a specific neural cell type. In case of neuronal differentiation, 
besides active transcription of neuronal genes, it is essential that the 
transcription of genes encoding for a glial fate is suppressed and, in case of 
glial cell differentiation, vice versa (Fan et al., 2005; Song and Ghosh, 2004; 
Nakashima et al., 2001; Hirabayashi and Gotoh, 2010).  It has become clear 
that epigenetic programming is implicated in specifying the fate of NSCs, in 
particular, in the silencing of genes that encode for alternative cell fates 
(Nakashima et al., 2009). Polycomb group (PcG) proteins have emerged as 
central players in such repressive epigenetic programming events.  
PcG proteins were originally identified in Drosophila melanogaster (D. 
melanogaster) as factors necessary to preserve cell-fate decisions throughout 
embryogenesis by silencing Hox  genes in a body-segment-specific manner 
(Kennison, 1995; Schwartz et al., 2004). PcG proteins are transcription 
repressors that function by modulating chromatin structure of target genes by 
altering higher-order chromatin structure (Schwartz and Pirrotta, 2007; 
Sparmann and van, 2006). Hundreds of genes are silenced by polycomb 
proteins, including dozens of genes that encode crucial developmental 
regulators in organisms ranging from plants to human (Simon and Kingston, 
2009). 
PcG proteins are structurally and functionally diverse and form large multimeric 
complexes of two general types: Polycomb repressive complex-1 (PRC1) and -
2 (PRC2)(Ringrose and Paro, 2004). Biochemical purification of PRC1 from 
mammalian cells has revealed the presence of a number of subunits including 
BMI1/MEL18, RING1A/RING1B/RNF2, hPC 1–3, hPH1–3, and YY1, among 
others (Levine et al., 2004). PRC2 contains Eed, Suz12, and the 
methyltransferase Ezh2 that catalyzes histone H3 lysine 27 trimethylation 
(H3K27me3)(Cao and Zhang, 2004; Shen et al., 2008). Both Suz12 and Eed 
are required for complex stability and for the methyltransferase activity of the 
Ezh2 (Pasini et al., 2004). A common contention of the current models is that Ezh2 target genes during NSC differentiation 
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PRC2 initiates transcriptional repression, whereas PRC1 maintains the 
repressive state. Ezh2-mediated H3K27 methylation is required for the function 
of PRC1 and ultimate target gene silencing (Cao et al., 2005). Ezh2-mediated 
transcriptional silencing depends upon its evolutionarily conserved catalytic 
SET domain, which imparts histone methyltransferase activity to the complex 
(Cao and Zhang, 2004). Functional mutations in the components of PRCs 
eradicate the aptitude of embryonic stem (ES) cells to be pluripotent (Surani et 
al., 2007; Boyer et al., 2006). Indeed, genome-wide chromatin 
immunoprecipitation (ChIP) studies and other approaches have greatly 
expanded our knowledge of the PRCs and it has become evident that 
transcription factors and signaling components with key roles in cell fate 
decisions are the most frequent PRC2 targets in a wide variety of 
organisms(Simon and Lange, 2008). 
Ezh2, the crucial catalytic component of PRC2 has received considerable 
attention during recent years. In accordance with the suggested function of 
PRC2 in maintaining ES pluripotency and ES self-renewal, Ezh2 is highly 
expressed in ES cells and down regulated during differentiation towards 
somatic cells (O'Carroll et al., 2001). Using a conditional knockout strategy, 
Ezh2 was also shown to be required for H3K27me3 formation in pluripotent 
epiblast cells that ultimately give rise to derivatives of the three germ layers 
(Erhardt et al., 2003). In addition to its role in early embryonic development, 
Ezh2 has also been implicated in the maintenance and self-renewal of adult 
multipotent stem cells. For example, Ezh2 has been shown to preserve the 
long-term repopulating potential of haematopoietic stem cells in serial 
transplantation experiments (Kamminga et al., 2006). In muscle tissue, Ezh2 
appears to be necessary for maintaining the population of muscle cell 
precursors called myoblasts (Caretti et al., 2004). 
Recently, we have demonstrated the expression of Ezh2 in embryonic neural 
stem cells (Sher et al., 2008). Its expression in undifferentiated NSCs and 
subsequent downregulation during the differentiation into neurons or 
astrocytes, suggested a role of Ezh2 in the maintenance and self-renewal of 
these multipotent stem cells. Surprisingly, Ezh2 remained highly expressed in 
NSCs that differentiated toward the oligodendrocytic cell lineage. Ezh2 
expression was present in the proliferating oligodendrocyte precursor cells 
(OPCs) up to the stage of premyelinating oligodendrocytes (pOLs); in mature, 
myelinating oligodendrocytes Ezh2 expression was no longer detectable(Sher 
et al., 2008). The differentiation stages of OPCs are most strikingly 
characterized by derepression, i.e. silencing of repressors of oligodendrocyte 
cell lineage genes and myelination genes (Liu and Casaccia, 2010). In view of Chapter 3 
￿ ￿￿￿
its known repressor functions, Ezh2 may play a role in the repressive 
epigenetic mechanisms during oligodendrocyte differentiation.   
In order to further investigate the role of Ezh2 in undifferentiated NSCs and in 
the differentiation of oligodendrocytes, we have used chromatin 
immunoprecipitation and massive parallel sequencing (Chip-Seq: high-
throughput sequencing) to map the Ezh2 targets in NSCs and pOLs. Moreover 
we detected Ezh2 co-expression with other core componets of PRC2 complex 
in NSCs and pOLs. We observed higher expression of Ezh2 in pOLs during 
remyelination in curizone mouse model for demyelination. 
 
3. MATERIAL & METHODS 
3.1. Cell culture 
 Primary mouse neural stem cell culture:  Neural stem cells (NSCs) were 
isolated from the telencephalon of C57/BL6 mouse embryos at embryonic day 
14 (E14). Cells were cultured in T25 (Nunc, Roskilde) tissue culture flasks 
containing proliferation medium, consisting of Neurobasal medium 
supplemented with 2% B27, human recombinant epidermal growth factor 
(EGF; 20ng/ml), basic fibroblast growth factor (bFGF; 20ng/ml), 1% GlutaMAX 
(Invitrogen) Primocin (100 μg/ml; Lonza), and heparin (5 μg/ml; Sigma-Aldrich) 
in a humidified 5% CO2/95% air incubator at 37°C. Within 3–5 days the cells 
grew as free-floating neurospheres. NSC differentiation was induced by 
withdrawing growth factors (EGF & bFGF) and heparin from the proliferation 
medium.  
Primary murine oligodendrocyte cultures: Mixed glial cultures were established 
from the brains of postnatal C57/BL6 pups in T75 cm
2  tissue culture flasks 
containing Dulbecco's modified Eagle's medium (DMEM) with10% FCS.  After 
10-14 days in vitro, the mixed glial cultures were placed for one to two hours on 
a shaker (150 rpm) at 37°C. The non adherent microglia were removed. To 
obtain oligodendrocyte precursor cells (OPCs), cultures were placed on shaker 
again (240rpm) overnight at 37
oC. On the following day the supernatants were 
centrifuged and the pellets were resuspended in culture medium and plated on 
uncoated culture dishes for 30 minutes at 37
oC. Microglia and astrocytes 
attached to the bottom of the culture dish, whereas oligodendrocyte precursor 
cells (OPCs) remained floating. In consecutive panning steps the floating cells 
were transferred from one culture dish to another until a pure (90-95%) OPC 
culture was obtained. The primary OPCs were cultured in standard SATO 
medium. During the first 2 days of culture, SATO medium was supplemented 
with Sonic hedgehog (100 ng/ml; R&D Systems) platelet-derived growth factor 
(PDGF)-  (10 ng/ml; R&D Systems) and basic fibroblast growth factor (bFGF; 
20ng/ml). During subsequent culturing, the OPCs differentiated and maturated Ezh2 target genes during NSC differentiation 
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along standard stages. At pOLs stage (RIP positive) the cells were used for the 
Chromatin Immunoprecipitation. 
3.2. Cuprizone model for demyelination 
C57BL/6 mice were put on a diet of 0.2% (w/w) cuprizone (Sigma-Aldrich, 
Zwijndrecht, The Netherlands, http://www.sigmaaldrich.com), a copper 
chelator. This diet leads to selective oligodendrocyte death followed by 
demyelination of axons mainly in the corpus callosum (Matsushima and Morell, 
2001).  Spontaneous remyelination can be seen as early as four days after 
withdrawal of cuprizone. The corpus callosum was dissected under a 
dissection microscope from control, five weeks demyelinating and two weeks 
remyelinating animals. Tissue lysates were prepared with RIPA buffer. From 
the same experimental groups separate brains were prepared for 
immunohistochemistry.  
3.3. Chromatin Immunoprecipitation (ChIP) 
Cells (mouse NSCs and mouse pOLs) were crosslinked with 1% formaldehyde 
for 10 minutes, lysed in the lysis Buffer (5mM PIPES, 85mM KCl, 0.5% NP-40; 
Sigma), subsequently in nuclear lyses buffer (50mM TRIS, 10mMEDTA, 1% 
SDS) and sonicated in a sonicator (Sonics Vibracell) with 15x 15 sec, output 3, 
duty cycle 50. The chromatin was precleared with Protein A Agarose/Salmon 
Sperm DNA (Millipore). Precleared chromatin was rotated with 5ug of anti Ezh2 
antibody (Diagenode; PAB-039-100) overnight at 4 °C. Then, 80 ul of Protein A 
Agarose/Salmon Sperm DNA was added and rotated for 2 hours at 4 °C.   
Protein A/anti Ezh2/Ezh2-chromatin immune complex was washed once with 
low salt immune complex wash buffer (150mM NaCl, 0.1% SDS, 1% Triton X-
100, 2mM EDTA, 20mM TRIS), once with high salt immune complex wash 
buffer (500mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM TRIS), 
once with LiCl immune complex wash buffer (0.25M LiCl,1% NP-40, 1% Na-
deoxycholate, 1mM EDTA , 10mM TRIS) and twice with TE buffer. The 
immune complex was eluted by adding twice 250ul freshly prepared elution 
buffer (0.1M NaHCO3, 1% SDS). The DNA protein cross-links were reversed 
by heating, the proteins were removed by treatment with proteinase K. and 
DNA was precipitated using Phenol/chloroform/IAA method. 
Within each ChIP experiment a negative control immunoprecipitation was 
performed using 5ug of Polyclonal Rabbit Anti-mouse Immunoglobulins (IgG). 
To verify the ChIP conditions a qPCR control on genomic DNA (gDNA) was 
performed. The enrichment of gDNA (known Ezh2 target) in 
immunoprecipitated with anti Ezh2 antibody verses negative control (IP with 
isotype control) was calculated with following formula: FC = 2^(ddCT), FC.error 
= ln(2) * ddSD * FC. Where FC: fold change, CT is cycle threshold, SD: 
standard deviation and d stands for delta. Chapter 3 
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3.4. Chromatin Immunoprecipitation followed by Ultra High-throughput 
Sequencing (ChIP-Seq) 
The purified co-precipitated DNA was processed for analysis on the Illumina 
Cluster Station and Genome Analyzer using the Illumina ChIP-Seq sample 
preparation kit (IP-102-1001). Following the instructions on the kit ‘A’ bases 
were added to the 3’ End of the DNA fragments and fragments were ligated to 
Adapters. Subsequently, the Adapter-Modified DNA fragments were run on a 
2% agarose gel to generate the DNA libraries based on fragments length (200 
±25bp). Finally the Adapter-Modified DNA fragment libraries were enriched by 
PCR. After validating the libraries by Bioanalyzer, the sequencing reactions 
were performed with system components and reagents.  
The sequence reads from the Genome Analyzer were aligned (Reference 
assembly/Read mapping) against the C57/BL6 mouse genome (NCBI) and 
"contigs" were assembled by using CLC bio: Genomics Workbench software. 
Both a ChIP- and a control sample were used for assembling to produce 
separate ChIP and control contigs. These contigs were then used as input to 
the ChIP-Seq function of the CLC Genomics Workbench which surveys the 
pattern in coverage to detect significant peaks. 
Annotations and pathways analysis of the peaks were done either by manual 
search in the databases or by using online software including The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (Huang et al., 
2009; Dennis, Jr. et al., 2003) and Ingenuity Pathways Analysis (IPA) 
(http://www.ingenuity.com/). 
3.5. shRNA knockdown of Ezh2 in NSCs and pOLs 
Ezh2 expression was silenced in NSCs and pOLs by using Ezh2 short hairpin 
RNA (shRNA). To that purpose, we transfected the cells with the following 
plasmid DNA construct: 
5’CCGGGCGTATAAAGACACCACCTAACTCGAGTTAGGTGGTGTCTTTATA
CGCTTTTTG-3’ (Sigma-Aldrich). All gene transfections were performed by 
using an electroporation-based transfection protocol (Lonza) 
 (http://www.lonzabio.com/cell-biology/transfection/). 
3.6. Western Blot Analysis 
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western 
blot analysis were used to detect Ezh2 and other protein expressions in 
undifferentiated NSCs and OPCs. Cell lysates were made in nuclear lysis 
buffer/RIPA buffer, containing Protease Inhibitor Cocktail (Sigma). Protein 
samples were made in Laemmli sample buffer and boiled for 5 minutes. 
Proteins were separated for 1.5 hours on a 7.5-15% SDS-polyacrylamide gel 
electrophoresis apparatus (Bio-Rad). Subsequently, proteins were transferred 
to nitrocellulose membranes by using semidry transfer buffer (25 mM Tris, 150 Ezh2 target genes during NSC differentiation 
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mM glycine, and 10% [v/v] methanol) and 3 mA/cm2 current for one to two 
hours. Nitrocellulose membranes were blocked with Odyssey Blocking Buffer 
(www.licor.com). Membranes were probed with antibodies overnight at 4°C. 
The antibodies against housekeeping proteins were used for normalization of 
proteins of interest expression levels. Membranes were washed four times (10 
minutes each) with TBS-T. Primary antibodies were detected using fluorescent 
secondary antibodies incubation at room temperature for one hour. After four 
washes in TBS-T, protein signals were detected by using the Odyssey Infrared 
Imaging System. The intensities of the protein signals were quantified using 
ImageJ software (NIH Image, Bethesda, MD).    
Statistical analysis of the results of three experiments was done by using 
Student’s t test. 
The specification of the primary and secondary antibodies we used can be 
found in Supplementary Table 1. 
3.7. RT-PCR Analysis 
Total RNA was isolated from NSCs and pOLs with or without Ezh2-shRNA 
treatment. Cells were lysed in guanidinium isothiocyanate/mercaptoethanol 
buffer and RNA was extracted with phenol-chloroform and precipitated using 
isopropanol. To degrade possible genomic DNA traces, DNase (Fermentas) 
was used.  One microgram of total RNA was used for reverse transcriptase 
(RT) reaction and 5ng of copy DNA was used in subsequent quantitative 
polymerase chain reaction (qPCR) amplification using appropriate primer pair 
for each gene. The primer pair sequences for each gene we used can be found 
in Supplementary Table 2. 
3.8. Immunocytochemistry 
Cell cultures were fixed with 4% paraformaldehyde (PFA) and immunostained 
using antibodies against specific proteins. For the immunostaining of brain 
tissue sections (fixed with 4% PFA) heat-induced antigen/epitope retrieval 
(HIER) (10 mM sodium citrate, 0.05%  Tween 20, pH 6.0) was used. The 
specification of the primary and secondary antibodies we used for 
immunocytochemistry can be found in Supplementary Table 1. 
3.9. Microscopy Analysis 
Microscopic analysis was performed using Zeiss (Axioskope 2) fluorescent 
microscope equipped with a Leica DFC300FX camera and the Leica 
Microsystems LAS program. The phase contrast images were made by 
Axiovert 40 CFl (ZEISS) microscope. Chapter 3 
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4. RESULTS 
4.1. Ezh2 expression in neural stem cells (NSCs) and premyelinating 
oligodendrocytes (pOLs) 
Previously we have reported prominent expression of Ezh2 in cultured 
embryonic neural stem cells (NSCs) and during their differentiation into the 
oligodendrocyte cell lineage; oligodendrocyte precursors (OPCs) up to the 
stage of premyelinating oligodendrocytes (pOLs) highly express Ezh2 (Sher et 
al., 2008). 
To examine whether Ezh2 is also expressed in adult NSCs and OPCs in-vivo, 
we performed immunohistochemistry on sections of adult mouse brain (figure 
1a). We found that indeed Ezh2 was expressed in adult NSCs, located in the 
subventricular zone (SVZ) (figure 1b-b’’) and the hippocampus (not shown) and 
in OPCs and pOLs for instance in the corpus callosum (figure 1c-c’’). We 
confirmed the Ezh2 protein expression by Western blot on tissue lysates from 
SVZ, hippocampus and in-vitro cultured adult NSCs (figure 1d). 
In normal brain, the number of OPCs in the corpus callosum (CC) is low, but it 
significantly increases during spontaneous remyelination after induced 
demyelination as a result of proliferation and recruitment of OPCs from 
neighboring areas and of differentiation of NSCs in the SVZ. 
To examine whether recruited migrating OPCs express Ezh2, we put mice on a 
diet of 0.2% cuprizone (an oligodendrocyte toxin)  resulting in complete 
demyelination of the corpus callosum and restored normal diet after 5 weeks, 
directly resulting in spontaneous remyelination activity. Immunohistochemistry 
on the sections of CC (figure1e) from cuprizone-fed mice at week 5 (5WD, i.e. 
at the stop of the cuprizone diet and start of remyelination) (figure 1f-f”), and at 
week 7 (two weeks of remyelination, 2WR) (figure 1g-g”) showed the changes 
in myelination, number of pOLs and consequently of Ezh2-positive cells in the 
CC in comparison to control (figure1c-c”). 
We accurately dissected out the CC from the three groups. Western blot 
analysis, in combination with oligodendrocyte marker NG2 on these CC 
samples, revealed clear bands of Ezh2 (91kDa) at week 5 (5WD) and 7 (2WR) 
(figure1h-i). 
We confirmed the presence of Ezh2-activity by including a Western Blot for 
K27H3Me3 (figure 1h). In control corpus callosum, the Ezh2 band was below 
detection level of our Western blot procedure (figure 1h). Our data indicate that 
Ezh2 expression is not only a relevant factor for OPC formation during 
embryogenesis but also for adult OPCs in the de- and remyelinating brain. 
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Figure 1 – NSCs and pOLs express Ezh2 in mouse brain. (a) Hoechst (nuclear) stained section of 
mouse brain. (b-b’’) Immunohistochemistry on subventricular zone (SVZ) sections of mouse brain, 
(b) = anti-nestin, (b’) = anti-Ezh2, (b’’) overlay of (b and b’) and Hoechst nuclear staining (blue). (c-
c’’) Immunohistochemistry on corpus callosum sections of mouse brain, (c) =anti-RIP (RIP=anti-
CNPase`, oligodendrocyte marker), (c’) = anti Ezh2, (c’’) overlay of (c), (c’) and Hoechst nuclear 
staining. (d) Western blot showing the expression of Ezh2 protein (91kDa band) in in-vitro cultured 
mouse adult NSCs and tissue lysates from SVZ and hippocampus.  
(e-h) OPCs in corpus callosum express Ezh2 during demyelination and remyelination in cuprizone 
fed mice. (e) Hoechst (nuclear) stained section of mouse brain. (f-f’’) Immunohistochemistry on 
corpus callosum sections of five weeks cuprizone fed mice (five weeks of demyelination= 5WD) (f) 
= anti-RIP, (f’) = anti-Ezh2, (f’’) = overlay of (f and f’) and Hoechst nuclear staining (blue). (g-g’’) 
Immunohistochemistry on corpus callosum section of brain of mouse fed for five weeks on 
cuprizone diet followed by two weeks on normal diet (=two weeks remyelination= 2WR), (g) = anti-
RIP, (g’) anti-Ezh2, (g’’) = overlay of (g and g’) and nuclear staining. (h) Western blot showing the 
loading control (beta-actin), Ezh2 and H3K27Me3 protein bands in lysates from corpus callosum of 
5WD and 2WR; in the corpus callosum of control mouse brain, the Ezh2 band was below the 
detection level. (i) Western blot on the same lysates used in (h) but immunoblotted against NG2 
antibody (an early oligodendrocyte marker). 
 
4.2. Ezh2 and PRC2 core components in mouse NSCs and pOLs 
To check the expression of other core components of PRC2 (Suz12 and Eed) 
besides Ezh2 in NSCs and during their differentiation into pOLs, we performed 
immunocytochemistry and Western Blot analysis on isolated embryonic NSCs Chapter 3 
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and pOLs and included mouse embryonic stem (ES) cells as controls. In all 
nestin (NSCs) and RIP (pOLs) positive cells, the expression of Ezh2, Eed and 
Suz12 was located in the nuclei (figure 2a,b). Western Blot analysis revealed 
Ezh2, Suz12 and Eed protein bands with molecular weights of respectively 
91kDa, 75-100 kDa and 60 kDa. However, in pOLs, we observed an additional 
band of Suz12 at a position 10-15 kDa higher than expected (figure 2c); this 
could be a potential SUMO modification as SUMOplot
TM analysis (Abgent; 
www.abgent.com/doc/sumoplot) has shown that the amino acid sequences of 
Suz12, Ezh2 and Eed can contain one or more SUMO consensus motives.  
 
 
 
 
Figure 2 - Core components of PRC2 (Ezh2, EED, & Suz12) are conserved between NSCs and 
pOLs. (a-b) Immunocytochemistry on cultured NSCs and pOLs shows the expression of Ezh2, 
Suz12 and EED. (Msi=anti-mushashi, a NSC marker; RIP=anti-CNPase oligodendrocyte marker; 
Hoechst=nuclear staining blue). (c) Western Blot showing the bands of Ezh2, Suz12, EED and 
beta-actin at expected heights. White arrow points at the additional band of Suz12 in pOLs, not 
present in NSCs and ESCs. (ESCs=embryonic stem cells. positive controls). 
 
4.3. Genome wide identification of target genes of Ezh2 in NSCs and 
pOLs  
To unravel the (differential) function of Ezh2 in NSCs and in premyelinating 
oligodendrocytes (pOLs), we identified the target genes of Ezh2 in both cell Ezh2 target genes during NSC differentiation 
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types by chromatin immunoprecipitation (ChIP)  using  anti-Ezh2 antibodies, 
followed by ultra high-throughput massive parallel sequencing (ChIP-Seq). We 
used Illumina
R sequencing technology for ultra high-throughput sequencing of 
enriched genomic DNA (IP with anti Ezh2) and background noise genomic 
DNA (IP with isotype control IgG) in both cell types. Using CLC genomic 
workbench software, we mapped the sequence files with the reference genome 
(mouse whole genome from NCBI data base). Using the same software, we 
extracted significant ChIP peaks after normalizing with background noise. We 
found 288 and 174 unique Ezh2 target genes in NSCs and pOLs respectively; 
29 genes were shared by both cell types (figure 3a,a’).  
 
 
 
Figure 3 - Ezh2 changes its target genes with differentiation from NSCs to pOLs. (a)  Venn 
diagram showing the number of unique and overlapping genes targeted by Ezh2 in NSCs and pOL; 
(a’) selected representative genes for each group. (b,c) Functional gene ontology (GO) analysis of 
Ezh2 target genes in NSCs and pOLs. The black bars represent -log of modified Fisher Exact P-
value. Fisher Exact is adopted to measure the gene-enrichment in annotation terms (DAVID’S 
online tool). The smaller the P-value, the more enriched a GO term is for genes of the given assay. 
Orange lines indicate the threshold of statistical significance (P-value). 
 
The complete lists of target genes in both cell types are provided in 
Supplementary Table 3, 4 at end of this chapter. This dynamism in the Ezh2 
target genes suggests that Ezh2 changes its occupancy during the 
differentiation of NSCs to pOLs. Chapter 3 
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In order to reveal general functional characteristics of the molecular programs 
involving Ezh2, we started to conduct a first gene ontology analysis on the 
target gene lists of NSCs and pOLs. 
In NSCs, we found that Ezh2 targeted genes mainly associated with gene 
ontology terms like transcription regulation, neurogenesis, developmental 
processes, anterior/posterior patterning, cell cycle, cell cycle control, cell 
proliferation and differentiation (figure 3b). 
In pOLs the significantly enriched gene ontology terms were cation transport, 
developmental processes, synaptic transmission, neurogenesis, 
neurotransmitter release, transport, protein  phosphorylation, cell death, 
neuronal activities, signal transduction, cell proliferation and differentiation, and 
mRNA transcription regulation (figure 3c). The genes shared by both NSCs and 
pOLs were mainly correlated with cell death, cell cycle, proliferation, genetic 
disorders, cancer, and metabolism. The first impression revealed by this gene 
ontology analysis suggests that in NSCs the repressive activity of Ezh2 is 
mainly targeted to genes involved in cell cycle control and differentiation while 
in pOLs Ezh2 mainly represses genes unassociated with the committed pOL 
lineage. 
4.4. Analysis of Ezh2 target genes in NSCs and pOLs 
Further insight in the function of the Ezh2 target genes in NSCs and in pOLs 
was obtained using the online tool Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7. DAVID tools are able to visualize genes on 
BioCarta & KEGG pathway maps and allow to determine the top canonical 
signaling, disease and metabolic pathways represented by the genes that are 
significantly enriched in a given cell type. We observed 10 significantly 
enriched pathways in NSCs and 12 in pOLs (figure 4a,b).  
Ezh2 target genes identified in NSCs strikingly contained key members of 
signaling pathways for TGF-beta, neurotrophins, pluripotency, axonal 
guidance, DNA methylation and transcriptional repression, glioma and 
insulin/IGF. Most of these pathways are active during differentiation, lineage 
commitment and under pathological conditions (e.g. glioma) and remain 
repressed and inactive during normal NSC self-renewal and maintenance.  
Ezh2 target genes identified in pOLs belong to Wnt/β-catenin, synaptic long 
term potentiation, calcium, Sonic hedgehog, ionotropic glutamate receptor, 
MAPK, N-glycan biosynthesis/ degradation pathways and pathways active 
during neurodegenerative diseases and cancer. Ezh2 target genes during NSC differentiation 
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Figure 4 - Analysis of canonical signaling and metabolic pathways enriched in Ezh2 target genes 
in NSCs and pOLs. (a,b) Canonical signaling and metabolic pathways statistically enriched in Ezh2 
target genes in NSCs and pOLs, respectively (P<0.05). (a’,b’) Ezh2 target genes distribution based 
on literature survey for NSCs and pOLs. Chapter 3 
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Indeed, pathways like Wnt/β-catenin, synaptic long term potentiation, ionotropic 
glutamate receptor are supposed to be repressed during oligodendrocytic 
differentiation, but are required in mature neurons and astrocytes, activated 
during terminal neuronal or astrocytic differentiation. 
The MAPK signaling pathway is necessary only during terminal differentiation 
into myelinating oligodendrocytes and indeed should be silenced by Ezh2 in 
pOLs. Ttc21b (THM1) is a negative regulator of Sonic hedgehog signaling 
(Tran et al., 2008; Stottmann et al., 2009), which is necessary for normal 
oligodendrocyte differentiation. We found THM1 as target gene of Ezh2 in 
pOLs indicating that its repression by Ezh2 is necessary to enable proper sonic 
hedgehog signaling. 
Additionally, we performed analysis on both lists of Ezh2 target genes based 
on literature survey (figure 4a’,b’). 
This literature survey analysis as well as the gene ontology and the DAVID 
analysis all point to a role for Ezh2 in preventing differentiation and in 
maintaining “stemcellness” in NSCs and in suppressing neuronal and astrocytic 
lineage genes in differentiating pOLs.  
4.5. Functional link between Ezh2 binding and repression of target genes 
in NSCs and pOLs 
We analyzed upregulation of the expression of Ezh2 target genes after 
silencing of Ezh2 with shRNA to further validate the Ezh2 target genes found in 
both cell types. 
Approximately 48h (NSCs) and 25h (pOLs) after transfection with the Ezh2-
shRNA plasmid, lysates were prepared for protein analysis. Western blot 
analysis confirmed that the Ezh2-shRNA plasmid efficiently and acutely 
inhibited the protein synthesis of Ezh2. Knockdown of Ezh2 should result in a 
decrease in global H3K27 tri-methylation activity which is an Ezh2 associated 
gene repression mark. Western blot analysis with the same lysates indeed 
showed a significant reduction in H3k27me3 in both cell types (figure 5a,b). 
 
After confirming the knockdown of Ezh2, we selected a set of Ezh2 target 
genes (based on ChIP-Seq peak analyses and functional relevance) for each 
cell type. Quantitative PCR analysis of transcript levels of the Ezh2 targets 
genes showed that acute reduction of Ezh2 protein in NSCs and pOLs resulted 
in increased expression of most of its target genes. In NSCs, reduction of Ezh2 
resulted in at least a two fold increase in the transcript abundance for 85% of 
22 Ezh2 target genes tested. In pOLs, the silencing of Ezh2 even resulted in at 
least a threefold increase in transcript abundance for approximately 75% of 22 
tested Ezh2 target genes (figure 5c,d); the expression of control genes 
remained largely unaffected in both cell types. Ezh2 target genes during NSC differentiation 
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Figure 5 - Acute Ezh2 reduction in NSCs and pOLs mediated by Ezh2-shRNA. (a,b) Western blot 
showing the reduction in Ezh2 protein in comparison to control after in vitro transfection with Ezh2-
shRNA, both in NSCs and pOLs. Reduction in Ezh2 protein resulted in a decrease in global level of 
H3K27 tri-methylation, an Ezh2-associated gene repression mark (17kDa band). (c,d) De-
repression of tested Ezh2 target genes after knocking down Ezh2 protein expression in NSCs and 
pOLs. Green depicts genes not targeted by Ezh2, orange shows Ezh2 targeted genes which are 
not derepressed after knocking down expression of Ezh2, while blue represents Ezh2 target genes 
which showed derepression after knocking down expression of Ezh2 in NSCs and pOLs. The 
transcript levels were quantified by real-time PCR, normalized to GAPDH control and represented 
as a fold change between Ezh2-shRNA and wild type cells (both NSCs and pOLs). Bars represent 
mean of three independent experiments ± S.D. 
 
4.6. Acute suppression of Ezh2 induced apoptosis in NSCs 
To determine the significance of Ezh2 activity for NSCs maintenance and self-
renewal, we followed Ezh2-shRNA transfected NSCs up to three days in 
culture as they developed into neurospheres during their clonal expansion. We 
observed dramatic changes in neurosphere morphology (figure 6a, b): Ezh2 
silenced neurospheres were smaller; more flattened and contained many dying 
cells in comparison to controls as revealed by propidium iodide staining (figure 
6a’,b’). Immunostaining for the proliferation marker Ki67 revealed a strong 
reduction of proliferation activity (figure 6c,d). Cleaved caspase 3 
immunostaining confirmed the increase in apoptosis (figure 6e,e’,f,f’ and g). 
These effects of Ezh2-shRNA on NSCs were further confirmed in Western Blot 
analysis using anti-PCNA (another proliferation marker) and anti-cleaved 
caspase 3 antibodies (figure 6h,h’).  
Our results indicate that acute suppression of Ezh2-activity in NSCs 
deregulates mechanisms involved in proliferation and cell survival. Chapter 3 
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Figure 6 - Acute reduction of Ezh2 induces apoptosis in NSCs. (a,b) Phase contrast images of 
cultures of NSC neurospheres in control and after Ezh2 silencing. (a’,b’) Propidium iodide staining 
of these cultures reveals the increase in numbers of dead cells after Ezh2 silencing. (c,d) 
Immunostaining for the proliferation marker Ki67 (green) and overlay with Hoechst nuclear staining 
(blue) on dissociated neurospheres in mock control NSCs (c) and NSCs treated with Ezh2-shRNA 
(d), 48h after transfection). (e,f) Immunostaining on dissociated neurospheres for the apoptosis 
marker, cleaved caspase 3 (green). (e’,f’) Overlay of the same cultures combining immunostaining 
for cleaved caspase 3 (green), with nestin (red) and Hoechst nuclear staining (blue), (g) 
Quantification of proliferating (Ki67-positive) and apoptotic (cleaved caspase 3-positive) NSCs in 
mock control and NSCs cultures treated with Ezh2-shRNA. (h) Western blot of protein samples 
prepared after 48h of mock (control) and Ezh2-shRNA transfection. Western blot shows a decrease 
in Ezh2 and PCNA (a proliferation marker) and an increase in cleaved caspase 3 bands in NSCs 
treated with Ezh2-shRNA compared to mock control. (h’) Quantification of band density in (h) 
normalized to house keeping protein gamma tubulin. Bars represent mean of three independent 
experiments ± S.D.; Student-t-test was used to calculate significance (p<0.05). 
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4.7. Acute suppression of Ezh2 increased proteins levels associated with 
cell cycle arrest and cell death in NSCs 
Our ChIP-Seq data analysis revealed several Ezh2 target genes like Cdkn2a, 
Tcf21, Six1, and Dnmt3a, which are involved in cell cycle control, cell death 
and cellular compromise. To check whether Ezh2-shRNA treatment in NSCs 
resulted in activation of cell cycle arrest and cell death pathways, we analyzed 
the expression of Tcf21 and Cdkn2a.  RT-qPCR analysis showed an 8 and 12 
fold increase in transcript levels of Tcf21 and Cdkn2a, respectively (figure 7a). 
  
 
Figure 7 – Cell cycle regulation and TGF-beta signaling in Ezh2-shRNA treated NSCs. (a) Real-
time quantitative PCR analysis of Tcf21 and Cdkn2a in mock control and Ezh2-shRNA treated 
NSCs. (b) Western blot showing the upregulation of p16 (product of Cdkn2a) protein after knocking 
down the expression of Ezh2 in NSCs. (b’) Graph showing the quantification of b. (c) Real-time 
quantitative PCR analysis of Gdf6, Gdf7 gene transcripts in mock control and Ezh2-shRNA treated 
NSCs. (d) TGF-beta signaling activation in Ezh2-shRNA treated NSCs was verified by 
immunoblotting for Smads (Smad1, Smad2, Smad3, Smad5 and Smad8). (d’) Graph showing the 
quantification of Smads bands in d.  Chapter 3 
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In addition, immunoblotting with anti-p16 (a protein product of Cdkn2a) showed 
a 250% increase in band (18kDa) intensity in Ezh2-shRNA treated samples 
compared to mock control (figure 7b,b’). These results indicate that Ezh2 is 
involved in the repression of cell cycle inhibitory and cell death pathways in 
NSCs. 
4.8. Acute suppression of Ezh2 activated TGF-beta signaling in NSCs 
The DAVID analysis revealed a significant involvement of Ezh2 target genes in 
NSCs in the TGF-beta signaling  pathway. TGF-beta signaling plays an 
important role in various physiological and pathophysiological processes in the 
brain (Aigner and Bogdahn, 2008). Various studies have demonstrated the 
involvement of TGF-beta signaling in suppressing NSC proliferation and self 
renewal (Aigner and Bogdahn, 2008; Wachs et al., 2006). Gdf6 and Gdf7, 
subfamily members of the TGF-beta superfamily, appear to be Ezh2 target 
genes in NSCs. Suppressing Ezh2 activity should activate Gdf6 and Gdf7 
expression, which should lead to activation of TGF-beta signaling and an 
upregulation of Smads, the downstream effectors of TGF-beta signaling. 
Indeed, with RT-qPCR analysis, we found a seven to ten fold upregulation in 
the transcripts of Gdf6 and Gdf7 in Ezh2-shRNA treated NSCs (figure 7c). 
Moreover, Western Blot analysis revealed an increase in the expression of 
Smads (Smad1, Smad2, Smad3, Smad5 and Smad8) in Ezh2-shRNA treated 
NSCs (figure 7d,d’). These findings indicate that Ezh2 in NSCs controls the 
expression of subfamily members of the TGF-beta superfamily in NSCs and 
prevents their inhibitory action on proliferation and self renewal. 
4.9. Acute suppression of Ezh2 induced apoptosis in pOLs. 
The ChIP-Seq data suggested that Ezh2 is necessary for the establishment 
and the survival of the oligodendrocyte cell lineage. To elucidate the role of 
Ezh2 in developing oligodendrocytes, we silenced the expression of Ezh2 by 
Ezh2-shRNA in A2B5-positive OPC enriched cultures (~90%) (figure 8). OPCs 
treated with Ezh2-shRNA rapidly developed an abnormal morphology: they 
retracted their extensions (figure 8a,b), underwent apoptosis (figure 8c,d) and 
lost RIP immunostaining (figure 8c’,d’); quantification of these processes in 
figure 8e. Western Blot analysis on cleaved caspase 3 confirmed these 
observations (figure 8f,f’).  
Next we examined potential mechanisms underlying the Ezh2 dependent 
apoptosis of pOLs. 
4.10. Ezh2 represses Wnt signaling pathways in pOLs 
Activation of canonical Wnt signaling has been shown to inhibit oligodendrocyte 
differentiation (Ye et al., 2009; Shimizu et al., 2005; Feigenson et al., 2009). 
Our ChIP-Seq data revealed that wingless-type family member 7B (Wnt7b) and 
Smoothened (Smo) are target genes of Ezh2 in pOLs. Ezh2 target genes during NSC differentiation 
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Figure 8 - Acute suppression of Ezh2 induces apoptosis in pOLs. (a,b) Phase contrast images of 
cultures of pOLs in mock control (a) and after Ezh2-shRNA treatment (b), 25h after transfection. 
(c,d) Immunostaining for apoptosis marker, cleaved caspase 3 (green) on cultures of pOLs with 
and without Ezh2 silencing. (c’,d’) Overlay of the same cultures as in (c,d) combining the 
immunostaining for cleaved caspase 3 (green) with RIP (red), and Hoechst nuclear staining (blue), 
in mock control pOLs and pOLs treated with Ezh2-shRNA. (e) Quantification of apoptotic (cleaved 
caspase 3-positive) and differentiating (RIP-positive) cells in Ezh2-shRNA treated and mock control 
pOLs. (f) Western blot of protein samples prepared after 25h of mock transfection (control) and 
Ezh2-shRNA transfection. Western blot shows a decrease in Ezh2 and a strong increase in 
cleaved caspase 3 bands in pOLs treated with Ezh2-shRNA compared to mock control. PCNA (a 
proliferation marker) expression remained about the same in both conditions. (f’) Quantification of 
band densities of (f) normalized to house keeping protein band gamma tubulin. Bars in both graphs 
represent mean of three independent experiments ± S.D.; Student-t-test was used to calculate 
significance (p<0.05).   Chapter 3 
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Wnt7b is a short range paracrine signal required for Wnt pathway responses 
involving programmed cell death (Lobov et al., 2005). We validated Wnt7b as 
an Ezh2 target gene in pOLs by silencing Ezh2 via Ezh2-shRNA: a more than 
10 fold increase in the transcript levels of Wnt7b was observed in the treated 
pOLs.Thus, apoptosis of pOLs deficient of Ezh2 may have been induced by the 
expression of Wnt7b, which diffuses towards neighboring pOLs and activate 
toxic Wnt pathway signaling.  
 
 
 
Figure 9 - Wnt and Shh signaling pathways in Ezh2-shRNA treated OPCs. (a-d’) Immunostaining 
of control and Ezh2-shRNA treated OPCs revealed expression of beta catenin, an integral 
component of the Wnt signaling pathway. (a,a’) Green=anti-PDGFrec alpha (an early 
oligodendrocyte marker), (b,b’) Red=anti-beta catenin, (c,c’) Blue=Hoechst nuclear staining, (d,d’) 
Overlay of green, red and blue.  (e) Immunoblotting for Gli1, after 25 h of transfection, revealed 
decrease in Gli1 band of 100kDa in Ezh2-shRNA treated OPCs cultures compared to mock control. 
(e’) Band density quantification normalized to beta actin. Bars represent mean of three independent 
experiments ± S.D. Ezh2 target genes during NSC differentiation 
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The simultaneous upregulation of Smo in the absence of Ezh2 may have 
strengthened this effect (Arimura et al., 2009). To investigate whether the 
expression of Wnt7b and Smo in pOLs lacking Ezh2 indeed results in the 
activation of the Wnt signaling pathway, we performed immunostaining for 
beta-catenin an integral component of Wnt signaling pathway.  We observed 
that more than 90% of the Ezh2-shRNA treated pOLs were positive for beta-
catenin; whereas control pOLs contained only a few beta-catenin positive cells 
(figure 9a-d’). In addition, we detected an upregulation of the beta-catenin 
signaling transcriptional target Id2 in the pOLs lacking Ezh2. The idea that 
Ezh2 may be a potential regulator of Wnt signaling in pOLs was strengthened 
by the fact that DKK1, an inhibitor of Wnt signaling, could partially rescue Ezh2-
shRNA treated pOLs (Supplementary figure 1 at the end of this chapter). 
4.11. Ezh2 is essential for stable Sonic Hedgehog (Shh) signaling in 
pOLs. 
Shh signaling essentially contributes to oligodendrocyte specification and is 
required during an early phase of their development in mammalian brain (Lu et 
al., 2000; Alberta et al., 2001; Nery et al., 2001). Tetratricopeptide repeat 
protein 21B (Ttc21b) encodes a novel  protein,  THM1, which acts as an 
antagonist of mouse Shh signaling downstream of Smo and upstream of Gli 
transcription factors(Tran et al., 2008). Ttc21b appears to be a target gene of 
Ezh2 according to our ChIP-Seq data and indeed was upregulated in Ezh2-
shRNA treated pOLs (see figure 5d). Upregulation of Ttc21b transcription after 
knockdown of Ezh2 may lead to disturbed Shh signaling and so contribute to 
the apoptosis of Ezh2-shRNA pOLs. To examine disturbed Shh signaling in 
Ezh2 knockdown pOLs, we performed a Western Blot for Gli1, since THM1 
works upstream of this transcription factor. We found a clear decrease in the 
transcription factor Gli1 protein in pOLs treated with Ezh2-shRNA (figure 9e,e’). 
These findings show the involvement of Ezh2 in regulating Shh signaling in 
pOLs, of importance for their survival. 
4.12. Ezh2 regulates the expression of NMDA receptor subunits in pOLs 
The studies provide compelling evidence for the involvement of 
oligodendrocyte NMDA receptors in glutamate-mediated damage to these cells 
in injury and disease (Wong, 2006). Interestingly, ChIP-Seq discovered Grin2a 
(NMDR2a/NR2a) and Grin2b (NMDR2b/NR2b) as Ezh2 target genes in pOLs. 
Immunostaining for Grin2a and Grin2b in control cultures showed only a small 
percentage of pOLs positive for these NMDA receptor subunits:  however, a 
vast majority of Ezh2 knockdown pOLs, appeared to express these receptor 
subunits (figure 10a-I,a’-i’) and this upregulation of Grin2a was confirmed in 
immunoblots (figure 10j,j’) These findings suggest yet another mechanism of Chapter 3 
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apoptosis induction by silencing Ezh2 activity in pOLs, i.e. via upregulation of 
NMDA receptor subunits.  
  
 
 
Figure 10 - Grin2a and Grin2b expression in Ezh2-shRNA treated OPCs. (a-d) 
Immunocytochemistry for mock control and for (a’-d’) Ezh2-shRNA treated OPCs shows that the 
number of Grin2a positive cells is increased after Ezh2 silencing. Red: anti-PDGFrec alpha, Green: 
anti-Grin2a, Blue: Hoechst nuclear staining. (f-i) Immunostaining for mock control and for (f’-i’) 
Ezh2-shRNA treated OPCs shows an increase in Grin2b positive cells in Ezh2-shRNA treated 
OPCs cultures.  Red: anti-PDGFrec alpha, Green: anti-Grin2b, Blue: Hoechst nuclear staining. (j) 
Western blot for Grin2a shows a thicker band of Grin2a (165 kDa) in Ezh2-shRNA treated OPCs 
cultures. (j’) Quantification of band intensities in j. 
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5. DISCUSSION 
Previously, we have shown that the PcG protein Ezh2 is expressed in cultured 
embryonic NSCs and premyelinating oligodendrocytes (Sher et al., 2008). In 
the present study, we extended these observations with in-vivo data on the 
expression of Ezh2 in adult NSCs and most prominently in OPCs recruited for 
remyelination in adult mice put on a 0.2% cuprizone diet. Our ChIP-Seq 
analysis revealed both unique (resp. 288 and 174) as well as (a small group of 
29) overlapping target genes of Ezh2 in NSCs and pre-myelinating 
oligodendrocytes (pOLs). The Ezh2 silencing experiments present evidence for 
the involvement of Ezh2 in proliferation and self-renewal in NSCs by 
specifically targeting genes involved in cell death, cellular compromise, cell 
cycle arrest (e.g., p16 pathway) and sets of genes involved in NSC 
differentiation. Genes targeted by Ezh2 in pOLs appear to be mainly 
associated with cell death signaling and neuronal and astrocytic lineage 
determination. 
The differential function of Ezh2 in NSCs and in pOLs may not necessary only 
be related to differences in target genes, but may also be determined by a 
different composition and so a different activity of the PRC2 complex. Previous 
studies have shown that, in general, the core components of PRC2 are 
interdependent (Bracken et al., 2006; Pasini et al., 2004; Montgomery et al., 
2005) and indeed in our experiments the core components of PRC2, Ezh2, 
Suz12 and EED were present in both NSCs and pOLs. However, in pOLs we 
detected the presence of an additional isoform of Suz12, possibly a sumoylated 
modification of this component, which may affect PRC2 activity and the 
resulting recruitment of PRC1 influencing the transcription of one or more 
genes in a differential way. 
The target genes for Ezh2 that we found in NSCs and in pOLs substantially 
overlap with those observed in previous studies in which PRC2 targets were 
identified through chip-on-chip experiments in embryonic stem cells(Boyer et 
al., 2006; Bracken et al., 2006). Our data clearly show a shift in targeting by 
Ezh2 during the differentiation of NSCs into an oligodendrocytic cell lineage, 
with only a small group of genes, mainly associated with more basic processes 
regulating cell cycle, basal metabolism and (preventing) tumor formation, 
targeted in both cell types. The present findings provide a novel insight in the 
specific role and the mechanism of action of Ezh2 in undifferentiated 
multipotent stem cells and during their differentiation into a tissue-specific cell 
type. This role is different from the classical view on Ezh2 activity in embryonic 
stem cells, which proposes that Ezh2 is down regulated once a specific cell 
fate choice is made. It is in line with the emerging view that PcG protein 
complexes dynamically regulate the gene hierarchy during cell fate choice up Chapter 3 
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to different levels of differentiation (Schuettengruber and Cavalli, 2009). Our 
findings are also in line with studies on the role of Ezh2 in other tissue-specific 
multipotent stem cells like for instance in the skin: Ezh2 expressing basal 
progenitor cells in the skin give rise to several epidermal cell types and by 
controlling spatial and temporal epigenetic modifications Ezh2 orchestrates 
gene expression during the differentiation into epidermis-specific cell types in a 
stepwise fashion (Ezhkova et al., 2009) 
We have used Ezh2-shRNA to knock down Ezh2 expression providing us with 
the opportunity to analyze the immediate consequences for gene expression 
under the control of Ezh2.  Ezh2-shRNA efficiently and specifically reduced 
Ezh2 protein in both cell types, which was confirmed by the observed reduction 
of H3K27me3 levels as a consequence of the reduced methyltransferase 
activity by the Ezh2 Set-domain. The large majority of Ezh2 target genes tested 
became derepressed (85% in NSCs and 75% in pOLs) as a result of specific 
silencing of Ezh2 by Ezh2-shRNA, consistent with previous studies (Boyer et 
al., 2006; Bracken et al., 2006). Only 15% in NSCs and 25% in pOLs of the 
tested Ezh2 target genes did not show derepression. The reason for this might 
be that the expression of these target genes are under control by additional 
layers of epigenetic repression e.g. DNA methylation and H3K9 methylation 
together with HP1 protein.  
In our studies, Ezh2 knockdown resulted in a profound decrease in NSC 
proliferation and an increase in cell death. We conclude that Ezh2 is critical for 
normal NSC survival and self-renewal. This is in line with previous studies 
linking Ezh2 to cell survival and proliferation (Bello et al., 2007)
, (Suva et al., 
2009; Kamminga et al., 2006). We identified several target genes of Ezh2 that 
appear to be involved in these processes: Cdkn2a, Tcf21, Six1, Dnmt3a, all 
involved in cell cycle control, cell death and cellular compromise. We found a 
strong increase in the p16 protein encoded by Cdkn2a after Ezh2 silencing. 
P16 acts as a negative regulator of proliferation of normal cells by interacting 
with CDK4 and CDK6; this inhibits their ability to interact with cyclins D and to 
phosphorylate the retinoblastoma protein and so to maintain a stable Rb-E2F 
complex, which represses cell cycle progression. Our data suggest that Ezh2 
silencing leads to derepression of p16 transcription and subsequent promotion 
of cell cycle exit. It would be interesting to check whether p16 silencing can 
rescue the phenotype instigated by Ezh2-shRNA; for that, the use of Ezh2-
conditional knockout mice would be optimal. Other target genes of Ezh2 likely 
involved in its control of proliferation and survival of NSCs are Gdf6 and Gdf7; 
subfamily members of the TGF-beta superfamily, which when derepressed 
activate TGF-beta signaling. TGF-beta signaling is involved in various 
physiological and pathophysiological processes of the brain. It appears to be Ezh2 target genes during NSC differentiation 
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induced in the adult brain after injury or hypoxia and during neurodegeneration 
when it modulates and dampens inflammatory responses (Aigner and 
Bogdahn, 2008). TGF- beta signaling has been thought to limit the self-repair of 
the brain by inhibiting neural stem cell proliferation (Aigner and Bogdahn, 2008; 
Golestaneh and Mishra, 2005). Moreover, in-vitro assays have shown that 
TGF-beta signaling activation resulted in a strong suppression of NSCs 
proliferation and self renewal (Wachs et al., 2006). The identification of Gdf6 
and Gdf7 as Ezh2 target genes has implicated TGF-beta signaling for the first 
time in the Ezh2 controlled regulation of NSC proliferation and survival. 
The Ezh2 silencing experiments in pOLs showed the critical role of Ezh2 in 
oligodendrocyte differentiation and survival. The list of target genes of Ezh2 we 
identified in pOLs provided us clues for potential mechanisms underlying cell 
death and impairment of differentiation in pOLs, of which Wnt and Shh 
signaling appears to be the most relevant ones. Activation of canonical Wnt 
signaling has been shown to inhibit oligodendrocyte differentiation(Ye et al., 
2009; Shimizu et al., 2005). A study has shown that shRNA-mediated acute 
knockdown of Bmi1 (a key member of PRC1) results in the upregulation of Wnt 
signaling and its transcriptional targets in embryonic mouse brain (Fasano et 
al., 2007). This is in accordance with our data, which indicate that Ezh2 
regulate Wnt signaling pathways by targeting ligands for members of the 
Frizzled family of seven transmembrane receptors, in particular Wnt7b. Our 
data also reveal molecular control of Ezh2 on the Shh signaling pathway, by 
targeting a major suppressor of Shh signaling, i.e. THM1. Impairment of Shh 
signaling can induce apoptosis (Stecca et al., 2005), as this signaling is 
necessary for transcription of Olig1 and Olig2, the genes tightly associated with 
oligodendrocytic lineage (Lu et al., 2000). Besides Wnt and Shh signaling 
pathways, a third Ezh2-controlled pathway seems to be involved in pOLs 
death: Study reports (Matute et al., 1997; Wong, 2006; Carter, 2007) provide 
compelling evidence for the involvement of oligodendrocyte NMDA receptors in 
glutamate-mediated damage to oligodendrocytes in injury and disease. We 
discovered Grin2a (NMDR2a/NR2a) and Grin2b (NMDR2a/NR2b) as Ezh2 
target genes in pOLs. Indeed Ezh2 silencing experiments showed their 
upregulation, suggesting apoptosis induction in pOLs, i.e. derepression and 
upregulation of NMDA receptor subunits.  In addition to that, we have detected 
at least 35 Ezh2 targets in pOLs whose expression is associated with cell 
death. Especially the fact that pOLs have an exceptional large gene 
transcription repertoire for Ezh2 controlled cell death, suggests an important 
physiological role for Ezh2 in fate determination of pOLs. During embryonic 
myelination and in adult remyelination events, the local number of pOLs is 
likely to exceed the number of pOLs actually required for (re) myelination. The Chapter 3 
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surplus of pOLs has to be cleared by apoptosis and this may very well be 
effectuated via the silencing of Ezh2 induced by still unknown extrinsic factors. 
In surviving pOLs, Ezh2 is required to maintain a specific gene expression 
pattern and is indispensable for the proceeding differentiation of pOLs towards 
a myelinating mature oligodendrocyte. 
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8. Supplementary information 
8.1. Supplementary Table 1 
Specifications of primary and secondary antibodies used for Chromatin 
Immunoprecipitation, Western Blot, and Immunocytochemistry 
 
 
 
 
 Chapter 3: Supplementary information 
￿ ￿￿￿￿
8.2. Supplementary table 2 
Sequences of primer pairs used for RT-qPCR analysis 
Gene (NCBI Symbol)  FW Sequence (5' -> 3')  BW Sequence (5' -> 3') 
Gata1 TGGGGACCTCAGAACCCTTG  GGCTGCATTTGGGGAAGTG 
Adam10 ATGGTGTTGCCGACAGTGTTA  GTTTGGCACGCTGGTGTTTTT 
Emp55 AAGGAGGCAGGACTGAAGTTT GCTTAGCCAGGTACTTGTCTTT 
Msx1 TGAAGGCCGAAAGCCCCGAG  GGTGCATGCTGGGGGACTCA 
Runx1 GCGGAGCGGTAGAGGCAAGA  AGGTGGCAACTTGTGGCGGA 
Nkx6.2 GCCAAGTGAAGGTGTGGTTCCAG  TAGCCGACGCCATCTCTGCC 
Otx2 GTGGGCTACCCCGCCACC  AGAACGTCGAGCTGTGCCCT 
Bub3 TGCCACAGGTGGTTCGGATGG  GGAAGCGATGCTGGTGGGGT 
Fhit TCCTTCGCCCTGGTGAATAG  CCACTTCATCAGGATGTAGGTCA 
Dnmt3a GAGGGAACTGAGACCCCAC  CTGGAAGGTGAGTCTTGGCA 
En1 CGTCCGTCCTCTGGTCCACG  GCGGCCGCTTGTCTTCCTTC 
En2 CCGGCCTTCTTCAGGTCCCA  GCGAGGCCGCTTGTCCTCTT 
Nfix AGTCCAGCTTTCCTGACTTCT  AGTCCAGCTTTCCTGACTTCT 
Pitx2 GCCCGAGTCCGGGTTTGGTT GCTGGTTGCGTTCCCGCTTT 
Otp CTAGCGCTGCGTATCGGGCT  TGGAACCAGACCTGCACCCG 
Msx2 CGAAGACGGAGCACCGTGGA  TCATATGTCTGGGCGGCGGG 
Hoxd13 CGCACGCTTCTCTCGGAGGT  TGGTCGGTACGCTGCTGCTC 
Hoxc9 GCCGACCTGGACCCTAGCAA  GGGGCAGCGCTTCTTCCTTG 
Hoxd8 GGCGAGGACCCAGACCACTT  CCAGGAGCTGCTTGTGGTCTCA 
Gata6 ACCACCTCAGGGGTAGGGGC  ACTGTTCTCGGGGTTGGCGT 
Gata4 CTGGCCAGGACTGCCGCTT  GCGCAGCTGCTAGCTCCAGA 
Olig2 TCCCCAGAACCCGATGATCTT CGTGGACGAGGACACAGTC 
Tmem10 ACACTGCCATCGAATACGACA TGGATCAAGGTAAACAGCAAAGC 
Adamts4 ATGGCCTCAATCCATCCCAG  AAGCAGGGTTGGAATCTTTGC 
Myt1 ATGCCAACGGCAGTTTCC  TTGTCTTGAACTTTGGGCTGAGA 
Runx2 ATGCTTCATTCGCCTCACAAA GCACTCACTGACTCGGTTGG 
Hey2 CGCGATGAAGCGCCCTTGTG  GCTTGTAGCGTGCCCAGGGT 
Kit CCGGCTCTGTGTCCGCTGTG  CCTTGATGGCTGCCCGCACT 
Bcor TCAGCTCAGCCGAGAGCAGC AGCGCATCATTGCACGCTCAC 
Lrig2 AGGCAGGCAGCCATCAGCAA GTACCAGCGCCACCGTCAGT 
Hdac4 GGAGAGGGACGGTGCAGCAG  CCCCAGGCCTGTGACAAGGG 
Nav3 GCCACAGCACCCTGGAGACA  TGTCAGGTTGGGGATGGCCC 
Nfix CAGGGCAGTTCCCCACGCAT  GGGGGCTCCCTGGTCTGACT 
Atg5 CTGCGCCTCTGCAGGACAGT  CAAAGCCAAACCGAGGTGCCG 
Kamk1d ACCCTCGGAACTGGGGCCTT  CTCCTTGCCCTTCAGCGCCT 
Klf6 CCCGACATGGATGTGCTCCCA  CTCCAGGCAGGTCTGTTGCCA 
Kcnd3 GGGCACAAAAGAAGGCCCGC GAGGAGCCCATTGCGCTTGC 
Wnt7b CGTCGCTTTGTGGATGCCCG  CCAGAACCTTTCTGCCCGCCT 
Foxp1 CAAAGAGCGCCTGCAAGCCA  GATTCAGGGGCTGAGGGGCA 
Grin2a ACGTGACAGAACGCGAACTT TCAGTGCGGTTCATCAATAACG 
Grin2b TCAAACCCTCGACACCCGCC  CCAAAGCGTCCCCTTCCGGT Ezh2 target genes during NSC differentiation 
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Id2 CCTGGACAGAACCAGGCGTCC  TCAGATGCCTGCAAGGACAGGATG 
Gli1 CCAAGCCAACTTTATGTCAGGG AGCCCGCTTCTTTGTTAATTTGA 
Gdf6 TATCGCGCCCCTAGAGTACG  ATGCTAATGGGAGTCAGTTTGG 
Gdf7 GAGGGCGTTTGCGACTTTC  CTGCTTGTAGACCACGTTGTT 
Ctnnb1 ATGGAGCCGGACAGAAAAGC CTTGCCACTCAGGGAAGGA 
Ttc21b GGATGGGCGGTCCCAAGTCC  GCAGCTCTCGAGCCTGCTGTA 
Cdkn2a CGCAGGTTCTTGGTCACTGT TGTTCACGAAAGCCAGAGCG 
Tcf21 CCCACTAAGAAAAGCCCGCTC  CCGTTCTCGTACTTGTCGTTG 
Msi1 CCGCACGACCCCTGCAAGAT GCCGAAGTATTCGCGCAGCC 
Msi2 GCCACGGCATAGCTGGACCT  GACGGCAATGGAAGCGCCTG 
Sox2 GCATGGACAGCTACGCGCAC  AGCCCAGCTGCTCCTGCATC 
Vimentin ACAAGGCCCGTGTCGAGGTG  CCTGCAATTTCTCTCGCAGCCG 
Cd133 (Prom1)  TGGGCTTGCTGTGTGGTGTGT  GCCGAATCCAACCCCAGCCA 
Nestin AGGTGGGCAGCAACTGGCA  TCAGCCTCCAGCAGAGTCCTGT 
CXCR4 TCCAAGGGCCACCAGAAGCG AACTTGGCCCCGAGGAAGGC 
Hes5 CGACATCCTGGAGATGGCC  GCGAAGGCTTTGCTGTGTTT 
Id4 TCCCGCCCAACAAGAAAGT  GCAGGTCCAGGATGTAGTCGAT 
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8.3. Supplementary table 3 
Complete list of Ezh2 target genes (gene symbols) in NSCs   
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8.4. Supplementary table 4 
Complete list of Ezh2 target genes (gene symbols) in pOLs 
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8.5. Supplementary fiure S1 
 
 
 
Figure S1 - Ezh2 represses Wnt signaling pathways in pOLs. Knockdown of Ezh2 can activate 
Wnt signaling pathway in pOLs. The phase contrast images of pOLs cultures show that the DKK1, 
an inhibitor of Wnt signaling, could partially rescue Ezh2-shRNA treated pOLs phenotype. (a) 
Control culture of pOLs, (b) Ezh2-shRNA treated culture of pOLs, (c) pOLs culture treated with 
Ezh2-shRNA and 10ng/ml DKK1. (d) Knockdown of Ezh2 in pOLs results in upregulation of Wnt 
transcriptional target. Graph represents RT-qPCR analysis showing more than 5 fold increase in 
transcript level of Id2 in Ezh2-shRNA treated pOLs cultures compared to the control.  Id2 is a Wnt, 
beta-catenin signaling transcriptional target. 
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1. ABSTRACT 
Recently, we have demonstrated the expression of the polycomb group protein 
Ezh2 in embryonic and adult neural stem cells. Although Ezh2 remained highly 
expressed when neural stem cells differentiate into oligodendrocyte precursor 
cells, it is downregulated during the differentiation into neurons or astrocytes. 
This is in accordance with the differentiation repressive role Ezh2 is thought to 
play in the maintenance and selfrenewal of stem cells. To establish the 
importance of downregulation of Ezh2 for becoming stable differentiated 
mature astrocytes, we have studied the effect of forced Ezh2 expression in 
mature mouse astrocytes. Upon forced expression of this polycomb group 
protein, cultured astrocytes retracted their cell extensions and became 
proliferating round/bipolar cells that occasionally formed small neurosphere-like 
clusters. Analysis of the expression profile of these Ezh2-expressing astrocytes 
reveal downregulation of typical astrocytic genes, like GFAP and S100, and 
upregulation of genes that are generally expressed in neural stem cells, like 
nestin, Sox2, musashi, and CD133. However, these neural stem cell-like cells 
lack a differentiation potential, indicating that overexpression of Ezh2 alone is 
insufficient for a complete dedifferentiation. Chapter 4 
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2. INTRODUCTION 
The development of the nervous system is the product of the activity of 
multipotent neural progenitor/stem cells that sequentially pass through phases 
of expansion, neurogenesis and astrogenesis. The specific differentiation of 
neural stem cells (NSCs) to neurons, astrocytes or oligodendrocytes is 
triggered by a multitude of extrinsic factors that cause the NSCs to stop 
proliferating and to start expressing the gene programme that underlies the 
generation of a specific neural phenotypes. At the same time, transcription of 
gene programmes encoding for other neural phenotypes has to be prevented 
and silenced. Various signaling pathways and epigenetic regulatory 
mechanisms have been suggested to be involved. For instance, the 
suppression of astrocytic genes during neuronal differentiation of NSCs has 
been ascribed to the inaccessibility of STAT responsive elements in the 
astrocytic genes due to DNA or histone H3K9 methylation (Fan et al., 2005; 
Song and Ghosh, 2004; Takizawa et al., 2001), to the inactivation of these 
genes by erbB4-NCoR (Sardi et al., 2006) or by STAT-protein inactivation by 
proneural basic helix-loop-helix (bHLH) transcription factors, like neurogenin 1 
(Guillemot, 2007; Nieto et al., 2001; Tomita et al., 2000).  
Central players regulating the accessibility for transcription of lineage specific 
genes during stem cell differentiation are the polycomb group (PcG) proteins. 
PcG proteins are transcription repressors that function by modulating the 
chromatin structure. They act in complexes, so-called polycomb repressive 
complexes (PRC), of which PRC1 and PRC2 are the most prominent ones (for 
a recent review (Simon and Kingston, 2009)). Besides the histone binding 
domain RbAp48, the core components of mouse PRC2 are Eed, Suz12 and 
the methyltransferase Ezh2 which catalyzes histone H3 lysine 27 
trimethylation. Upon this H3 lysine 27 trimethylation, PRC1 is recruited, which 
contains the ubiquitin ligase Ring1, an essential component for longterm PcG 
mediated repression. The PcG proteins play a critical role in the maintenance 
of pluripotent embryonic stem (ES) cells. However, it has become clear that 
they also may be involved in the maintenance and fate choice of multipotent 
stem cells, like haematopoietic stem cells. 
A number of recent papers have demonstrated the involvement of PcG proteins 
in the maintenance of the multipotent neural stem cells and their fate choice 
during differentiation (Hirabayashi et al., 2009; Mohn et al., 2008; Sher et al., 
2008). We were the first to demonstrate the presence of the PRC2 protein 
Ezh2 in embryonic and adult NSCs (Sher et al., 2008). In accordance with the 
role Ezh2 is thought to play in the maintenance and selfrenewal of ES cells and 
the repression of lineage-determining genes, Ezh2 was down-regulated when 
NSCs differentiated into neurons or astrocytes. Remarkably, Ezh2 remained Forced Ezh2-overexpression in astrocytes 
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highly expressed in differentiating oligodendrocytes suggesting a different 
function of Ezh2 in this cell lineage (Sher et al., 2008). To further examine the 
mechanisms of neural fate determination and subsequent stabilisation, we 
have induced the expression of Ezh2 in mature mouse astrocytes and 
investigated the consequences of this epigenetic modulation for the 
maintenance of their differentiated state.  
 
3. MATERIAL & METHODS  
3.1. Cell Cultures 
Primary Murine Neural Stem Cell Culture 
Neural stem cells (NSCs) were isolated from the telencephalon of C57/BL6 
mouse embryos at embryonic day 14 (E14).  Briefly, the telencephalon was cut 
into small pieces at room temperature and after mechanical trituration in ice-
cold phosphate-buffered saline; the tissue was incubated with Accutase 
(Sigma-Aldrich, Zwijndrecht, The Netherlands, http://www.sigmaaldrich.com) 
for 10 to 15 minutes at 37°C. After repeated trituration, the cell suspension was 
passed through a cell strainer (70-mm pore size; BD Falcon, Franklin Lakes, 
NJ, http://www.bdbiosciences.com) and seeded (1–1.5 million cells) in T25 
(Nunc, Roskilde, Denmark, http://www. nuncbrand.com) tissue culture flasks 
containing proliferation medium, which consisted of Neurobasal medium 
(Invitrogen, Breda, The Netherlands, http://www.invitrogen.com) supplemented 
with B27 (2%, Invitrogen), human recombinant epidermal growth factor (EGF) 
(20 ng/ml, Invitrogen), basic fibroblast growth factor (bFGF) (20 ng/ml; 
Invitrogen), GlutaMAX (1%; GIBCO, Grand Island, NY, 
  http://www.invitrogen.com), Primocin (100 mg/ml), and heparin (5 mg/ml; 
Sigma-Aldrich) in a humidified 5% CO2/95% air incubator at 37°C. Within 3–5 
days the cells grew as free-floating neurospheres and were dissociated and 
passaged with the use of Accutase. To induce the differentiation of NSCs into 
the three neural cell types, neurospheres were exposed to Accutase for 5–10 
minutes and dissociated by triturating. Subsequently, the cells were plated in 
poly-L-lysine and laminin-coated chamber slides (Nunc), at approximately 
15,000 cells per well in Neurobasal medium supplemented with B27 for 5 days 
at 5% CO2 and 37°C. 
Primary Murine Astrocyte Culture 
Astrocytes were obtained from mixed glia cultures established from postnatal 
mouse brains. Brains from postnatal C57/BL6 mice were rapidly isolated, and 
after removal of meninges the cortices were dissected in icecold medium A 
(Hanks’ balanced salt solution supplemented with 1.5% glucose and 1.5% 
HEPES). Cortices were dissociated mechanically by trituration in medium A 
and subsequently by trypsinization for 20 minutes at 37°C in medium A Chapter 4 
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supplemented with 0.25% trypsin and 1,000 U/ml DNase I. After inhibition of 
trypsin with medium A containing 0.1 mg/ml trypsin inhibitor (Sigma-Aldrich), 
20% fetal calf serum (FCS), and 1,000 U/ml DNase I, the cells were centrifuged 
for 10 minutes at 800 rpm. Single-cell suspensions were seeded in T75 cm2 
culture flasks (Greiner Bio-One, Alphen a/d Rijn, The Netherlands, 
http://www.gbo.com/en) containing Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% FCS, 1% glutamine, 1% sodium pyrupyruvate, and 
Primocin. After 7–10 days in vitro, the mixed glial cultures were placed 
overnight on a shaker (150 rpm) at 37°C, and on the following day the 
nonadherent glial cells were removed. Next, astrocytic monolayers were 
carefully separated from the underlying adherent microglia by a mild 
trypsinization step and plated in new T75 cm2 tissue culture flasks. In the 
following weeks, the overnight shaking and trypsinization steps were repeated 
until pure astrocyte cultures (approximately 98%) were obtained.  
Primary Murine Oligodendrocyte Culture 
The above T75 cm2 flasks containing mixed glial culture were shaken 
overnight at 37°C. Subsequently, the supernatant-containing detached cells 
were centrifuged at 500 rpm and the pellet was resuspended in culture medium 
and plated in uncoated culture dishes for 30 minutes. Microglia and astrocytes 
attached to the bottom of the culture dish, whereas oligodendrocyte precursor 
cells (OPCs) remained floating. In consecutive turns the floating cells were 
transferred from one culture dish to another until a pure (approximately 95%) 
OPC culture was obtained. After centrifugation, the primary OPCs were 
cultured in defined SATO medium (oligodendrocytes specific)  
Primary Murine Cortical Neuronal Culture 
Cultures of cortical neurons were established from postnatal brains. In brief, 
cortices of C57/BL6 embryonic day 17 embryos were excised and collected in 
ice-cold HBSS supplemented with 30% glucose. Meninges were removed, and 
brain tissue was dissociated by trituration in Neurobasal-B27 medium 
(supplemented with 0.4% glucose, 2 mM L-glutamine, and 0.01% 
penicillin/streptomycin) and filtered through a cell strainer. After one washing 
step, cells were seeded on poly-D-lysine (10 mg/ml)-coated six-well plates and 
maintained in Neurobasal/B27 medium for 7-10 days in a humidified 
atmosphere (5% CO2/95% air) at 37°C. 
3.2. Ezh2-gene transfection 
Ezh2 containing plasmid was constructed by cloning Ezh2 gene in pCDNA3.1 
vector. This plasmid was used for the transient forced expression of Ezh2 in 
astrocytes. Gene transfections were performed by using an electroporesis-
based transfection protocol (Amaxa GmbH, Cologne, Germany, 
http://amaxa.com) specifically designed for the transfection of mouse Forced Ezh2-overexpression in astrocytes 
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astrocytes by Amaxa. By using Accutase, 2-3 million cells were collected from 
T75 tissue culture flasks and were transfected with 5-7ug of plasmid DNA 
containing Ezh2. For control transfections, the same vector containing DNA-
encoding green fluorescent protein (eGFP) was used. After transfection, the 
cells were cultured up to 10 days in a humidified 5% CO2-95% air incubator at 
37°C in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FCS, 
1% glutamine, 1% sodium pyruvate, EGF (20ng/ml) bFGF ( 20ng/ml) and 
Primocin. After 10 days of culture another boost of overexpression was given 
using the same procedure. After 15 days of culturing from the day of first 
transfection samples were collected for qPCR and western blot analysis  
3.3. RT-PCR, primers  
The primers used in this study are listed in table 1 
3.4. Western Blot 
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western 
blot analysis were used to detect Ezh2 and other protein expressions in NSCs 
pOLs astrocytes and neurons. Cell lysates were made in Laemmli buffer and 
boiled for 5 minutes. Proteins were separated for 1.5 hours on a 10% SDS-
polyacrylamide gel electrophoresis apparatus (Bio-Rad). Subsequently, 
proteins were transferred to nitrocellulose membranes by using semidry 
transfer buffer (25 mM Tris, 150 mM glycine, and 10% [v/v] methanol) and 3 
mA/cm2 current for 45–50 minutes. Nitrocellulose membranes were blocked 
with Odyssey Blocking Buffer (www.licor.com3% milk in TBS-T for 1 hour at 
room temperature. Membranes were probed with antibodies overnight at 4°C. 
The antibodies against housekeeping proteins were used for normalization of 
proteins of interest expression levels. Membranes were washed four times (5 
minutes each) with TBS-T. Primary antibodies were detected using fluorescent 
secondary antibodies incubation at room temperature for one hour. After four 
washes in TBS-T, protein signals were detected by using Odyssey Infrared 
Imaging System (LI-COR Biosciences). 
The intensities of the protein signals were quantified by using ImageJ software 
(NIH Image, Bethesda, MD). 
Statistical analysis of the results of three experiments was done by using 
Student’s t test. 
The following primary antibodies were used for Western blotting: 
anti-Ezh2 (BD transduction laboratories; 612666), anti-beta actin (ab6276; 
Abcam), anti-PCNA a proliferation marker (Abcam; ab29), anti-EED (Millipore; 
09-774) and anti-Suz12 (Diagenode; CS-029-100).  Primary antibodies were 
detected using the following secondary antibodies: IRDye 680 (LI-COR 
Biosciences; 926-32222) and IRDye 800CW (LI-COR Biosciences; 926-32213) 
 Chapter 4 
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3.5. Immunohistochemistry 
Undifferentiated and differentiated NSCs cultures were fixed with 4% 
paraformaldehyde and immunostained for markers of various neural cell types. 
The following antibodies were used: Undifferentiated NSCs: anti-nestin 
(ab22035, Abcam) to identify neurons, anti-microtubule-associated protein-2 
(AB5622, Millipore) astrocytes: anti-glial fibrillary acidic protein (MAB3402, 
Millipore) and pOLs: anti-oligodendrocytes clone NS-1 (MAB1580, Millipore)   
Fluorescein isothiocyanate- or Cy3-conjugated secondary antibodies and 
Hoechst nuclear staining were used to identify the labeled and unlabeled cells. 
Zeiss (Axioskope 2) fluorescent microscope equipped with a Leica DFC300FX 
camera and the Leica microsystem LAS program was used to make pictures. 
 
4. RESULTS  
 
 
Figure 1 – a. Immunohistochemical staining showing the expression of Ezh2 in cultured NSCs, in 
pre-oligodendrocytes (pOLs) and (weakly) in neurons but not in astrocytes. The various cell types 
are characterized via double staining for specific markers, i.e. nestin for NSCs, GFAP for 
astrocytes, MAP2 for neurons and RIP for pOLs. Similar data were obtained from PCR analysis (b) 
and with Western Blot (c). Forced Ezh2-overexpression in astrocytes 
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Immunohistochemical staining shows prominent expression of the polycomb 
group protein Ezh2 in cultured neural stem cells (NSCs) isolated from E14 
mouse embryo’s (figure 1a).  
Differentiation of the NSCs into an astrocytic phenotype is accompanied by a 
complete downregulation of Ezh2 expression, in contrast to a remnant weak 
expression upon differentiation into neurons and a high expression in freshly 
differentiated pre-oligodendrocytes (pOLs).The immunohistochemical data are 
confirmed by qPCR and Western Blot analysis ( figure 1b and c). 
Forcing expression of Ezh2 in a culture of pure mature astrocytes (figure 2a) 
results in a complete retraction of their astrocytic extensions and a switch to a 
round cell type within 5 days (figure 2b). These cells started to divide when 
exposed to EGF and FGF2, and occasionally the onset of small neurosphere-
like aggregate formation was observed. No significant cell death due to the 
forced Ezh2 overexpression was detected (data not shown). 
 
 
 
Figure 2 – a. Western Blot analysis shows the absence of Ezh2 expression in (control) astrocytes 
and the forced Ezh2-overexpression (OE) after gene transfection. b. After 5 days of culture, the 
Ezh2-overexpressing astrocytes loose their astrocytic phenotype with the flat extensions and turn 
into round dividing (arrows) cells; occasionally the onset of neurosphere formation was observed 
(open arrow). 
 Chapter 4 
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Comparing the expression profiles of control astrocytes (transfected with GFP- 
or noncoding DNA) with those of astrocytes 5 days after the forced 
overexpression of Ezh2, revealed a significant switch from an astrocytic profile 
into a more neural stem cell like phenotype: a steep downregulation of typical 
astrocytic genes, like GFAP and S100b, was accompanied by a clear induction 
of the expression of nestin, vimentin, Sox2, musashi 1/2 and CD133 (figure 
3a).  
Western Blot analysis of PCNA (proliferation cell nuclear antigen), a 
proliferation marker (figure 3b), shows an increase of approximately 50% in 
proliferation activity in the dedifferentiated astrocytes after induced Ezh2-
overexpression in medium containing the proliferation factors EGF and FGF2. 
However, withdrawal of these factors did not induce the differentiation of these 
neural stem cell-like cells. The observed incomplete dedifferentiation of 
astrocytes may have been due to an aberrant composition and function of the 
PRC2 complex. 
 
 
 
Figure 3 – a. Expression profiles of Ezh2-expressing astrocytes based on qPCR analysis; control 
expression levels are set as 1; forced Ezh2-expression results in a downregulation of typical 
astrocyte proteins and the upregulation of NSC markers (error bar is standard deviation; n=3). b. 
Western Blot analysis of the expression of PCNA, a proliferation marker, in control astrocytes and 
in Ezh2 OE astrocytes; quantification of this Western Blot shows a 60% increase in PCNA in Ezh2 
OE astrocytes in comparison to control ones (b’).  
 
Western Blot analysis was performed in order to check whether the forced 
expression of Ezh2 in astrocytes and the subsequent dedifferentiation into Forced Ezh2-overexpression in astrocytes 
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NSC-like cells was accompanied by an induction of the expression of the other 
core PRC2 components, Eed2 and Suz12.. Our results show that Suz12 (plus 
an additional isoform) was expressed but not Eed, indeed suggesting the 
presence of an incomplete PRC2 complex (figure 4). 
 
 
 
Figure 4 – Forced Ezh2-overexpression in astrocytes induces an incomplete upregulation of the 
other PRC2 components normally present in NSCs; Western Blot analysis shows induced 
expression of Suz12 but not of Eed2.  
 
5. DISCUSSION  
The differentiation of neural stem cells (NSCs) into astrocytes, neurons or 
oligodendrocytes is a unidirectional process leading to neural cell types of 
which the stability is epigenetically assured by chromatine modifications. 
Previously, we described that upon development of astrocytes the repressive 
epigenetic factor Ezh2 was completely downregulated. In order to study the 
importance of this downregulation of Ezh2, we induced the expression of Ezh2 
in mature astrocytes. This forced expression of Ezh2 indeed resulted in a 
(partial) dedifferentiation of the astrocytes towards NSCs.  
The formation of a mature astrocyte requires stable repression of non-
astrocytic genes (e.g. genes that support a neuronal or oligodendrocytic cell 
lineage) and the silencing of neural stem cell genes. Our data indicate that 
forced expression of the PcG protein Ezh2 results in the repression of genes 
directly or indirectly involved in determining the astrocytic cell lineage. Apart 
from this astrogenic repression, a concomitant derepression and/or reactivation 
of typical neural stem cell genes was observed. It is possible that products of Chapter 4 
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astrocytic genes suppress neural stem cell gene transcription; induced 
repression of these NSC-gene inhibitors by Ezh2 may have led to the 
derepression of the NSCs genes.  
Forced Ezh2 over-expression also resulted in an increase in proliferative 
activity in astrocytes transfected with Ezh2. 
Various studies on glioblastoma cancer stem cells have shown that Ezh2 
modulates genes implicated in cell cycle control. Disruption of Ezh2 signalling 
in glioblastoma stem cells has been shown to strongly impair self-renewal via 
c-Myc and prevents glioblastoma stem cell maintenance. Forced 
(over)expression of Ezh2 activated c-Myc transcription and stimulated self-
renewal proliferation and (re)activation of stem cell properties (Suva et al., 
2009). 
As demonstrated by Hirabayashi et al. (Hirabayashi et al., 2009), during the 
differentiation of NSCs into astrocytes, the cell fate choice into neurons is 
prevented by Ezh2 and its role in the PRC2 complex repressing the promotor 
of the proneural gene neurogenin1. Apparently, this provisionary repression in 
the NSCs during astrocytic differentiation is replaced by a more stable 
repression in the mature astrocyte via DNA methylation which no longer 
requires the action of PRCs. Apparently, this stable neurogenin1 silencing 
seems still preserved in the astrocytes that dedifferentiated due to forced Ezh2 
expression since no neuronal genes were derepressed or reactivated (data not 
shown). 
The incomplete dedifferentiation of the astrocytes towards a neural stem cell 
state by forcing singularly the Ezh2 expression raises several interesting 
questions for future research: what is the action on transcription of Ezh2 alone 
or within an incomplete PRC2 complex, what would dedifferentiation be like if 
the other components and an intact PRC2 complex was induced in the 
astrocytes and which are the target genes involved?  
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1. ABSTRACT 
A major issue in the potential application of neural stem cell (NSC)-based cell 
replacement therapy for demyelinating diseases is the question regarding the 
survival, functional behaviour and stability of implanted NSC-derived OPCs over 
an extended period. To address this issue, we have employed Bioluminescence 
Imaging (BLI) as a non-invasive longitudinal in-vivo monitoring technique and 
followed the fate of NSCs, isolated from luciferase-GFP-actin transgenic mice, 
after stereotactic implantation in the demyelinated corpus callosum of 
cuprizone-fed mice. We compared normal NSCs with NSCs that were primed to 
become OPCs by the induction of Olig2 overexpression (Olig2-NSCs) (Copray 
et al., 2006). BLI, validated by immunohistochemistry revealed that, after a 
steep cell loss after implantation during the first 3 weeks, approximately 10% of 
the Olig2-NSCs stably survived for two months after implantation, in contrast to 
<1% of the normal NSCs. Immunohistochemistry at light and 
electronmicroscopic level, revealed that the surviving Olig2-NSCs, in majority, 
had differentiated into an oligodendrocytic cell lineage and contributed to 
remyelination of axons in the corpus callosum. The number of axons 
remyelinated by the implanted cells, however, was a small fraction of the total 
number of axons remyelinated by endogenous oligodendrocytes. Apparently, 
most of the implanted NSCs do not survive the transition into an inappropriate 
nonneurogenic niche, compressed by surrounding host tissue, in hostile, 
inflammatory conditions created by activated microglia. Only the ones that 
manage to differentiate rapidly into a mature neural cell type and become 
functionally integrated survive.  Chapter 5 
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2. INTRODUCTION 
Neural stem cells (NSCs) are considered as a potential source for 
oligodendrocyte precursor cells (OPCs) to be used in cell based remyelination 
therapies for multiple sclerosis (MS) and other de-myelinating diseases 
(Einstein et al., 2006; Goldman et al., 2006; Karussis and Kassis, 2007; 
Keirstead, 2005; Miller and Bai, 2007; Pluchino et al., 2003; Pluchino and 
Martino, 2005; Pluchino et al., 2005). The newly described procedure to 
endoscopically harvest NSCs from the ventrical wall has opened the option to 
obtain autologous NSCs from MS patients and so to generate in-vitro a 
sufficient amount of transplantable autologous remyelinating cells (Westerlund 
et al., 2005). Furthermore, novel protocols to re-program somatic cells 
(fibroblasts, lymphocytes) into embryonic stem cell-like cells, the so-called 
induced pluripotent stem cells (IPS) via gene transfection of 4 “pluripotent” 
transcription factors (Oct4, Sox2, Klf4 and cMyc) offer ample possibilities to 
obtain autologous NSCs (Takahashi et al., 2007; Wernig et al., 2008; Yu et al., 
2007; Hanna et al., 2008; Meissner et al., 2007).  In-vitro differentiation of 
NSCs into OPCs can be achieved by supplementing the differentiation medium 
with specific cocktails of oligodendrogenic factors or by forcing the 
(over)expression of transcription factors shown to play a decisive role in 
embryonic oligodendrocytic cell lineage commitment (Balasubramaniyan et al., 
2004; Cheng et al., 2007; Copray et al., 2006; Liu et al., 2007; Pedraza et al., 
2008; Zhang et al., 2005; Zhou et al., 2001). We have shown that gene 
transfection of Olig2 can promote the differentiation of mouse NSCs into an 
oligodendrocytic cell lineage (Copray et al., 2006). The remyelinating capacity 
of these NSC-derived OPCs was demonstrated in the cuprizone mouse model: 
feeding 0.2% (w/w) cuprizone induces the selective oligodendrocyte death in 
major axon bundles and leads to demyelination of the corpus callosum. In a 
short term (2 weeks) study it was shown that NSC-derived OPCs did 
remyelinate denuded axons in cuprizone-fed mice (Copray et al., 2006). A 
major issue in the potential application of NSC-based cell replacement therapy 
obviously is the question regarding the survival, functional behaviour and 
stability of implanted NSC-derived OPCs over an extended period. To address 
this problem, a variety of non-invasive imaging techniques has become 
available enabling the longitudinal monitoring of the fate of labelled grafted 
cells in small experimental animals. One of them is Bioluminescence Imaging 
(BLI), which enables the detection of luciferase-expressing cells in intact 
animals. To study the feasibility of the BLI approach in the cuprizone mouse 
model for demyelination and to examine the long-term fate of NSC-derived 
OPCs in this model, we have stereotactically implanted Olig2-transfected 
NSCs, isolated from luciferase-GFP-actin transgenic mice, into the Longterm tracking of implanted NSCs & Olig2 NSCs 
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demyelinated corpus callosum and followed their survivability, fate and 
functionality. 
 
3. MATERIALS & METHODS 
3.1. Animals 
FVB and FVB luciferase-GFP–actin transgenic mice were used in all 
experiments. They were housed under standard conditions with free access to 
food and water. All animal experiments were designed and carried out in 
accordance with the National Institute of Health Guide for the Care and Use of 
Laboratory Animals and regulations of the local Experimental Animal 
Committee. 
3.2. Cuprizone mouse model 
FVB mice were put on a diet of 0.2% (w/w) cuprizone (Sigma Aldrich, 
Zwijndrecht, The Netherlands), a copper chelator. This diet leads to selective 
oligodendrocyte death followed by demyelination of axons mainly in the corpus 
callosum. During short-term exposure (<6 weeks), dying oligodendrocytes are 
replaced by oligodendrocyte precursors cells (OPCs) located in the corpus 
callosum and adjacent tissues. However, feeding cuprizone diet for a longer 
term (>12 weeks) results in depletion of the pool of endogenous OPCs in the 
corpus callosum and finally leads to its complete demyelination (Mason et al., 
2004). This long-term cuprizone-diet model with the denuded corpus callosum 
axons has been shown adequate to study the remyelination potential of 
implanted OPCs. 
 3.3. Neural stem cells 
Neural stem cells (NSCs) were isolated from the telencephalon of luciferase–
GFP-actin transgenic mouse embryos at E14. Briefly, the telencephalon was 
cut into small pieces at room temperature and after mechanically trituration in 
ice-cold phosphate buffer saline (PBS, 0.1M) the tissue was incubated with 
accutase (Sigma Aldrich, Zwijndrecht, The Netherlands) for 15 minutes at 37C
o
. 
After repeated trituration, the cell suspension was passed through a cell 
strainer (70 μm pore size; Falcon, Franklin Lakes, NJ) and seeded (1-1.5 
million cells) in T25cm
2 (Nunc, Roskilde, Denmark) tissue culture flasks 
containing proliferation medium, which consisted of Neurobasal medium 
(Invitrogen, Breda, The Netherlands) supplemented with B27 (2%, Invitrogen), 
human recombinant epidermal growth factor (EGF) (20ng/ml, Invitrogen), basic 
fibroblast growth factor (bFGF) (20ng/ml; Invitrogen), glutamax (1%; Gibco), 
primocin (100μg/ml) and heparin (5μg/ml; Sigma Aldrich) in a humidified 5% 
CO2/95% air incubator at 37°C. Within 3-5 days the cells grew as free-floating 
neurospheres which were dissociated with the use of accutase and passaged 
every 3
rd day. Luciferase expression in isolated and cultured luciferase–GFP-Chapter 5 
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actin transgenic NSCs was verified with a standard luciferase assay in a 
Bioluminometer.  
3.4. Gene transfection 
Overexpression of Olig2 was induced in NSCs by transfection of pIRES 
expression vector containing the Olig2 gene (972 bp). Transfection was 
performed using an electroporation protocol (Amaxa GmbH, Cologna, 
Germany) specifically designed for the transfection of embryonic mouse NSCs. 
For control transfections, a vector expressing green fluorescent protein (eGFP) 
provided by Amaxa was used. The transfection efficiency of this procedure for 
mouse NSCs is approximately 70% and results in the transient expression of 
the transfected gene lasting up to 10-12 days.  
3.5. Western Blot analysis 
SDS-PAGE gel electrophoresis and Western Blot analysis was used to 
demonstrate the actual Olig2 (over)expression in the transfected luciferase-
GFP-actin NSCs. Samples of the transfected NSCs were centrifuged 72 hours 
following gene transfection. After centrifugation cells were re-suspended in 
Radio Immuno Precipitation Assay (RIPA) buffer along with a cocktail of 
protease inhibitors. Resuspensions were sonicated for 5 seconds and 
centrifuged for 10 min at 12000 RPM and 4°C. Supernatants were mixed with 
Laemmli Buffer and boiled for 5 minutes. Proteins were separated for 1,5h on a 
10% SDS-polyacrylamide gel electrophoresis apparatus (Biorad, Hercules, 
CA). Subsequently, proteins were transferred to nitrocellulose membranes 
using semi-dry transfer buffer (25mM Tris, 150mM glycin, 10% (v/v) methanol) 
and 3 mA/cm
2 current for 45-50 minutes. Nitrocellulose membranes were 
blocked with 3% milk in TBS-T (0,1% Tween-20) for 1h at room temperature. 
Subsequently membranes were probed overnight at 4°C using mouse anti-
Olig2 antibody (Abcam, Cambridge, UK, ab290) at 1:1000 dilution in blocking 
solution and mouse anti-β-actin (Abcam, ab6276) at 1:5000 dilution. (The 
expression of the housekeeping gene β-actin was used for normalization of 
Olig2 expression levels). Primary anti-Olig2-antibody and anti-β-actin antibody 
were detected using horseradish peroxidase (HRP)-conjugated anti-mouse IgG 
(Dako, Glostrup, Denmark, P0260). Incubation with secondary antibody was 
performed for 1h at room temperature at 1:10000 dilutions in blocking solution. 
After washing, protein signals were detected with the enhanced 
chemiluminescence detection system (ECL, Amersham Biosciences, 
Roosendaal, The Netherlands). Signals were visualized on X-ray film (Konica 
Minolta, Nieuwegein, The Netherlands) and quantified. The intensities of the 
protein signals were quantified using Image J software (NIH Image, Bethesda, 
Md). Measured intensities (pixel-counts) of β-actin were used to normalize the 
intensities of the Olig2 signals. Normalized intensities of Olig2-samples were Longterm tracking of implanted NSCs & Olig2 NSCs 
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used to calculate the relative expression level of Olig2. Statistical analysis of 
the results of 3 experiments was done using Student’s t-test.  
3.6. Flow cytometry 
To determine the effect of Olig2 overexpression on differentiation of luciferase–
GFP-actin transgenic NSCs towards oligodendrocytes flow cytometric analysis 
was performed. After 72 hours of transfection, cells were subjected for 
differentiation (24hours) on poly-l-lysine and laminin coated T75cm
2  tissue 
culture flasks in (oligodendrocyte-specific) SATO medium consisting of 
Dulbecco’s Modified Eagle’s medium (DMEM) with the following additives: 
glutamax (1%) putrescine (16 µg/ml; Sigma), thyroxin (T4, 400 ng/ml; Sigma), 
triiodothyroxin (T3, 400 ng/ml; Sigma), progesterone (6.2 ng/ ml; Sigma), 
sodium selenite (5 ng/ml; Sigma), bovine serum albumin (BSA, 100 µg/ml; 
Sigma), insulin (5 µg/ml; Sigma), transferrin (50 µg/ml; Sigma),  B27 (2%) and 
primocin (100ng/ml). Flow cytometry was performed with antibody against 
CD140a/platelet derived growth factor receptor alpha (PDGFRa) an 
oligodendrocytes precursor cell (OPCs) marker (eBioscience 12-1401). After 
achieving partial differentiation, cells were detached by using cell scratcher and 
washed with PBS. After washing, cells were incubated for 10 minutes on ice in 
total volume of 100ul ice-cold PBS, 5% fetal calf serum (FCS) and 
phycoerythrin (PE) conjugated anti-mouse CD140a (PDGFRa) 0.4ug per 
million cells. In the same concentration an isotypic control, rat IgG2a k 
(eBioscience) was also used. Subsequently, cells were washed, pelletted by 
centrifugation and re-suspended in 300 μl of PBS. Cells were analyzed with 
488 nm laser FACS Calibur with 530/30nm, 585/42nm and 670nm/LP filters 
using Cell Quest software (Becton Dickinson). For the analysis of 
flowcytometric measurements WinMDI 2.8 software was used. At least five 
thousand cells were analyzed for each immunocytochemical staining. OPCs 
population was determined based on their characteristic expression pattern of 
CD140a. 
3.7. Implantation of NSCs 
At 12 weeks after the start of the cuprizone diet, mice were divided into two 
groups; one group (n=6) received control luciferase-GFP-actin transgenic 
NSCs transfected with GFP while the other group (n=6) was given luciferase-
GFP-actin transgenic NSCs transfected with Olig2. Using the following 
stereotactic co-ordinates (in reference to Bregma point): +0.98mm 
(anterioposterior axis), -1.75mm (lateromedial axis), -2.25mm (vertical axis) 
(Paxinos and Franklin, 2001), suspensions of 100,000 cells in 3µl PBS were 
slowly injected into the corpus callosum of ketamine-anesthetized mice using a 
10 µl Hamilton injection syringe (22s/2"/3) (Hamilton, Reno, Nevada, 80365). 
Every injection was done within a standardized time-window, i.e. 5 minutes Chapter 5 
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injection time and 2 minutes deposition rest, before needle retraction in order to 
prevent potential variation in the effect of shearing forces.  After the 
implantation of the NSCs, mice were taken off the cuprizone diet and put back 
on normal diet to avoid degeneration of the NSC-derived freshly formed OPCs 
by cuprizone. 
3.8. Bioluminescence imaging 
For the in-vivo longitudinal tracking of the cell grafts, each animal was imaged 
twice a week with the use of the IVIS Imaging System 100 Series of Xenogen 
Corporation (Caliper Life Sciences, Alameda, Ca). At each imaging session, 
each mouse received an intraperitoneal injection of D-luciferin (300mg/kg) in 
normal physiological salt solution. Ten minutes after the D-luciferin injection, 
animals were anaesthetized with isoflurane (2.5% isoflurane in oxygen, 
1.5L/min) and placed in a standardized position in the chamber of the CCD-
camera system. The Living Image® 2.5 software program (Xenogen 
Corporation), was used for data analysis. Images representing luciferin light 
intensity, ranging from blue (least intense) to red (most intense), were merged 
with the reference image to enable anatomical localization. Images were 
displayed and regions of interest (ROIs) were quantified in terms of radiance 
(photons/sec/cm2/sr). 
3.9. Immunohistochemistry 
At 60 days after implantation, mice were perfused transcardially with 4% 
paraformaldehyde (PFA) under isoflurane anaesthesia. Brains were excised 
and sectioned on a cryostat for immunohistochemical analysis of the cell 
implants. To locate implanted luciferase-GFP-actin transgenic cells goat anti-
luciferase (Chemicon, Millipore, Amsterdam, The Netherlands, ab3256) and 
rabbit anti-GFP (Abcam, ab290) antibodies were used, following heat induced 
epitope retrieval (HIER) method (10mM Sodium Citrate , 0.05% Tween 20, pH 
6.0). 
To analyze the survival and differentiation of the implanted cells, the following 
primary antibodies directed against oligodendrocyte-, neuron- or astrocyte-
markers were used: for astrocytes, anti glial fibrillary acidic protein (GFAP) 
(Chemicon, mab3402); for neurons, anti microtubule-associated protein 
(MAP2) (Chemicon, ab5622); for oligodendrocytes, anti-RIP (Chemicon, 
mab1580), anti-platelet derived growth factor receptor alpha (PDGFR-α) (Santa 
Cruz Biotechnology Inc, Santa Cruz, Ca) anti-NG2 (Chemicon, ab5320), and 
anti-myelin basic protein (MBP) (Chemicon, ab980). In addition, anti-KI67 
(Chemicon, ab9260) was used to label mitotic cells. 
Subsequently, various fluorescent secondary antibodies were used to visualize 
the specific primary immunoreaction product in single and double 
immunohistochemical stainings.  Longterm tracking of implanted NSCs & Olig2 NSCs 
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3.10. Cell counting 
Quantitative analysis of implanted cells in both groups was carried out by 
counting GFP-positive cells in cryostat sections that contained the entire 
implantation area of the corpus callosum by using Fluorescent Microscope 
equipped with a Leica DFC300FX camera and the Leica microsystem LAS 
program. Quantification of different cell types was done based on cell type 
specific immuno double staining (GFP/cell specific marker).  Percentages of 
various cell types were calculated against total number of GFP positive cells in 
the injection area. Statistical analysis of the results of all six animals in each 
group was performed using Student’s t-test 
3.11. Electronmicroscopy 
A number of 4% FPA fixated brains containing cell implants were processed for 
electronmicroscopy to evaluate the de- and remyelination of the corpus 
callosum and the contribution of implanted cells in myelination. 100-µm
 
sections of the corpus callosum area were cut on a Vibratome
  tissue slicer 
(Warner Instruments, Hamden, CT)
 and processed for 3,3’-diamino-benzidine 
(DAB)-peroxidase immunohistochemistry using primary antibodies directed 
against GFP with the antigen retrieval method (HIER)  and peroxidase-
conjugated secondary antibodies to identify the implanted luciferase-GFP-actin 
transgenic cells at ultrastructural level. Intensification of the DAB reaction 
product was effectuated using the silver-gold-substituted-peroxidase (GSSP) 
method (Liem et al., 2001; Liposits et al., 1982). The GSSP-treated vibratome 
sections were rinsed briefly in 0.1
 M sodium acetate cacodylate buffer, pH 7.6 
and postfixed for 1 hour in 1% osmium tetroxide (w/v) in the same buffer. The 
sections were then dehydrated and embedded in Epon 812. Semithin (1-µm) 
sections
 were stained with toluidine blue to check for the presence of
 relevant 
areas before cutting ultrathin sections (60 nm) that
 were counterstained with 
uranyl acetate and lead citrate and
  examined using a Philips CM-100 
electronmicroscope (Philips,
 Eindhoven, The Netherlands). 
 
4. RESULTS 
4.1. Characterization of luciferase-GFP-actin transgenic NSCs 
We prepared NSC cultures from luciferase-GFP-actin transgenic embryos at 
embryonic day 14 (E14). Neurospheres in expansion medium showed very 
high GFP signal under the inversed fluorescent microscope (figure 1a). 
However, after fixation, the GFP signal was no longer visible presumably due 
to changes in molecular configuration. To demonstrate luciferase expression in 
dissociated, 4%PFA fixated, luciferase-GFP-actin transgenic NSCs, we 
performed immunostaining resulting in a clear luciferase signal (figure 1b). To 
check the intensity of the luciferase signal emitted by these cells in-vitro, we Chapter 5 
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compared them with wild type NSCs using a luminometer. Luminometer 
analysis showed a very high luciferase activity in transgenic cells in comparison 
to control (wild-type NSCs) (figure 1f).  
 
 
 
Figure 1 - Neural stem cells (NSCs) isolated from luciferase-GFP-actin transgenic mice form GFP 
positive neurospheres in-vitro (a) and each neural stem cell produces luciferase after dissociation 
(b). After withdrawal of growth factors, these neural stem cells differentiate into GFAP-positive 
astrocytes (c), MAP-2–positive neurons (d) and RIP-positive oligodendrocytes (e). Blue= Hoechst 
nuclear staining. Bar in a = 200μm, bar in b =50μm, bar in c-e =100μm. Luminometer analysis of 
the luciferase production by luciferase-GFP-actin transgenic NSCs revealed a very high level of 
expression (f). 
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To establish the normal differentiation potential of the luciferase-GFP-actin 
transgenic NSCs, we cultured them in basic differentiation medium for five to 
six days. Immunostaining of these differentiated cultures by using different 
neural cell markers confirmed that these cells indeed differentiated into 
neurons, astrocytes and oligodendrocytes (figure 1c-e), in an approximately 
similar ratio (astrocytes 55%, neurons 35%, oligodendrocytes 8%) as described 
before for wild-type E14 NSCs (Balasubramaniyan et al., 2004; Copray et al., 
2006). 
4.2. Oligodendrocyte differentiation of luciferase-GFP-actin transgenic 
NSCs 
Overexpression of Olig2 in E14 wild-type NSCs during differentiation promotes 
their differentiation into oligodendrocyte precursors cells (OPC) which develop 
into fully functional myelinating oligodendrocytes in-vivo (Copray et al., 2006). 
 
 
Figure 2 - Nonviral transfection of the luciferase-GFP-actin transgenic NSCs with the Olig2 gene 
results in overexpression of this transcription factor as demonstrated with Western Blotting (a), an 
expression approximately 16 times as high as nontransfected controls (a’). Oligodendrocyte 
differentiation was analyzed by Flow Cytometry using anti-PDGFr-a and showed a clear increase in 
the population of anti-PDGFr-a PE positive cells in Olig2 transfected luciferase-GFP-actin 
transgenic NSCs in comparison to control luciferase-GFP-actin transgenic NSCs (b)Flow 
cytometric analysis of oligodendrocyte differentiation of luciferase-GFP-actin transgenic Olig2-
NSCs and control NSCs. On the Y-axis number of events (cells) with a fluorescence activity (X-
axis) due to labeling by a PE-conjugated antibody directed against PDGF receptor a.  Chapter 5 
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To investigate whether a similar stimulation of oligodendrocyte differentiation 
could be induced in luciferase-GFP-actin transgenic NSCs, we transiently 
overexpressed Olig2 in these cells via nonviral gene transfection with Amaxa. 
We confirmed Olig2 overexpression with Western Blot analysis, which showed 
a 16-fold increase (figure 2a-a’). The Olig2-overexpressing luciferase-GFP-
actin transgenic NSCs were cultured in differentiation medium. Analysis of 
OPC differentiation was done using Flow Cytometry with antibodies directed 
against the platelet-derived growth factor alpha-receptor (PDGFr-α), a marker 
of OPCs (figure 2b). The data obtained from Flow Cytometry analysis indicated 
that overexpression of Olig2 in luciferase-GFP-actin transgenic NSCs tripled 
the number of OPCs obtained after differentiation in comparison to control 
GFP-transfected NSCs (figure 2b) confirming that also in the luciferase-GFP-
actin transgenic NSCs overexpression of Olig2 promotes oligodendrocyte 
differentiation.  
4.3. Bioluminescence imaging of implanted NSCs 
To examine the longterm behaviour of NSC-derived OPCs that were 
stereotactically deposited in the demyelinated corpus callosum, we have used 
two groups of cuprizone fed mice: group 1 (n=6) injected with normal (control 
GFP-transfected) luciferase-GFP-actin transgenic NSCs and group 2 (n=6) 
with Olig2-transfected luciferase-GFP-actin transgenic NSCs (Olig2-NSCs). 
After the implantation of the NSCs, mice were taken off the cuprizone diet and 
put back on normal diet to avoid degeneration of the NSC-derived freshly 
formed OPCs by cuprizone. 
Using the in-vivo imaging (IVIS) system (Xenogen Corporation), the first 
scanning for luciferase activity in both groups of animals was performed three 
days after stereotactic injection of the NSCs (figure 3). 
At that time point, both groups showed a very intense luciferase signal that was 
concentrated at the site of implantation (1.5-2.0x10
9 photons/sec/cm2/sr). 
During the following 2 weeks, in both groups, the signal intensity steeply 
decreased to less than 15% of the first measurement (2,5x10
8 
photons/sec/cm2/sr), suggesting massive cell death after implantation (figure 
3). However, whereas the signal in the first group of cuprizone-fed mice, 
implanted with control luciferase-GFP-actin NSCs continue to decrease and 
became undetectable from day 50, the remaining implanted Olig2-transfected 
luciferase-GFP-actin cells in group 2 survived and showed intense, stable 
luciferase activity until the end of the study (figure 3). It should be added that 
throughout the study the luciferase signal in both groups remained 
concentrated at the site of injection and no spreading to other parts of the brain 
or the body was detected. 
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Figure 3 - IVIS analysis of control (blue) and Olig-2 transfected (purple) luciferase-GFP-actin 
transgenic NSCs stereotactically implanted in the corpus callosum of cuprizone fed mice. (a) 
Regions of interest were measured during 60 days and the intensity of the signals was expressed 
as radiance (photons/sec/cm
2/sr). Each point is the mean of 6 animals ± standard deviation. (b) 
Examples of IVIS scans at the indicated time points of 2 mice, one receiving control NSCs, the 
other receiving Olig2-NSCs. Color bar indicates the intensity levels. 
 
At the end of the experiment, the stable luciferase signal in the group that 
received the Olig2 transfected NSCs was almost 10% of the initial signal 
suggesting that a minority of the implanted cells survived and that most of the 
implanted cells either died or lost their luciferase expression/activity. Chapter 5 
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Immunohistochemical analysis of the implantation sites of the brains of both 
groups fixated at day 60, was performed to examine these possibilities. 
4.4. Immunohistochemical analysis of cell implants 
Immunohistochemical analysis was performed on 14μm cryosections of 4% 
PFA-fixated brains of mice perfused 60 days after implantation. First of all, we 
examined the presence and location of implanted luciferine-GFP-actin 
transgenic cells using anti-GFP immunostaining. In accordance to the IVIS 
data, we were able to detect 9372 ± 3043 GFP-positive cells in group 2 mice 
that received the Olig2-transfected luciferase-GFP-actin transgenic NSCs, 
accounting for approximately 10% of the initial cell graft; likewise, in group 1 
mice that received control NSCs and lacked detectable luciferase activity in 
IVIS scans at day 60, only a few of the implanted cells could be found in the 
histological sections, on average 785 ± 654 GFP-positive cells (less than 1% of 
the number of initially implanted cells (figure 4). In both groups, all the 
implanted cells were located in the corpus callosum at or close to the 
implantation site. To establish any proliferative activity of the implanted NSCs, 
we performed double immunostaining for GFP and KI67, a proliferation marker: 
no GFP/KI67 double-positive cells could be detected in the corpus callosum of 
both groups (data not shown). 
 
 
 
Figure 4 - Bar graph showing the number of surviving luciferase-GFP-actin transgenic Olig2-NSCs 
cells and control NSCs 2 months after implantation.  
 
In order to examine the fate of the surviving Olig2-NSCs two months after 
implantation, we have performed double immunolabelling to identify the Longterm tracking of implanted NSCs & Olig2 NSCs 
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implanted luciferase-GFP-actin transgenic cells, to determine their differential 
state. 
 
 
 
Figure 5 - Immunohistochemical analysis of luciferase-GFP-actin transgenic Olig2-NSCs implanted 
in the corpus callosum of cuprizone treated mice. Double immunostaining for GFP (a) and for 
GFAP (a’) revealed two double-labelled cells (a”, arrows) among the implanted surviving Olig2-
NSCs that has differentiated into an astrocytic cell lineage. Likewise, sporadically implanted Olig2-
NSCs were found to differentiate into neurons (arrows), as shown by double immunostaining for 
GFP and MAP2 (b-b”). However, several of the implanted Olig2-NSCs, surviving after 2 months, 
differentiated into OPCs (arrows) as revealed by double immunostaining for GFP and RIP (c-c”); 
arrowheads indicate endogenous OPCs. Blue nuclei: Hoechst staining, CC= corpus callosum. Bar 
(for all figures) = 50 μm. 
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Stem Cells 2009;27:1582–1591  ￿￿￿ 
Only a low number of GFP/GFAP double labeled cells could be detected (figure 
5a-a”) indicative for astrocytes and only a few of GFP-positive implanted cells 
expressed MAP2, a marker for a neuronal fate (figure 5b-b”). In the Olig2-
NSCs implanted corpus callosum, among endogenous oligodendrocyte 
progenitor cells (OPCs), many RIP/GFP-positive cells were found indicating 
recent differentiation of Olig2-NSCs into OPCs (figure 5c-c”). 
 
 
 
Figure 6 - Double immunostaining for GFP and MBP of implanted luciferase-GFP-actin transgenic 
Olig2-NSCs to demonstrate their differentiation into mature oligodendrocytes. (a-a”) A group of 
GFP-positive Olig2-NSCs at the site of implantation just below the corpus callosum (CC) contains 
cells that have differentiated into mature oligodendrocytes according to their GFP/MBP double 
staining. (b-b”) Slightly more lateral from the implantation site in the corpus callosum, more GFP-
positive Olig2-NSCs can be detected which had differentiated into oligodendrocytes  (c-c’) Detail of 
an implanted GFP-positive Olig2-NSC that had differentiated into a mature oligodendrocyte with 
typical MBP-positive extensions; a neighbouring endogenous oligodendrocyte is indicated by an 
arrowhead. Blue nuclei: Hoechst staining. Bars in a and b = 50 μm, bar in c = 20 μm; Str= striatum  
(d) Graph showing the number of neural cell types differentiated from surviving Olig2-NSCs and 
control NSCs at the implantation site: olig=oligodendrocytes (RIP+BMP stained cells), 
astro=astrocytes, neu=neuron, un=undifferentiated (nestin-positive). Longterm tracking of implanted NSCs & Olig2 NSCs 
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However, the majority of GFP-positive implanted Olig2-NSCs had already 
differentiated into mature myelin-producing oligodendrocytes according to the 
presence of many GFP/MBP (myelin basic protein) double labelled cells (figure 
6a-c). 
Analysis of the fate of the few surviving control luciferase-GFP-actin NSCs 
revealed that they had differentiated into an oligodendrocytic cell lineage, into 
astrocytes and neurons (figure 6d). 
In both implants, infrequently undifferentiated (nestin-positive) NSCs were 
found (not shown). 
4.5. Ultrastructure of implantation site 
In order to confirm the actual contribution of implanted NSC-derived 
oligodendrocytes in myelin formation, we have performed electronmicroscopic 
(EM) analysis of the corpus callosum at the implantation site. 
The implanted luciferase-GFP-actin transgenic cells were identified in the EM-
sections by DAB-based immunohistochemistry for the presence of GFP; the 
reaction product was intensified with the silver-gold-substituted-peroxidase 
(GSSP) method, resulting in clear black granular deposits. 
Specific immunostaining with anti-GFP required antigen retrieval pretreatment 
(HIER), which unfortunately caused deterioration of the general ultrastructure. 
However, implanted cells could be clearly recognized by GSSP granules 
located within the cytoplasm in the soma and in cell extensions (figure 7). 
Moreover, labeling was found trapped in freshly formed myelin at various 
stages of formation, in particular at stages that the myelin-compaction was not 
yet completed and new myelin still contained thin rims of cytoplasm (figure 7). 
These findings imply the differentiation of implanted luciferase-GFP-actin 
transgenic cells into oligodendrocytes contributing to new myelin formation. 
The number of myelinated axons containing GFP incorporation appeared to be 
only a small fraction of the total number of myelinated axons. Since GFP is not 
membrane bound and only confined to the cytoplasm, it is difficult to detect in 
the scarse cytoplasm still present in compact myelin. 
Accordingly, it was not possible to establish the exact number of axons that has 
been remyelinated by implanted Olig2-NSCs versus the number of axons that 
has been remyelinated by endogenous OPCs recruited from surrounding 
tissues to the demyelinated site in the corpus callosum after stopping the 
cuprizone diet. The same applies for the quantification of axons myelinated by 
implanted normal control NSCs (figure 7); according to the light microscopic 
observations, the number of axons remyelinated by them should be very 
limited. 
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Figure 7 - Ultrastructure of the corpus callosum after implantation of luciferase-GFP-actin 
transgenic Olig2-NSCs (a-h) and luciferase-GFP-actin transgenic control NSCs (i- i’) after GSSP-
intensified immunodetection of the GFP ( black granules). (a). A GFP-positive labelled extension of 
an implanted Olig2-NSC has contacted and myelinated an axon (*). (b) Besides 3 slightly older 
axons remyelinated by GFP-positive implanted cells, a GFP-labelled oligodendrocyte extension 
can be detected which has just enclosed an axon (arrow). (c-d) A thin rim of cytoplasm left over 
after remyelination of an axon contains an accumulations of GSSP-intensified GFP granules. (e) 
On this overview 2 axons (arrows), remyelinated by dense granules containing oligodendrocytes, 
can be seen lying between axons remyelinated by endogenous oligodendrocytes. Arrowheads 
points to an extension of an implanted Olig2-NSC. (f) A GSSP-labeled extension has just 
enwrapped a demyelinated axon (*). (g) Detail of an axon, enwrapped by an intensely GFP-labelled 
oligodendrocyte extension. (h) GFP-labeling in this newly pre-compact myelinated axon is present 
in the internal cytoplasm as well as in the external cytoplasm ring. (i) Overview of the corpus 
callosum after implantation of control luciferase-GFP-actin transgenic NSCs. Among many 
unmyelinated and myelinated axons, an axon is located freshly remyelinated by an implanted GFP-
positive cell; boxed area is magnified in (i’). Bars in a, b, f, and g = 2 μm; c, d, h and i’ =  1 μm; e 
and i =  5 μm 
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5. DISCUSSION 
The present experiments show that Bioluminescence Imaging enables the 
longterm noninvasive in-vivo monitoring of implanted NSCs in the brain of 
experimental animals. Using this technique, we could demonstrate that, in 
contrast to control NSCs, approximately 10% of the Olig2-overexpressing 
NSCs, after a steep loss in the first 3 weeks after implantation, stably survived 
at the site of implantation. Identification of the surviving cells revealed that the 
majority of these Olig2-NSCs had become functional myelinating 
oligodendrocytes, whereas a minority had remain undifferentiated or had 
differentiated into neurons and astrocytes.  
With the development of highly sensitive camera systems, Bioluminescence 
Imaging (BLI) has become an adequate technique to monitor luciferase-
expressing cells in intact animals. The applicability of BLI in our NSC 
transplantation experiments confirm other recent BLI reports on NSC 
transplantation (Hwang et al., 2008; Waerzeggers et al., 2008) and 
endogenous NSC migration (Reumers et al., 2008). The dispersed 785 cells, 
apparently surviving after 2 months in the mice that received normal NSCs, 
were beyond the detection level of the present IVIS configuration. In our 
present BLI set-up, only the viability and location of the implanted cells could 
be monitored. Future coupling of luciferase gene activation in the implanted 
cells to the promotor of specific oligodendrocyte genes, like MBP or CNPase, 
will enable us to monitor the appearance of oligodendrocyte functionality of 
implanted NSCs in intact mice.  
The loss of the majority of stereotactically implanted NSCs in the first 3 weeks 
after injection is a wellknown phenomenon in NSC transplantation in adult 
nonneurogenic brain areas; if they do survive they merely differentiate into 
astrocytes (Suhonen et al., 1996). Most NSCs do not survive the exposure to 
shearing forces during injection, the transition into an inappropriate 
nonneurogenic niche, the compression by surrounding host tissue, and the 
hostile, inflammatory conditions created by activated microglia. For implanted 
NSCs to eventually survive, it is thought a prerequisite that they differentiate 
and become functionally integrated in the host circuitry. So, in the present set-
up, most of the surviving Olig2-NSCs detected with IVIS after 2 months in the 
cuprizone-demyelinated corpus callosum appeared to be functionally 
integrated, myelinating oligodendrocytes. As Olig2 overexpression induces 
OPC-formation in NSCs in a much more effective way in comparison to control 
NSCs (Copray et al., 2006), this explains the differences in surviving cells 
between Olig2-overexpressing and control NSCs after stereotactic implantation 
in the cuprizone-lesioned brain. In both groups of cell implants, only 
sporadically surviving NSCs had differentiated into astrocytes and neurons.   Chapter 5 
Stem Cells 2009;27:1582–1591  ￿￿￿ 
Electronmicroscopical analysis confirmed the contribution of the implanted 
Olig2-NSCs to remyelination. The percentage of myelinated axons that was 
remyelinated by implanted, (luciferase-) GFP-labeled NSCs appeared to be 
very low.  Since GFP is not membrane bound and only confined to the 
cytoplasm, the immunoreaction product becomes difficult to detect in the 
scarse cytoplasm present in compact myelin and so we may underestimate the 
number of axons remyelinated by exogenous oligodendrocytes.  However, it is 
evident that the vast majority of the corpus callosum axons were remyelinated 
by endogenous OPCs recruited from surrounding areas that repopulated the 
corpus callosum after the mice were taken of the cuprizone diet and transferred 
back to normal food. This switch back to normal food occurred directly after 
implantation to avoid degeneration of the NSC-derived freshly formed OPCs by 
cuprizone.  Because of the prominent contribution of endogenous OPCs in 
remyelination, significant differences in recovery patterns in cuprizone-induced 
locomotor behaviour between nonimplanted mice, mice that received an Olig2-
NSCs implant, and mice that were implanted with control NSCs could not be 
detected (data not shown). 
In conclusion, BLI in combination with immunohistochemical and 
electronmicroscopical validation reveals that NSC-derived OPCs can become 
functionally stable myelinating oligodendrocytes when stereotactically 
implanted in or close by a demyelinated lesion. However, the actual number 
that survived and differentiated into functional myelinating oligodendrocytes 
was low. Combining implantation with the local administration of anti-apoptotic 
factors, oligodendrogenesis promoting factors and/or factors that counteract 
the myelination inhibiting influences of the extracellular matrix and the 
inflammatory environment, may lead to further optimalization of the potential of 
the NSC implantation approach. 
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1. ABSTRACT  
In multiple sclerosis (MS), a chronic inflammatory relapsing demyelinating 
disease, failure to control or repair damage leads to progressive neurological 
disease and neurodegeneration. To aid repair and promote functional recovery, 
implantation of neural stem cells (NSCs) in animal models of MS demonstrate 
that these cells employ several therapeutic mechanisms, the major mechanism 
being immune regulation. To aid remyelination we have examined the efficacy 
of priming NSCs to become oligodendrocyte precursor cells (OPCs) by 
transient overexpression of Olig2 in a chronic relapsing demyelinating animal 
model of MS. The efficacy of intraventricular implantation of NSC-derived 
OPCs (Olig2-NSCs) was examined in the first episode of neurological disease 
and the chronic relapsing experimental autoimmune encephalomyelitis 
(CREAE). Upon injection at the onset of acute phase or the relapse phase of 
CREAE Olig2-NSCs directly migrated towards active lesions in the spinal cord 
as visualized by in-vivo Bioluminescence and Biofluorescence imaging and 
once in the spinal cord the majority of Olig2-NSCs differentiated into OPCs. 
The survival of Olig2-NSCs was significantly higher than that of injected control 
NSCs, which remained undifferentiated. Nevertheless both Olig2-NSCs and 
NSCs significantly reduced the clinical signs of acute and relapsing disease, 
even abrogating relapsing disease when administered early. 
We provide the first evidence that NSC-derived OPCs (Olig2-NSCs) ameliorate 
established chronic relapsing EAE in mice. Our experimental data in 
established neurological disease in mice indicates that such therapy may be 
effective in established relapsing-remitting MS preventing chronic progressive 
disease. Chapter 6 
￿ ￿￿￿ 
2. INTRODUCTION  
Multiple sclerosis (MS) is one of the most common neuroimmunological 
disorders of the central nervous system (CNS). It is distinguished by multiple 
autoimmune inflammatory assaults in the CNS, resulting in oligodendrocyte 
impairment and/or degeneration which leads to axonal demyelination, injury 
and dysfunction. Whereas the development of anti-inflammatory drugs for MS 
has made significant progress in the last decades, strategies for remyelination 
and axonal restoration require further development and refinement. Importantly 
developments in stem cell research, in particular the discovery of induced 
pluripotent stem (IPS) cells enabling the generation of infinite numbers of 
autologous NSCs (Scheper and Copray, 2009), have revived the idea of cell-
based therapy as an approach for inducing remyelination and, with that, the 
slowing or preventing of axonal degeneration. Unprecedently, a potentially 
clinical relevant source for transplantable remyelinating cells has become 
within reach. 
Indeed, endogenous NSCs residing in specific germinal niches in the CNS are 
thought to produce new oligodendrocyte precursor cells (OPCs) and so to 
contribute to myelin repair after a demyelinating assault. However, the efficacy 
of these endogenous NSCs in contributing to myelin repair is limited (for a 
review see (Pluchino and Martino, 2008) Transplantation of exogenous NSCs 
signifies an alternative and potentially more efficient therapeutic approach to 
accomplish remyelination in MS. A number of studies in the experimental 
autoimmune encephalomyelitis (EAE) mouse model for MS (for a review see 
(Buchet and Baron-VanEvercooren A., 2009) have shown that NSCs indeed 
have a beneficial effect after grafting and significantly reduced clinical scores. 
Recently, human neural stem cells were administered to nonhuman primates in 
which EAE was induced and similar observations were made (Pluchino et al., 
2009). However, the beneficial effect on EAE symptoms appeared not (or at 
least not directly) to be achieved by promotion of remyelination but by the 
reduction of inflammation via various trophic, immunomodulatory and even T-
cell apoptosis-inducing factors produced by the undifferentiated NSCs (Einstein 
et al., 2003; Einstein et al., 2006; Einstein et al., 2007; Pluchino et al., 2003; 
Pluchino et al., 2005; Pluchino and Martino, 2008; Pluchino et al., 2009b). 
These studies reveal that grafted undifferentiated NSCs, although optimally 
equipped for homing to the lesions, show only marginal differentiation into 
remyelinating oligodendrocytes at the site of the lesion. In a recent study, we 
have primed NSCs towards an oligodendrocyte cell lineage by the induced 
overexpression of Olig2 (Copray et al., 2006) before transplanting them into the 
demyelinated corpus callosum of cuprizone-fed mice to induce chronic 
demyelination (Sher et al., 2009). We compared the long-term survival and Grafting of NSCs & Olig2-NSCs in EAE model 
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functional behaviour of these Olig2-NSCs with implanted undifferentiated NSCs 
and found that, in contrast to undifferentiated NSCs, Olig2-NSCs survived and 
developed into myelinating oligodendrocytes contributing to the remyelination 
of the corpus callosum (Sher et al., 2009). Recently, a similar approach with 
human NSCs was successful in transplantation experiments in the lesioned 
white matter of rat spinal cord namely that grafted human Olig2-NSCs, in 
contrast to undifferentiated NSCs, significantly aided remyelination and 
promoted locomotor recovery (Hwang et al., 2009).  
Obviously, the conditions in the demyelination lesions in these animal models 
are not comparable to the inflammatory conditions in demyelination lesions in 
MS; the presence of reactive T-cells, monocytes, macrophages, activated 
microglia and astrocytes as well as the proinflammatory milieu of e.g. cytokines 
and chemokines produced by these cells may affect the migration, survival and 
remyelination activity of implanted NSCs and Olig2-NSCs. 
Therefore, in the present study, we have investigated the survival, migration 
and functional behaviour of Olig2-NSCs compared to NSCs after 
intraventricular injection in a chronic inflammatory model of MS i.e. chronic 
relapsing EAE mouse, the animal disease model which has been widely 
accepted to sufficiently mimic inflammatory demyelination lesions as observed 
in MS. 
 
3. MATERIAL & METHODS  
3.1. Animals 
The EAE implantation experiments were performed in 8-10 week old female 
FVB (n=32) and Biozzi ABH (n=24) mice. In addition we have used FVB 
luciferase-GFP-actin transgenic mice for the isolation of luciferase-GFP 
positive-NSCs.  All mice were housed under standard conditions with free 
access to food and water. All animal experiments were designed and carried 
out in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and regulations of the local Experimental Animal 
Committee. 
3.2. Experimental Autoimmune Encephalomyelitis (EAE)  
FVB mice: Female FVB mice were injected subcutaneously with a sonicated 
emulsion consisting of 200 μg human recombinant MOG 35-55 emulsified in 
incomplete Freund's adjuvant (IFA) supplemented with 60 μg killed 
mycobacteria tuberculosis, on day 0 and 7 as described previously (Amor et 
al., 1993; Amor et al., 1994; Amor et al., 1996; Baker et al., 1990; Hwang et al., 
2009).  Immediately and 24 h after immunisation the FVB mice were also 
injected i.p. with 200ng of pertussis toxin, derived from Bordetella pertussis Chapter 6 
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(Speywood, Porton Down, UK) dissolved in sterile water. In FVB mice this 
induction protocol induces a monophasic acute form of EAE.  
Biozzi ABH mice: To examine the effects of NSC implantation in chronic 
relapsing-remitting EAE in which myelin damage is more prominent in the 
relapse phases Biozzi ABH mice were used. The same immunisation protocol 
was used as described above, in which lyophilised homologous spinal cord in 
PBS replaced the MOG peptide. Animals were weighed daily and assessed for 
neurological symptoms from day 7 post-inoculation.  
Symptoms of EAE were scored as follows: 0= normal, 1= limp tail, 2= impaired 
righting reflex, 3= partial hind-limb paralysis, 4= total hind-limb paralysis, 5= 
moribund (euthanised). 
3.3 Neural stem cells (NSCs) 
NSCs were isolated from the telencephalon of either luciferase-GFP-actin 
transgenic mouse embryos or Biozzi ABH embryos at embryonic day E14. 
Briefly, the telencephalon was cut into small pieces at room temperature, and 
following mechanical trituration in ice-cold phosphate buffered saline (PBS, 0.1 
M), small pieces of tissue were incubated with accutase (Sigma-Aldrich) for 10 
minutes at 37°C. After repeated trituration, the cell suspension was passed 
through a cell strainer (70μm pore size; Falcon, Franklin Lakes, NJ, 
http://www.bdbiosciences.com) and seeded (1-1.5 million cells) in T25 cm2 
tissue culture flasks (Nunc, Roskilde, Denmark, http://www.nuncbrand.com) 
containing proliferation medium, which consisted of Neurobasal medium 
(Invitrogen, Breda, The Netherlands, http://www.invitrogen.com) supplemented 
with B27 (2%; Invitrogen), human recombinant epidermal growth factor (20 
ng/ml; Invitrogen), basic fibroblast growth factor (20 ng/ml; Invitrogen), 
glutamax (1%; Gibco, Grand Island, NY, http://www.invitrogen.com), primocin 
(100 µg/ml), and heparin (5µg/ml; Sigma-Aldrich) in a humidified 5% CO2/95% 
air incubator at 37°C. Luciferase expression in isolated and cultured NSCs 
isolated from luciferase-GFP-actin transgenic FVB mice was verified with a 
standard luciferase assay in a bioluminometer. The NSCs isolated from the 
Biozzi ABH mice were labeled before implantation either by transfection of the 
firefly luciferase gene (see below) or by uptake of dragon green fluorophores 
(Bangs Laboratories, Inc. Fishers, IN 46038 USA): 1.7µl (approximately 5 x 10
6 
particles) of fluorophores were added per ml of medium 24 hours before the 
implantation of the cells. Labeling efficiency was approximately 90%. 
3.4. Gene Transfection 
Overexpression of Olig2 was induced in NSCs isolated form the luciferase-GFP 
transgenic FVB mice by transfection of an internal ribosome entry site plasmid 
(pIRES) expression vector containing the Olig2 gene; the parallel 
undifferentiated NSC group of FVB mice received a similar control transfection Grafting of NSCs & Olig2-NSCs in EAE model 
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with GFP. NSCs isolated from Biozzi ABH mice were transfected with the same 
pIRES vector containing the firefly luciferase gene or the Olig2 gene. In both 
cases transfection was performed using an Amaxa electroporation protocol 
(Amaxa GmbH. Cologna, Germany, http://www.amaxa.com) specifically 
designed for the transfection of embryonic mouse NSCs.  The transfection 
efficiency of this procedure for mouse NSCs is approximately 70% and results 
in the transient expression of the transfected gene lasting up to 10-12 days. 
3.5. Implantation of NSCs 
FVB mice: To examine the effect of NSC implantation in the acute phase of 
EAE FVB mice were divided into three groups: group 1, that received an 
injection at the first signs of EAE (n=10), group 2, that received an injection 
after recovering from the first relapse (n=8) and group 3, the control group 
which was not EAE immunized (n=4). Using a standard stereotactic procedure, 
half of the mice in group 1 and 2 received an intraventricular injection of 1.5 x 
10
5  NSCs while the other half received 1.5 x 10
5  Olig2-NSCs; stereotactic 
coordinates used (in relation to Bregma): anterior-posterior: - 0.5; lateral; - 1.0; 
vertical: -2.6  (Paxinos atlas, 2002). The mice in group 3 only received Olig2-
NSCs. Sham mouse (n=2) were injected with only PBS.  
Biozzi mice: To examine the effects of NSC implants in the relapse-remitting 
form of EAE, in which the symptoms in the relapse are thought to be caused 
predominantly by demyelination EAE was induced in Biozzi ABH mice. Once 
clinical neurological EAE was observed the mice were randomly allocated into 
2 groups: one group (n=8) received an intraventricular implantation (same 
protocol as described above) at first signs of the primary relapse and the 
second group (n=6) were injected intraventricularly at the onset of the relapse. 
Similar to the EAE FVB mice, half of each group received 1.5 x 10
5 NSCs while 
the other half received 1.5 x 10
5 Olig2-NSCs. 
3.6. In-vivo bioluminescence and fluorescence tracing of implants. 
For the in-vivo tracking of the luciferase-positive cell grafts, each animal was 
imaged three to four times per week with the use of the IVIS Imaging System 
200 Series of Xenogen Corporation (Caliper Life Sciences, Alameda, CA, 
http://www.caliperls.com). At each imaging session, each mouse received an 
i.p. injection of D-luciferin (300 mg/kg) in normal physiological salt solution. Ten 
minutes after the D-luciferin injection, animals were anesthetized with 
isoflurane (2.5% isoflurane in oxygen, 1.5 l/minute) and placed in a 
standardized position in the chamber of a charge coupled device camera 
system. The Dragon green labelled cells were traced by using the fluorescein 
filter sets of the IVIS. The Living Image 2.5 software program (Xenogen 
Corporation, Caliper Life Sciences) was used for data analysis. Images 
representing luciferin and fluorescein light intensity, ranging from blue to red Chapter 6 
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(for luciferase) and from black to yellow (fluorescein), were merged with the 
reference image to enable anatomical localization. Images were displayed and 
regions of interest were quantified in terms of radiance (photons/second per 
cm2/sr).  
3.7. Immunohistochemistry 
At 8-10 days after implantation i.e day 12 in the FVB and day 50 in the Biozzi 
mice,  mice were perfused transcardially with 4% paraformaldehyde (PFA) 
under isoflurane anesthesia. In addition as controls, EAE mice that did not 
receive an implant were perfusion fixated at various time points. Spinal cords 
were excised and sectioned on a cryostat. Some sections were stained with 
cresyl-violet for overview, or for Luxol Fast Blue to stain for myelin. Most of the 
tissues were used for immunohistochemistry. To identify luciferase-GFP or 
luciferase labeled implanted cells, immunostaining was performed, after heat-
induced antigen/epitope retrieval (HIER) (10 mM sodium citrate, 0.05% Tween 
20, pH 6.0) (required for luciferase immunostaining) using goat anti-luciferase 
(ab3256; Chemicon, Millipore, Amsterdam, The Netherlands, 
http://www.millipore.com) or rabbit anti-GFP (ab290; Abcam). 
To evaluate the survival and differentiation of the cell implants, the following 
primary antibodies directed against marker proteins specifically expressed by 
freshly differentiated oligodendrocytes, neurons, or astrocytes were used: for 
astroblasts, anti-S100β (11420, 1:400; ICN Biomedicals, Inc., 
http://www.mpbio.com) for neuroblasts, anti-doublecortin (DCX) (AB5910, 
1:500; Millipore-Chemicon) and for oligodendrocyte precursor cells, anti-RIP 
(mab1580; Millipore-Chemicon) or anti-NG2 (ab5320; Millipore-Chemicon). 
Subsequently, various fluorescent secondary antibodies were used to visualize 
the specific primary immunoreaction product in single and double 
immunohistochemical staining. 
3.8. Chemotaxis assay  
NSCs and Olig2-NSCs migration in response to CXCL12 and CXCL9 was 
assessed using a 48-well chemotaxis microchamber (Neuroprobe, AP48, 
Gaithersburg, MD, USA). A volume of 28 µl of chemokine solution (in 
neurobasal medium at concentrations of 10 nM) or control medium 
(Neurobasal medium) was added to the lower wells. A total of 5 x10
4 cells per 
50 µl were used in the assay. The chamber was incubated at 37°C, 5% CO2, in 
a humidified atmosphere for 4-5 h. After the incubation, the filter was fixed in 
Fast Green in 100% methanol with the concentration of 0.002 g/l (Diff-Quik Fix, 
Dade Behring, Düdingen, Fribourg, Switzerland) and stained twice, first in stain 
solution 1, containing 1.22 g/l eosin G in phosphatase buffer with the pH value 
of 6.6 (Diff-QuikI), and then in stain solution 2, containing 1.1 g/l thiazine dye in 
phosphate buffer with the pH 6.6. After staining, the filter membrane was Grafting of NSCs & Olig2-NSCs in EAE model 
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cleaned on the upper side and dried. Migrated cells were counted with a scored 
eyepiece [3 fields (1 mm2) per well] and migrated cells per chamber were 
calculated. The data are presented as percentages of control migration ± SEM 
and were analysed by Student’s t-test. Control migration in response to 
neurobasal media is set to 100%. P values < 0.05 were considered significant. 
3.9. RT-PCR 
Total RNA was isolated from NSCs and Olig2-NSCs. Cells were lysed in 
guanidinium isothiocyanate/mercaptoethanol buffer and RNA was extracted 
with phenol-chloroform and precipitated by using isopropanol. To degrade 
possible genomic DNA traces, DNase (Fermentis) was used.  One microgram 
of total RNA was used for RT reaction and 2 µl of the RT reaction were used in 
subsequent PCR amplification using following primer pairs; CXCR4, forward: 
‘5TCCAAGGGCCACCAGAAGCG3’ 
backward: 5’AACTTGGCCCC GAGGAA GGC3’ 
CXCR3, forward: 
 5’GCCAAGCCATGTACCTTGAGGTTAGT3’ 
backward: 
 5’AGGTGTCCGTGCTGCTCAGG3’.  
3.10. Cell counting  
Quantitative analysis of implanted cells was carried out by counting GFP
+ or 
dragon green fluorophores
+ cells in coronal cryostat sections of the spinal cord 
using a fluorescent microscope equipped with a Leica DFC300FX camera and 
the Leica microsystem LAS program (Leica, Heerbrugg, Switzerland, 
http://www.leica.com). The spinal cord was cut in three equal segments 
containing respectively the cervical, thoracic, and lumbar spinal cord. Every 
10th section (14μm) of this segment was collected and put on glass slides for 
immunofluorescent staining procedures. For each spinal segment, 10 
subsequent sections were analyzed and used for cell counting. The number of 
cells in the spinal cord was calculated by summation of the number of cells in 
each of the three spinal cord segments multiplied by a factor 10. Quantification 
of different cell types was done based on cell type–specific immuno-double 
staining (GFP or dragon green fluorophores/cell-specific marker). The result of 
Statistical analysis of the results of all animals in each group was performed 
using Student’s t-test.  
 
4. RESULTS  
4.1. EAE in FVB mice strain 
Induction of EAE in the FVB mice results in an acute monophasic course of the 
clinical score as depicted in figure 1a. The typical pattern of disease progress 
starts at day 10-12 after immunisation, with a peak at day 17-18 and a recovery Chapter 6 
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which is almost complete at day 27-28. The arrows in figure 1a indicate the 
time points of injection of the NSCs. It should be stated that the clinical 
symptoms in this monophasic, acute form of EAE are the result of extensive 
inflammation with massive cell infiltration (figure 1b) and edema formation in 
the spinal cord with only minor secondary contribution of actual demyelination 
and subsequent axonal injury. 
 
 
 
 
Figure 1 - EAE progression and clinical scoring of FVB mice. (a) The clinical scores of EAE in FVB 
mice (n=10;± standard error of the means) reveal a clear monophasic pattern; arrows indicate the 
time points of intraventricular injection of NSCs and Olig2-NSCs. (b) Sections of spinal cord stained 
for cresyl-violet (CV) taken at peak of clinical score show extensive cellular infiltration in the 
funiculus white matter; compared with healthy control mice. 
 
4.2. Intraventricularly injected neural stem cells migrate only to active 
EAE lesions 
Luciferase-labelled NSCs and luciferase-labelled Olig2-NSCs were implanted 
in the FVB mice intraventricularly and their distribution and migration monitored 
using IVIS 200 Bioluminescence imaging system. 
In the first week after implantation the migration of the implanted cells from the 
site of intraventricular injection towards the spinal cord depended on the 
presence of active EAE lesions (figure 2). Quantification of the 
bioluminescence in the EAE mice shows that the original signal at the site of 
deposition in the brain ventricle decreases, whereas the signal in the spinal 
cord increases (figure 2a-d and g). No differences were observed between the 
migration of NSCs or Olig2-NSCs in the EAE mice, indicating a similar 
responsiveness to the signals from the spinal cord lesions. In control mice and 
in mice that had been implanted intraventricularly after recovery from the first 
EAE relapse (late EAE, see arrow figure 1), no migration of implanted cells Grafting of NSCs & Olig2-NSCs in EAE model 
￿ ￿￿￿￿
C
h a p t e r   6
 
towards the spinal cord was detected (figure 2e, f and g) illustrating that only 
active lesions produce attractants for the implanted cells. 
 
 
 
Figure 2 - Distribution of luciferase-labelled NSCs and Olig-NSCs in the first week after 
stereotactic implantation in the ventricles (± standard error of the means). (A-E) NSCs and Olig2-
NSCs migrate only towards the spinal cord in FVB mice with active EAE lesions. (e & f) The 
patterns of bioluminescence activity in the spinal cord of EAE mice reveal a similar level of 
migration for NSCs and Olig2-NSCs only when active lesions are present. (g) Examples of IVIS 
scans in control and implanted mice 
 Chapter 6 
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After a week, the level of bioluminescence activity in the spinal cord and the 
brain stabilizes. 
We analyzed the expression of the major chemokine receptors of NSCs, 
CXCR3 and CXCR4, both in undifferentiated NSCs and Olig2-NSCs and 
performed a chemotaxis assay for the chemokines CXCL3 and CXCL12. The 
results, depicted in figure 3, confirm the similar migratory capacities of NSCs 
and Olig2-NSCs as observed in the implantation experiments. 
 
 
 
 
Figure 3 - Chemokine signalling in NSCs and Olig2-NSCs. (A) Both NSCs and Olig2-NSCs 
express the major chemokine receptors CXCR3 & CXCR4 as shown with RT-PCR analysis and (B) 
reveal an equal migratory response to the chemokines CXCL12 and CXCL3 in a chemotaxis 
assay.  
 
4.3. NSCs as well as Olig2-NSCs reduce clinical score in acute EAE. 
Figure 4 shows the clinical EAE score of FVB mice after injection of NSCs and 
Olig2-NSCs at day 12 when mice exhibited a clinical score of 1 (limptail). 
Intraventricular injection of both NSCs and Olig2-NSCs induced a significant 
decrease in the clinical score. Grafting of NSCs & Olig2-NSCs in EAE model 
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Figure 4 - EAE progression and clinical scoring of FVB mice. The intraventricular injection of NSCs 
(n=5) or Olig2-NSCs (n=5) at the beginning of EAE (arrow) blocks EAE progression and strongly 
reduces the clinical scores. 
 
 
 
 
Figure 5 - Immunohistochemical analysis of spinal cord of FVB-EAE mice after intraventricular 
injections with labelled NSCs or Olig2-NSCs. (a, b) GFP-labelled cells have migrated from the 
intraventricular injection site in the brain to the spinal cord and are located in the lesions 
(green=GFP; blue=Hoechst nuclear staining). (c - f). Double immunostaining for GFP (green) and 
RIP (red) shows examples of injected Olig2-NSCs that differentiated into OPCs (blue= Hoechst 
nuclear staining). (g) The bar graph shows the number of intraventricularly injected Olig2-NSCs 
and NSCs that were found in the spinal cord of EAE FVB mice (n=5, mean ± standard deviation). 
(h) Quantification of the differentiation pattern of the injected NSCs and Olig2-NSCs found back in 
the spinal cord shows that a majority of the Olig2-NSCs differentiated into OPCs, whereas most of 
the NSCs stayed undifferentiated (=nestin-positive) (n=5, mean ± standard deviation). Bar=100μm 
(for A,B), =50μm (for C-F). 
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Immunohistochemical analysis of the spinal cord of FVB-EAE mice following 
intraventricular injections with labelled NSCs or Olig2-NSCs at day 20-23 
revealed the presence of intraventricularly injected cells in the spinal cord 
(figure 5a-f). The posterior, lateral and anterior funiculi of the EAE spinal cord 
were highly cellular and contained numerous infiltrated cells (figure 5a). The 
luciferase-GFP positive injected cells were detected amongst these cell 
infiltrations in the funiculus areas. Quantification of the number of implanted 
cells in these sections of spinal cord still present 10 days after injection, 
revealed a slightly higher but not significantly survival rate for the Olig2-NSC in 
comparison to the NSCs. With double immunostaining, the identity of the 
differentiation direction of the injected cells was determined (figure 5 g-h). The 
majority of the injected NSCs were still undifferentiated as revealed by their 
nestin staining, with only a small percentage differentiating towards a OPC cell 
type (NG2 or RIP-positive) and relatively few towards neurons (doublecortin 
staining) or astrocytes (S100 or GFAP staining). 
The majority of the injected Olig2-NSCs in the EAE spinal cord, however, 
appear to develop into OPCs (NG2-positive) as was expected because of their 
OPC-primed state. However, none of these cells expressed MBP (data not 
shown) indicating that none of them actually reached a mature myelinating 
stage; this is line with the fact that demyelination hardly occur in these primary 
acute relapses in EAE and so no new remyelinating cells are required. 
4.4. EAE in Biozzi ABH mice  
Induction of EAE in the Biozzi ABH mice resulted in a chronic relapsing-
remitting pattern of disease (figure 6a) in which the first attack (the acute 
phase) started between day 10-12, with a peak at day 22 and a return to 
normal scores around day 30. As in the monophasic course of FVB mice, the 
clinical symptoms in this acute form of EAE are the result of extensive 
inflammation with massive cell infiltration and edema in the spinal cord. A 
second neurological phase (relapse) was observed 15 days later, reaching a 
plateau at score 3 from day 55 till 65 until the clinical score decreased to 
almost baseline scores around day 70. Relapsing disease is associated with 
demyelination in this mouse model (Baker et al., 1990) 
4.5. NSCs and Olig2-NSCs delay or prevent the onset of relapses in Biozzi 
EAE mice 
To investigate the effect of intraventricular injections of NSCs and the OPC-
primed Olig2-NSCs on the clinical course of EAE in the Biozzi mice we injected 
both cell suspensions at day 12 at the first signs of disease (figure 7). Like in 
FVB mice, both intraventricularly injected cell suspensions affected the clinical 
score in Biozzi mice with an even more dramatic reduction, leading to a 
complete inhibition of neurological signs at day 20. Grafting of NSCs & Olig2-NSCs in EAE model 
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Figure 6 - EAE progression and clinical scoring in Biozzi mice. (a). The clinical scores of EAE in 
these mice (n=10;± standard error of the means) reveal a more chronic pattern with an acute 
disease phase and remittance phase followed by a relapse approximately 50 days after 
immunisation pattern that shows a typical high extended flattened peak of clinical score; arrows 
indicate the timepoints of intraventricular injections of NSCs and Olig2-NSCs. (b). Sections of 
spinal cord stained for Luxol Fast Blue (LFB) taken at peak of relapse show demyelination in the 
funiculus white matter; compare with control. 
 
We continued to monitor these animals for the appearance of a relapse and 
noted that this relapse was significantly delayed with approximately 10 days 
with the typical extended peak significantly shortened in case of NSCs 
injections and even completely abolished in case of Olig2-NSCs injections 
(figure 7). Chapter 6 
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Figure 7 - EAE progression and clinical scoring in Biozzi mice after intraventricular NSCs and 
Olig2-NSCs injections. NSCs and Olig2-NSCs injected intraventricularly at the onset of acute EAE 
(arrow) directly prevent the further development of clinical symptoms and reduce the clinical 
scores. Moreover, the injection of NSCs (pink, n=4) significantly delays the relaps and abolishes 
the occurrence of a typical extended score peak; the Olig2-NSCs injections (yellow, n=4) appear to 
completely prevent the occurrence of a relapse in Biozzi EAE mice). 
  
 
Figure 8 - Intraventricularly injected NSCs and Olig2-NSCs in Biozzi EAE mice at onset of relapse. 
Both injected cell suspensions migrate towards active secondary EAE lesions in Biozzi mice as 
visualized and quantified with bioluminescence in a and a’ or with biofluorescence in b and b’ 
 
 
 
Figure 9 - EAE progression and clinical scoring in Biozzi mice after the injection of NSCs and 
Olig2-NSCs at the onset of a relapse (arrow). Both types of cell injections (pink and yellow, n=3 for 
both groups) directly prevent the progression of a relapse. Grafting of NSCs & Olig2-NSCs in EAE model 
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4.6. Intraventricularly injected NSCs migrate also to active relapse EAE 
lesions.  
In order to investigate the migratory response of intraventricularly injected 
NSCs to the lesioned spinal cord in the relapse phase, luciferase or dragon 
green fluorophore-labelled NSCs and Olig2-NSCs were intraventricularly 
injected in Biozzi mice at the onset of the relapse, when mice exhibited a score 
1, i.e. at approximately 50 days after immunization. 
As depicted in figure 8, bioluminescence and fluorescence in-vivo monitoring 
revealed that NSCs and Olig2-NSCs migrated from the site of injection towards 
the spinal cord lesions, indicating that these secondary lesions produced 
sufficient chemotactic signals to attract the implanted cells. 
4.7. NSCs and Olig2-NSCs implanted at the onset of relapsing disease 
reduce clinical scores 
Next we examined the impact of injecting NSCs and Olig2-NSCs during 
established EAE i.e. at the onset of the clinical relapse (figure 9). Like in the 
primary acute stage, both NSCs and Olig2-NSCs reduced the clinical score 
and prevented disease progression to severe disability as observed in the 
untreated control EAE mice. 
When the clinical scores returned to 0.5 approximately 10 days after injection, 
the mice were perfused for immunohistochemical analysis (figure 10). 
Immunohistochemical analysis of the spinal cord of these mice revealed the 
presence of intraventricularly injected dragon green fluorophore-labelled cells 
in the more superficial regions of the posterior, lateral and anterior funiculus of 
the spinal cord (figure 10a-f). 
Quantitative analysis of the presence, distribution and differentiation pattern of 
the NSCs and Olig2-NSCs revealed similar patterns as described for NSCs 
and Olig2-NSCs injected at the onset of the primary relapse in the FVB mice 
(figure 10 g and h); however, the total number of cells found in the spinal cord 
of Biozzi mice after injection at the onset of the relapse was almost double in 
comparison to the studies in FVB mice (figure 5g and h). 
Similar to the FVB mice, a majority of the injected Olig2-NSCs, in contrast to 
most undifferentiated injected NSCs, started to differentiate into early OPCs in 
the spinal cord at the relapse in Biozzi mice. 
 (figure 11e); injected cells could be identified in electronmicroscopy sections 
by the large electron-dense particles of the dragon green fluorophores (figure 
11a-e). 
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Figure 10 - Immunohistochemical analysis of spinal cord of Biozzi EAE mice after intraventricular 
injections with labelled NSCs or Olig2-NSCs at the onset of the relapse. (a) Cresyl violet stained 
section of Biozzi EAE spinal cord, (b) GFP-labelled cells have migrated from the intraventricular 
injection site in the brain to the spinal cord and are located in the lesions (green=GFP; 
blue=Hoechst nuclear staining) (c - f). Double immunostaining for dragon green fluorescein (Fluo, 
green) and RIP (red) shows examples of injected Olig2-NSCs that differentiated into OPCs (blue= 
Hoechst nuclear staining). (g) The bar graph shows the number of intraventricularly injected Olig2-
NSCs and NSCs that were found in the spinal cord of EAE Biozzi mice (n=3, mean ± standard 
deviation). (h). Quantification of the differentiation pattern of the injected NSCs and Olig2-NSCs in 
the secondary lesions in the spinal cord shows that a majority of the Olig2-NSCs differentiated into 
OPCs, whereas most of the NSCs stayed undifferentiated (=nestin-positive) (n=3, mean ± standard 
deviation). Bar=100μm (for a,b), =50μm (for c-f). 
 
The rapid inhibitory effect of the intraventricularly injected NSCs and Olig2-
NSCs on the course of the relapse in the Biozzi mice prevented the occurrence 
of the otherwise chronic clinical episode associated with demyelination. 
Therefore it was unlikely that strong triggers would be present in the lesion to 
induce the further maturation of Olig2-NSC derived OPCs into myelinating 
oligodendrocytes. Still, however, electronmicroscopy revealed the sporadic 
presence of injected OPCs that did contribute to myelin sheath formation 
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Figure 11 - Electronmicroscopy of Biozzi spinal cord after cell injections at onset of secondary EAE 
lesions. (a). Toluidin-blue 1μm section of a lesion site shows the presence of many  implanted cells 
recognizable by the labeling with black fluorophore particles; (b) outside the lesion site no grafted 
cells can be detected. (C). Amidst myelinated and unmyelinated fibers (part of) a grafted Olig2-
NSC cell (area magnified in d; cell in black) containing a large labeling particle (arrow) is located. 
(e). Example of an (particle labelled, arrow) implanted Olig2-NSC (cell contour in black) 
contributing to remyelination of an axon.  Bars: =10 μm (in a and b), =2μm (in c) and =1μm (in d 
and e) 
 
5. DISCUSSION 
Neural stem cells (NSCs) have been reported to be effective as a therapeutic 
strategy for neurodegenerative disorders such as the inflammatory 
demyelinating and neurodegenerative disease multiple sclerosis (MS). Rather 
than promoting repair directly NSC are thought to act by releasing a milieu of 
both neuroprotective factors and anti-inflammatory molecules. To aid the repair 
process with regard to remyelination we have designed NSCs to become 
oligodendrocyte precursor cells (OPCs) by transient overexpression of Olig2. 
Both NSC and Olig2-NSCs were transplanted into mice with chronic relapsing 
EAE. Our results of intraventricular implantation of neural stem cells (NSCs) at 
the onset of acute EAE disease confirm previous observations that 
undifferentiated NSCs are able to reduce the clinical symptoms associated with 
the primary acute or chronic response to experimental autoimmune 
encephalomyelitis (EAE). No obvious differences were observed between 
NSCs and OPC-primed NSCs (Olig2-NSCs) suggesting that remyelination 
activity was not significantly contributing to these effects during this acute 
phase. Similar effects were observed when NSCs or Olig2-NSCs were injected Chapter 6 
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at the onset of a relapse in Biozzi EAE mice which better mimics established 
neurological disease in MS patients. In addition, we found that NSCs or Olig2-
NSCs injected intraventricularly at the onset of the very first symptoms, induced 
a delay or a complete inhibition, respectively, of the occurrence of a relapse. 
These data suggest that NSCs are able to modulate immune responses i.e T-
cell activity, B cells responses or indeed microglia / macrophage activation at 
the onset of the relapse via still unknown mechanisms either at the local level 
in the spinal cord or at a more peripheral level for instance in the lymph nodes. 
Various studies have shown that forced expression of the transcription factor 
Olig2 in NSCs promote their differentiation into OPCs (Copray et al., 2006; 
Maire et al., 2009). Transient overexpression of Olig2 in NSCs primed these 
cells to become OPCs after stereotactic injection in the corpus callosum of 
cuprizone-fed mice, an animal model for demyelination:  in contrast to control 
NSCs, Olig2-NSCs were able to survive, to differentiate into mature 
oligodendrocytes and to remyelinate axons in the cuprizone mouse model for 
demyelination (Copray et al., 2006; Sher et al., 2009). Migratory activity of 
Olig2-NSCs was evident in these studies but limited since they were 
stereotactically injected near the site of demyelination. In the present studies 
we aimed to investigate the migration of NSCs and Olig2-NSCs after 
intraventricular injection towards lesions in the EAE mouse model for MS. It is 
well documented that NSCs express a wide variety of chemokine receptors (Ji 
et al., 2004; Tran et al., 2004; Tran et al., 2007) and the observed migration of 
NSCs towards lesions and for instance glioblastoma appear to depend on 
CXCR3/CXCL3 and CXCR4/CCL12 signalling (Carbajal et al., 2010; 
Dziembowska et al., 2005; van der Meulen et al., 2009). In order to check 
whether forced Olig2 expression did not alter the NSC specific expression of 
chemokine receptors and change the migratory capacity, we verified the 
expression of the major chemokine receptors CXCR3 and CXCR4 in Olig2-
NSCs and their response to the ligands CXCL3 and CXCL12. As illustrated by 
in-vivo bioluminescence and biofluorescence imaging, NSCs as well as Olig2-
NSCs migrated to the active EAE lesions in the spinal cord, apparently 
attracted by chemokines produced only by active lesions. In some injection 
experiments with the Biozzi mice, we labelled Olig2-NSCs with large dragon 
green fluorophore particles; the presence of these intracellular particles did not 
influence the migratory capacity of these cells to EAE lesions as was also 
previously demonstrated for NSCs containing similar sized magnetic particles 
(Ben-Hur et al., 2007). 
Intraventricular injection at the onset of the first acute phase but also of the 
relapse phase resulted in a direct migration of both NSCs and Olig2-NSCs 
towards the lesioned sites in the spinal cord. Their presence directly induced a Grafting of NSCs & Olig2-NSCs in EAE model 
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significant reduction in the clinical score confirming the findings of other EAE 
implantation studies (Einstein et al., 2003; Einstein et al., 2006; Einstein et al., 
2007; Pluchino et al., 2003; Pluchino and Martino, 2008; Pluchino et al., 
2009a). The mechanisms of this protective action have been ascribed to the 
production of a wide variety of trophic and immunomodulatory factors by NSCs 
that appear to restrain dendritic cell function and cause the selective death of 
reactive T-cells (Einstein et al., 2007; Pluchino et al., 2005; Pluchino et al., 
2009b). Most of the immunomodulatory interaction between the grafted NSCs 
and immune cells in our studies must have taken place at the spinal cord level, 
since we were unable to trace intraventricularly injected NSCs back in 
peripheral organs, like spleen or lung; only sporadically a few injected NSCs 
could be detected in cervical lymph nodes a week after injection (data not 
shown). We speculated that, in particular the OPC-primed NSCs, i.e. the Olig2-
NSCs, would additionally contribute to the reduction of symptoms with 
supportive remyelination activity. However, remyelination activity in the spinal 
cord lesions by the injected Olig2-NSCs was scarce and only detectable in the 
relapsing disease stage. The immediate effect of the intraventricular injected 
NSCs and Olig2-NSCs on inflammation and lesion formation presumable 
prevented wide scale demyelination to occur particularly in the relapse. To 
investigate an actual contribution to myelin repair by Olig2-NSCs in EAE 
lesions we should inject these cells at a later stage of the relapse phase of EAE 
in which demyelination is a prominent component (an experimental set up 
which faces insurmountable objections of the local ethical committee for 
experimental animal research). Despite a similar action, we observed 
considerable differences in the survival and differentiation in the spinal cord 
lesions between the NSCs and the Olig2-NSCs: the survival rate of Olig2-
NSCs was significantly higher, presumably due to the fact that most of them 
differentiate into OPCs, in comparison to control NSCs which in majority stayed 
undifferentiated. In addition, it has been reported in some studies that Olig2 
may play a role in supporting cell survival (Lin et al., 2005; Uchida et al., 2007). 
The most interesting finding of the present research is the fact that early 
injection of NSCs at the onset of the very first EAE symptoms delays and 
reduces the extent of a relapse and in case of Olig2-NSCs even completely 
prevents a relapse. Apparently, the presence of surviving injected NSCs and 
NSC-derived OPCs in the spinal cord modify local conditions and/or instruct 
local cells (like microglia) resulting in a reduced invasion and/or activity of 
aggressive T-cells. The mechanisms behind these effects of NSCs and Olig2-
NSCs obviously require further research, since they may be of considerable 
significance for a potential cell transplantation therapy for relapsing-remitting Chapter 6 
￿ ￿￿￿ 
MS (RRMS) patients aimed to suppress relapses and to prevent a transition 
towards the secondary progressive state. 
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Summary and conclusions 
The most disabilitating symptoms and functional deficits in the more 
progressed stages of multiple sclerosis (MS) are caused by axonal loss 
followed by retrograde neuronal degeneration. It has become clear that axonal 
degeneration is not only occurring in chronic lesions but signs of axonal injury 
have been detected already in acute lesions. Acute lesions in the relapsing-
remitting form of MS are caused by infiltrating reactive T-cells that induce 
inflammation and cytokine-release, damaging myelin and oligodendrocytes. 
Due to the temporal character of these relapses, axonal damage can be 
repaired by local oligodendrocyte precursor cells (OPCs), but in most cases 
parallel axonal circuitry takes over the lost axonal connections resulting in 
partial or complete functional recovery. The transition of relapsing-remitting MS 
to the secondary progressive form of MS marks the boundary of the plasticity of 
the brain where axonal loss can no longer be compensated. 
The present therapy for MS, with immunomodulatory drugs such as interferon-
β, glatiramer acetate, mitoxantrone or novel ones like alemtuzumab, rituximab, 
cladribine, fingolimod and laquinimod, is predominantly directed to reduce the 
invasion of aggressive T-cells; they do not prevent or restore axonal damage. It 
is clear that efficient treatment of MS must also include strategies to protect 
and restore axons from the very first signs of MS. Although various novel 
neuroprotective agents may become useful, the most effective way to protect 
an axon is to induce its remyelination as soon as possible either by promoting 
the myelinating activity of endogenous OPCs or by the implantation of 
exogenous remyelinating or remyelination-promoting cells.  
The lack of an ample source for autologous human myelinating cells, so far, 
has obstructed the application of such a cell based therapeutical approach. The 
extraordinary developments in various areas of stem cell research in the past 
10 years have given a new stimulus to cell based regenerative medicine, 
including neurodegenerative disorders such as MS. Pluripotent embryonic stem 
(ES) cells, indeed, have the potential to generate transplantable myelinating 
cells, but the clinical use of ES cells is limited because of the rejection 
response these heterologous cells will induce as well as their medical-ethical 
concerns. Autologous stem cells like mesenchymal stem cells (MSCs) have 
been considered as potential candidates for replacing lost oligodendrocytes 
(Martino et al., 2010; Uccelli and Mancardi, 2010). However, the proclaimed 
pluripotency of these cells is highly controversial and may be just considered 
an in-vitro artifact; their beneficial effects reported so far in MS animal models 
must be ascribed to a wide variety of trophic, anti-apoptotic and anti-
inflammatory factors they produce and presumably their (instructive) 
interactions with local microglia (Glennie et al., 2005; Uccelli et al., 2008; NSCs: potential applications in demyelinating disorders 
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Zappia et al., 2005); none of these implanted MSCs appeared to be able to 
differentiate into remyelinating cells (Bertani et al., 2005; Cho et al., 2005; 
Kopen et al., 1999; Montzka et al., 2009). Only neural stem cells (NSCs), 
obviously, must be considered as the most relevant, natural stem cell source 
for OPCs. Indeed, it has been shown possible to collect autologous adult NSCs 
from the ventrical wall via a relatively simple stereotactic endoscopic procedure 
(Westerlund et al., 2005); however, the number of NSCs that can be yielded 
and their multiplication rate is extremely low, making them unsuitable for any 
clinical application. The groundbreaking discovery (Takahashi and Yamanaka, 
2006) that somatic cells can be reprogrammed into induced pluripotent stem 
cells (IPS cells) has provided a novel unique source for autologous NSCs and 
for OPCs derived from them.  
The studies in this thesis address crucial issues related to the potential clinical 
use of NSC derived OPCs. Firstly, for a safe application, it is essential to 
differentiate NSCs into stable OPCs that can mature into myelinating 
oligodendrocytes after migrating to the site of denuded axons. Such stable 
differentiation can only be established if we understand the regulatory 
mechanisms underlying this differentiation process. Secondly, the longterm 
stability, safety and functionality of NSC-derived OPCs after intracerebral 
implantation have to be assured.  
So, the work presented in this thesis had two main objectives: 
C)  To investigate the epigenetic mechanisms underlying the specific 
differentiation of NSCs towards OPCs.  
D)  To monitor the survival, the migration, functionality and efficacy of 
grafted NSCs and NSC derived OPCs after intracerebral implantation 
in MS animal models using in-vivo imaging techniques e.g. 
Bioluminescence Imaging (BLI).  
 
In  Chapter 1, an introductory survey on current knowledge about 
oligodendrogenesis and the key extrinsic and intrinsic factors involved in this 
process, is given. Upon external triggering, a delicately controlled sequence of 
transcription factors commits the neural stem cell through subsequent stages to 
a myelin-forming oligodendrocyte. The expression of these transcription factors 
and so the transcription of lineage specific genes is ultimately controlled by 
various epigenetic mechanisms, reflected in changes in chromatin structure 
during the course of differentiation. Covalent enzymatic modifications of 
histones and methylation of DNA are major epigenetic regulatory mechanisms 
altering the chromatin state and with that determining the accessibility of 
certain gene programs for the transcription machinery. The polycomb group 
(PcG) proteins form a prominent family of nuclear proteins that mediate these Chapter 7: summary and conclusions 
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chromatin remodeling processes. They work in multimeric protein complexes, 
so-called polycomb repressive complexes (PRCs), like PRC1 and PRC2. PcGs 
have been shown to play an essential role during embryogenesis, where they 
repress the transcription of differentiation-related genes until their timed 
transcription is required for proper ongoing embryo formation. The PRC2 
complex is thought to initiate specific gene silencing through its key component 
Ezh2, a histone methyltransferase, which after recruitment to a specific gene 
target, trimethylates H3K27 and with that recruits the PRC1 complex for further 
stabilization of the repressed state (Ringrose and Paro, 2004; Schuettengruber 
et al., 2007; Sparmann and van, 2006; Simon and Kingston, 2009; 
Schuettengruber and Cavalli, 2009; Hirabayashi and Gotoh, 2010). Ezh2 is 
highly expressed in pluripotent embryonic stem cells, in most cancer type stem 
cells and in a few multipotent stem cells, e.g. haematopoietic stem cells 
(Kamminga et al., 2006).  
We started to investigate the expression of Ezh2 in multipotent mouse NSCs, 
as described in Chapter 2. The experimental data showed that embryonic 
mouse NSCs do express Ezh2. More or less as expected, in view of its known 
contribution in the differentiation of pluripotent stem cells and cancer stem 
cells, Ezh2 expression was downregulated upon their differentiation towards 
astrocytes or neurons. However, surprisingly when NSCs differentiated into an 
oligodendrocytic cell lineage, Ezh2 remained highly expressed during 
subsequent stages of oligodendrocytic differentiation until the stage of 
premyelinating oligodendrocytes (pOLs); in mature myelinating 
oligodendrocytes, Ezh2 expression disappears. Interference with Ezh2 
expression resulted in the impairment of the NSC proliferation and 
differentiation potential. Ezh2 overexpression and silencing in differentiating 
NSCs resulted in an increase and a reduction in the number of 
oligodendrocytes, respectively. These data suggested the involvement of Ezh2 
in stimulating/permitting the differentiation of NSCs towards OPCs and/or their 
proliferation.  
In Chapter 3 we further extended the data regarding the expression of Ezh2 in 
NSCs, demonstrating that it was expressed in-vivo in NSCs and OPCs in the 
adult mouse brain; increasing numbers of OPCs in the corpus callosum during 
remyelination in the cuprizone de/remyelination mouse model was 
accompanied by a rise in Ezh2 expression. Moreover, in this chapter, we 
continued to unravel the molecular mechanisms underlying the involvement of 
Ezh2 in the differentiation of NSCs towards an oligodendrocytic cell lineage. 
We explored the target genes of Ezh2 in NSCs and pOLs by using chromatin 
immunoprecipitation (ChIP) followed by ultra high-throughput massive parallel 
sequencing (ChIP-Seq). We found that Ezh2 changes its targets with NSCs: potential applications in demyelinating disorders 
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differentiation of the multipotent NSCs towards pOLs, as the vast majority of 
target genes were unique in both cell types. We found a small group of 
overlapping Ezh2 target genes (29) which appeared to be mainly associated 
with basic processes regulating cell cycle, basal metabolism and (preventing) 
tumor formation. The majority of the Ezh2 target genes in NSCs appeared to 
be involved in cell cycle control and differentiation, whereas in pOLs, Ezh2 
appeared to repress genes mainly associated with neuronal and astrocytic cell 
lineage development. The significance of Ezh2 target gene repression was 
illustrated by the fact that derepressing Ezh2 target genes completely blocked 
proliferation in NSCs and prevented proper differentiation in pOLs; in both cell 
types it ultimately led to apoptosis. With analysis of the Ezh2 target gene lists 
and subsequent validation experiments, we were able to pinpoint the specific 
Ezh2 target genes and pathways involved in these processes. In NSCs, these 
were Cdkn2a, Tcf21, Six1, Dnmt3a,  all involved in cell cycle control, cell death 
and cellular compromise and Gdf6 and Gdf7, subfamily members of the TGF-
beta superfamily. In pOLs, genes in Wnt (Wnt7b) and Shh (THM1) signaling 
appeared to be the most relevant ones repressed by Ezh2 as far as 
differentiation regulation is concerned. We found at least 35 Ezh2 targets in 
pOLs whose expression is associated with cell death among which Grin2a 
(NMDR2a/NR2a) and Grin2b (NMDR2a/NR2b); Ezh2 silencing resulted in the 
upregulation of these NMDA receptor subunits increasing the vulnerability for 
glutamate-mediated cell death. Apart from changes in the Ezh2 target genes, 
we found indications that the PRC2 complex has a different composition in the 
pOLs in comparison to the NSCs in particular with regards to the Suz12 
isoforms. It is clear that the switch in Ezh2 targets and the alteration in the 
PRC2 complex are essential events during the differentiation of NSCs into an 
oligodendrocyte cell lineage and it will be a major challenge to reveal the 
extrinsic factors that induces these changes. 
In contrast to oligodendrocyte differentiation, Ezh2 expression vanishes with 
the differentiation of NSCs into astrocytes. As a side-step in our research, we 
wanted to establish the significance of the downregulation of Ezh2 for astrocyte 
differentiation and so we induced overexpressed of Ezh2 in mouse postnatal 
astrocytes (Chapter 4). With forced expression of Ezh2, cultured astrocytes 
retracted their cell extensions and became proliferating round/bipolar cells that 
sporadically formed small neurosphere-like clusters. The expression profile of 
these Ezh2-expressing astrocytes revealed downregulation of typical astrocytic 
genes and upregulation of genes that are generally expressed in NSCs and 
increased proliferation. However, these NSC-like cells could not achieve a full 
NSC differentiation potential, presumably due to the fact that we were unable to Chapter 7: summary and conclusions 
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simultaneously upregulate the other PRC2 components and establish a 
functional PRC2 complex. 
Based on our findings described in the previous 3 chapters, we have 
composed a model explaining how Ezh2 is involved in regulating self-renewal 
and maintenance of NSCs and their differentiation towards neurons, 
astrocytes, and oligodendrocytes (figure 1). The model shows the stepwise 
changes in epigenetic architecture, in particular DNA methylation and histone 
modification, during cell fate determination. These epigenetic modifications are 
in most cases used to effectuate the silencing of gene programs which are 
inappropriate at a certain stage for a particular cell type.  Within these 
modifications, one can discriminate between modifications resulting in a more 
stringent permanent repression (mostly marked by DNA methylation and 
H3K9me3 together with heterochromatin binding protein 1 (HP1)) and more 
reversible modifications responsible for more transient silencing of gene 
programs (marked by specific histone modifications and Ezh2 recruitment). The 
SET domain of Ezh2 has methyltransferase activity and can trimethylate 
H3K27 which is recognized by PRC1 that makes the DNA inaccessible for RNA 
polymerase II (pol II). At some stages, gene programs can be in a poised state, 
meaning that they have both represssive (H3K27me3) as well permissive 
histone modifications (H3K4Me3); such a state makes it easy to switch 
immediately to full transcription if triggered. The model depicted in figure 1 
clearly indicates the specific epigenetic status and the set of genes silenced at 
each stage of NSC differentiation towards each of the 3 cell types. The 
involvement of Ezh2 in undifferentiated NSCs concerns the silencing of 
differentiation genes; in pOLs, Ezh2 establishes the silencing of neuronal and 
astrocytic lineage genes, specific NSC and late oligodendrocytic genes, as well 
as genes associated with abnormal conditions e.g. glioma and insult. 
Experimental alteration of Ezh2 activity in this stage may induce the 
dedifferentiation of pOLs to a NSC stage as described previously (Kondo and 
Raff, 2000). 
In Chapter 5 and Chapter 6 we address the second part of the research 
project and describe the implantation studies with NSCs and NSC-derived 
OPCs experiments in MS animal models. In Chapter 5 we describe 
implantation experiments with NSCs primed to become OPCs by transfection 
of the Olig2 gene (Olig2-tNSCs). These cells were stereotactically injected in 
the corpus callosum of mice on a diet of 0.2% cuprizone; this copper chelator 
causes oligodendrocyte death and demyelination of axons most prominently in 
the corpus callosum. Using NSCs from transgenic mice expressing luciferase 
under the control of the actin promotor, we were able to follow the fate of the 
implanted cells in-vivo with Bioluminescence over a period of 2 months.  NSCs: potential applications in demyelinating disorders 
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 Chapter 7: summary and conclusions 
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Bioluminescence signal analysis in the IVIS-200 validated by 
immunohistochemistry revealed that undifferentiated NSC grafts disappeared 
within three weeks after implantation, while substantial numbers of Olig2-
tNSCs survived until the end of the study (two months). 
Additionally, electronmicroscopic analysis revealed that most of these surviving 
implanted cells differentiated into oligodendrocytes, integrated at the lesion site 
and participated in remyelination of nude axons in the corpus callosum. 
The cuprizone mouse model merely mimics the demyelination aspect of MS 
without. To study the fate of Olig2-tNSCs in an animal model that mimics the 
inflammation and demyelination aspect of MS more closely, we injected these 
cells intraventricularly in mice with experimental autoimmune encephalomyelitis 
(EAE) (Chapter 6). We examined the efficacy of intraventricular implantation of 
undifferentiated NSCs and Olig2-tNSCs in the acute form of EAE and in 
chronic relapsing experimental autoimmune encephalomyelitis (CREAE). We 
found that upon injection at the onset of acute phase or the relapse phase of 
CREAE, NSCs as well as Olig2-NSCs migrated only towards active lesions in 
the spinal cord. Both Olig2-tNSCs and undifferentiated NSCs significantly 
reduced the clinical signs of acute EAE when administered early after onset of 
the first symptoms. Interestingly, in CREAE, NSC injections delayed a relapse 
while Olig2-tNSCs injection even abrogated a relapse when administered at the 
beginning of the acute phase. The mechanisms underling the effects of the 
implanted NSCs and in particular Olig2-tNSCs on the occurrence of clinical 
symptoms still have to be revealed. In accordance to previous studies by 
Pluchino et al, (2003, 2005) NSCs and Olig2-tNSCs may reduce clinical 
symptoms by the release of various anti-inflammatory and trophic factors. An 
indication for a potential contribution of Olig2-tNSCs in remyelination (as 
observed in the cuprizone model) was only observed during the relapse phase, 
since only in this phase some demyelination actually occurred. 
In conclusion, this thesis on one side adds to our understandings of the 
epigenetic mechanisms involved in the differentiation of NSCs towards 
oligodendrocytes, while on the other hand it demonstrates the restorative 
potential of NSCs and NSCs-derived OPCs for the treatment of MS.  NSCs: potential applications in demyelinating disorders 
￿ ￿￿￿￿
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De meest invaliderende symptomen in de meer gevorderde stadia van multiple 
sclerose (MS) worden veroorzaakt door het geheel verloren gaan van axonen 
en uiteindelijk van de neuronen zelf. Axonale degeneratie treedt niet alleen op 
in chronische laesies maar lijkt zich ook al voor te doen in vroege acute 
laesies. Dergelijke acute laesies in de relapsing-remitting vorm van MS worden 
veroorzaakt door het binnendringen in het centraal zenuwstelsel van 
agressieve, reactieve T-cellen die uiteindelijk lokale ontstekingen induceren 
waarbij allerlei cytokines vrijkomen met als gevolg de beschadiging van 
myeline en oligodendrocyten. In de relapsing-remitting vorm van MS zijn deze 
relapses tijdelijk en na het verdwijnen van de actieve inflammatie kunnen lokale 
OPCs (oligodendrocyte precursorcellen) het myeline herstellen en daarmee 
axonale schade deels te niet doen; in de meeste gevallen is dit echter 
ontoereikend en worden de gevolgen van axonale beschadiging 
gecompenseerd doordat parallelle axonale circuits de verloren verbindingen 
overnemen. Deze plasticiteit van het centraal zenuwstelsel kent zijn grenzen 
en op een gegeven moment kunnen de gevolgen van axonaal verlies niet 
langer meer gecompenseerd worden: relapsing-remitting MS gaat dan over in 
de secondaire progressieve vorm van MS.  
De huidige therapie voor MS, het voorschrijven van immunomodulerende 
medicijnen zoals interferon-β, glatiramer acetaat, mitoxantrone of nieuwere 
zoals natalizumab, is er voornamelijk op gericht om het binnendringen van 
agressieve T-cellen tegen te gaan, maar deze medicijnen hebben geen enkel 
effect op het voorkomen of herstellen van axonale schade. Nieuwe efficiënte 
behandelingen van MS dienen zich daarom ook te richten op het beschermen 
en herstellen van axonen, direct vanaf de eerste verschijnselen van MS. Er zijn 
allerlei nieuwe neuro(axo-)protectieve drugs in ontwikkeling die wellicht ook 
voor MS van belang kunnen worden. De meest effectieve manier om axonen te 
beschermen, echter, is er voor te zorgen dat zij zo snel mogelijk weer 
geremyeliniseerd worden hetzij door de myelinisatie-activiteit van endogene 
oligodendrocyten te stimuleren hetzij door het implanteren van nieuwe 
remyeliniserende of remyelinisatie-stimulerende cellen. 
Door het gebrek aan een geschikte bron voor autologe humane myeliniserende 
cellen is de laatste benadering tot dusverre nooit een reële optie geweest. De 
buitengewone ontwikkelingen in stamcelonderzoek van de laatste 10 jaar, 
echter, hebben nieuwe mogelijkheden gecreëerd voor de ontwikkeling van 
therapieën gebaseerd op celvervanging, bijvoorbeeld voor neurodegeneratieve 
ziektes, waaronder MS. Pluripotente embryonale stam (ES) cellen zijn een 
interessante kandidaat als bron voor remyeliniserende celimplantaten, maar 
hun toepassing in de kliniek stuit op aanzienlijke praktische (afstotingsreacties) Hoofdstuk 7: Nederlandse Samenvatting 
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en medisch-ethische bezwaren. De laatste tijd is er veel aandacht voor 
mesenchymale stamcellen als mogelijke bron voor oligodendrocyte-
transplantaten (Martino et al., 2010; Uccelli and Mancardi, 2010); echter, de 
veronderstelde pluripotentie van deze stamcellen staat ter discussie en is 
voornamelijk aangetoond in-vitro. De gunstige effecten van de toediening van 
deze mesenchymale stamcellen in MS-diermodellen moet toegeschreven 
worden aan het brede scala van trofische, anti-apoptotische en anti-
inflammatoire factoren die deze cellen blijken te produceren en wellicht aan 
hun specifieke modulatie van de activiteit van lokale microglia (Glennie et al., 
2005; Uccelli et al., 2008; Zappia et al., 2005); in geen van de onderzoeken 
konden mesenchymale stamcellen zich differentiëren tot myeline-vormende 
cellen (Bertani et al., 2005; Cho et al., 2005; Kopen et al., 1999; Montzka et al., 
2009). De meest voor de hand liggende bron voor oligodendrocyten en hun 
voorlopercellen zijn neurale stamcellen (NSCs). Hoewel het mogelijk is 
gebleken om patiënteigen neurale stamcellen uit de cerebrale ventrikelwand te 
verkrijgen via een relatief eenvoudige stereotactische endoscopische operatie 
(Westerlund et al., 2005), blijkt het aantal dat zo verzameld kan worden veel te 
klein te zijn voor een zinvolle klinische toepassing. De spectaculaire ontdekking 
dat gewone lichaamscellen gereprogrammeerd kunnen worden tot ES–achtige 
pluripotente stamcellen (induced pluripotent stem cells of IPS cellen) 
(Takahashi and Yamanaka, 2006) heeft een nieuwe bron voor eigen neurale 
stamcellen binnen bereik gebracht en daarmee de ontwikkeling van een 
remyelinisatie-therapie voor MS-patiënten met behulp van eigen 
oligodendrocyten nieuw leven ingeblazen.  
Dit proefschrift beschrijft onderzoek dat verricht is aan enkele cruciale aspecten 
van mogelijke klinische toepassing van uit neurale stamcellen verkregen 
OPCs. Cruciaal voor veilige toepassing is een gestandaardiseerde complete 
differentiatie van de NSCs tot functionele OPCs die de eigenschap hebben te 
migreren naar de te myeliniseren axonen en daar ter plekke ook uitrijpen tot 
myelinevormende oligodendrocyten. Een dergelijk in-vitro differentiatieprotocol 
kan slechts betrouwbaar ontwikkeld worden als we volledig inzicht hebben in 
de moleculaire mechanismen die dit differentiatieproces reguleren. Daarnaast 
cruciaal voor veilige klinische toepassing is de zekerheid dat de uit de NSCs 
verkregen oligodendrocyten na implantatie ook stabiel en functioneel blijven en 
niet bijvoorbeeld weer dedifferentiëren tot een ongedifferentieerd stamceltype. 
De twee belangrijkste doelstellingen van dit proefschrift waren:  
A)  Het onderzoeken van de epigenetische regulatie van de differentiatie 
van neurale stamcellen tot oligodendrocyte precursor cellen (OPCs) 
B)  Het volgen en vastleggen van het lot (overleving, migratie, myelinisatie 
activiteit etc..) van neurale stamcellen en uit neurale stamcellen NSCs: potentiële toepassingen in demyeliniserende aandoeningen 
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verkregen OPCs na intracerebrale implantatie in MS diermodellen met 
behulp van bioluminiscentie en biofluorescentie in-vivo imaging 
technieken.  
 
Hoofdstuk 1 bevat een overzicht over de huidige kennis van 
oligodendrogenese en bespreekt de belangrijkste intrinsieke en extrinsieke 
factoren betrokken bij dit proces. Extrinsieke factoren brengen een complexe 
signaalcascade op gang die de neurale stamcel via een nauwkeurig 
gereguleerde sequentiële expressie van transcriptiefactoren in verschillende 
stadia differentieert tot een myeline-vormende oligodendrocyte.  De expressie 
van de transcriptiefactoren en daarmee de selectieve transcriptie van de genen 
verantwoordelijk voor oligodendrocytevorming wordt gereguleerd via 
verschillende epigenetische mechanismen, zich uitend in veranderingen in de 
chromatinestructuur tijdens het differentiatieproces.  Covalente enzymatische 
modificaties van histonen en methylering van DNA zijn de belangrijkste 
epigenetische mechanismen verantwoordelijk voor de structurele 
veranderingen in chromatine, waarmee de toegankelijkheid van bepaalde gen 
programma’s voor de transcriptiemachinerie bepaald wordt. Een prominente 
familie van chromatineremodelerende nucleaire eiwitten is de familie van de 
polycomb group (PcG) proteins. Deze PcG-eiwitten zijn actief in multimere 
complexen, zogenaamde polycomb repressive complexes (PRCs), bijv. PRC1 
en PRC2. Tijdens embryogenese spelen de PcG-eiwitten een cruciale rol 
omdat ze ontijdige transcriptie van genprogramma’s onderdrukken en daarmee 
een normale ontwikkeling van het embryo mogelijk maken. Ezh2, een histone 
methyltransferase en belangrijkste component van het PRC2 complex, speelt 
een centrale rol in het onderdrukken van specifieke genexpressie (gene 
silencing) omdat het na rekrutering naar een bepaald gen, ter plekke het 
nucleosomale H3K27 trimethyleert en daarmee de rekrutering bewerkstelligt 
van het PRC1 complex dat verder zorgt voor de stabilisering van  genrepressie 
(Ringrose and Paro, 2004; Schuettengruber et al., 2007; Sparmann and van, 
2006; Simon and Kingston, 2009; Schuettengruber and Cavalli, 2009; 
Hirabayashi and Gotoh, 2010). Een hoge concentratie Ezh2 komt voor in 
pluripotente embryonale stamcellen, in de meeste kankerstamcellen en in 
enkele multipotente stamcellen, zoals de haematopoietische stamcellen 
(Kamminga et al., 2006).  
Wij begonnen met te onderzoeken of Ezh2 ook in multipotente neurale 
stamcellen (NSCs) tot expressie komt en konden dat inderdaad in embryonale 
muizen NSCs aantonen, zoals beschreven in hoofdstuk 2. In lijn met de 
verwachtingen, gebaseerd op de rol van Ezh2 tijdens de differentiatie van 
pluripotente stamcellen en kankerstamcellen, werd de expressie van Ezh2 Hoofdstuk 7: Nederlandse Samenvatting 
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onderdrukt op het moment dat de NSCs differentieerden in astrocyten en 
neuronen. Echter, de Ezh2-expressie bleef prominent aanwezig tijdens de 
differentiatie van NSCs tot OPCs en verdween pas op het moment dat die zich 
differentieerden tot myelinevormende oligodendrocyten. Verstoringen van de 
normale Ezh2-expressie resulteerden in afwijkingen in het proliferatieprofiel 
van NSCs en in hun differentiatiepotentiaal. Overexpressie van Ezh2 en 
onderdrukking ervan in differentiërende NSCs resulteerden, respectievelijk, in 
een toename en een afname in het aantal oligodendrocyten. Deze bevindingen 
suggereren de betrokkenheid van Ezh2 in het stimuleren dan wel mogelijk 
maken van de differentiatie van NSCs tot OPCs en wellicht van hun proliferatie.  
In hoofdstuk 3 vervolgen we het onderzoek naar Ezh2-expressie in NSCs en 
OPCs en tonen aan dat Ezh2 ook in die cellen in het adulte muisbrein 
voorkomt; de toename in het aantal OPCs in het corpus callosum tijdens 
verhoogde remyelinisatie-activiteit na stopzetten van het  cuprizone-dieet in 
volwassen muizen, ging gepaard met een toename in Ezh2 expressie. Om 
verder de moleculaire mechanismen achter de regulatie door Ezh2 van de 
differentiatie van NSCs tot OPCs te ontrafelen hebben we met behulp van 
chromatine-immunoprecipitatie gecombineerd met high-throughput parallelle 
sequencing (ChIP-Seq), de targetgenen van Ezh2 in kaart gebracht in NSCs 
en in premyeliniserende oligodendrocyten (pOLs). Wij vonden dat het 
merendeel van de Ezh2-targetgenen uniek waren in beide celtypes en dat 
slechts een zeer klein aantal (29) Ezh2-targetgenen voorkwamen in beide 
cellen. De overlappende genen betroffen genen betrokken in allerlei basale 
celprocessen zoals celcyclus voortgang, basaal metabolisme en het 
(voorkomen van) tumorvorming. De Ezh2-targetgenen in NSCs bleken 
voornamelijk betrokken bij celcyclusregulatie- en differentiatie processen; de 
Ezh2-targetgenen in pOLs bleken voornamelijk geassocieerd te zijn met het 
proces van neuronale en astrocyte differentiatie. Wanneer we de Ezh2-
targetgenen deblokkeerden (via silencing van Ezh2 met behulp van RNAi) 
raakte de proliferatie in NSCs verstoord en vond er geen verdere differentiatie 
in pOLs plaats; in beide celtypen resulteerde Ezh2-silencing  uiteindelijk in 
apoptosis. Met behulp van uitgebreide analyses van de lijst met Ezh2-
targetgenen verkregen via Chip-Seq in beide celtypes en verdere validatie 
experimenten, konden we meer specifiek de targetgenen en de cellulaire 
pathways identificeren betrokken bij deze processen. In NSCs bleken de 
belangrijkste genen: Cdkn2a, Tcf21, Six1, Dnmt3a, allen, als algemeen 
bekend, betrokken bij de controle van de celcyclus en celdood en Gdf6 and 
Gdf7, subfamilieleden van de TGF-beta superfamilie. In pOLs, bleken de 
genen coderend voor Wnt (Wnt7b)- en Shh (THM1)-signalering de meest 
relevante genen in differentiatieregulatie waarvan de expressie via Ezh2 NSCs: potentiële toepassingen in demyeliniserende aandoeningen 
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onderdrukt werd. Opmerkelijk genoeg vonden wij tenminste 35 Ezh2 
targetgenen in pOLs die op de een of andere manier betrokken waren bij 
celdoodinductie van pOLs, waaronder bijvoorbeeld Grin2a (NMDR2a/NR2a) en 
Grin2b (NMDR2a/NR2b). Ezh2-silencing in de pOLs resulteerde in de 
upregulatie van deze NMDA-receptorsubunits, waarmee hun kwetsbaarheid 
voor glutamaat-geïnduceerde celdood sterk vergroot werd.  
Naast een switch in de Ezh2-targetgenen in de overgang van NSCs naar 
OPCs, als boven beschreven, vonden wij aanwijzingen dat het PRC2-complex 
in de pOLs een andere samenstelling heeft dan die van de NSCs, met name 
wat betreft Suz12 iso-vormen. De experimenten beschreven in hoofdstuk 3 
laten zien dat de switch in Ezh2-targetgenen tijdens de differentiatie van NSCs 
tot OPCs en de verandering in het PRC2-complex cruciaal zijn voor de 
regulatie van dit differentiatiepad en vervolgonderzoek zal moeten ophelderen 
welke extrinsieke factoren precies (en hoe) deze overgangen op gang brengen.    
Als beschreven in hoofdstuk 2, verdwijnt Ezh2-expressie op het moment dat 
NSCs differentiëren tot neuronen en astrocyten, in tegenstelling tot 
oligodendrocyten. Om het belang van deze specifieke Ezh2-downregulatie voor 
astrocyte differentiatie te onderzoeken, hebben we het Ezh2 geforceerd tot 
expressie gebracht in postnatale astrocyten (hoofdstuk 4). Astrocyten waarin 
Ezh2 tot expressie kwam ondergingen snel karakteristieke veranderingen: zij 
trokken hun uitlopers terug en kregen het uiterlijk van ronde, prolifererende 
cellen die in enkele gevallen kleine neurosfeer-achtige clusters vormden. Het 
expressie profiel van deze cellen toonde  een complete downregulatie van 
typische astrocytegenen en een inductie van de expressie van typische neurale 
stamcelgenen; de cellen hadden een verhoogde proliferatie activiteit. Een 
volledige dedifferentiatie naar neurale stamcel vond niet plaats, waarschijnlijk 
vanwege het feit dat andere PRC2-componenten niet (in dezelfde mate) 
aanwezig waren als het Ezh2.   
Het tweede deel van het onderzoek komt aan de orde in de hoofdstukken 5 
en 6 waarin de implantatiestudies met NSCs en uit NSCs verkregen OPCs in 
diermodellen voor MS beschreven worden. NSCs en NSCs getransfecteerd 
met het Olig2 gen (Olig2-tNSCs), waarmee deze cellen geprimed worden tot 
OPCs, werden stereotactisch geïnjecteerd in het corpus callosum van muizen 
op een dieet van 0.2% cuprizone (hoofdstuk 5); cuprizone is een 
koperchelator dat degeneratie van oligodendrocyten induceert en daarmee het 
verlies van myeline, met name in de corpus callosum. Door gebruik te maken 
van NSCs geïsoleerd uit transgene muizen, waarin het luciferase-gen was 
ingebracht onder de controle van de actine promotor, konden wij de cellen in-
vivo na implantatie gedurende meer dan 2 maanden volgen met behulp van 
bioluminiscentie in de IVIS-200. Analyse van de IVIS-200 registraties en Hoofdstuk 7: Nederlandse Samenvatting 
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immunohistochemische validatie toonden dat ongedifferentieerde NSCs binnen 
3 weken na implantatie afgebroken en opgeruimd waren terwijl Olig2-tNSCs na 
2 maanden nog steeds aanwezig bleken; de meeste van deze Olig2-tNSCs 
hadden zich gedifferentieerd tot oligodendrocyten en droegen bij aan de 
remyelinisatie van gedemyeliniseerde axonen in het corpus callosum, zoals 
bleek uit EM analyses. 
Met het cuprizone muismodel wordt slechts het demyelinisatie-aspect van MS 
nagebootst zonder dat ontstekingsverschijnselen optreden. Een diermodel dat 
beide aspecten van MS nabootst is experimental autoimmune 
encephalomyelitis (EAE) en in dit diermodel hebben we NSCs en Olig2-tNSCs 
op verschillende tijdstippen intraventriculair ingebracht en het lot van deze 
cellen onderzocht (hoofdstuk 6). Als wij deze cellen injecteerden bij de eerste 
acute fase van EAE of direct bij de eerste verschijnselen van een relaps in 
chronische EAE (CREAE, hiervoor gebruikten wij Biozzi muizen) bleken NSCs 
zowel als de Olig2-tNSCs te migreren naar de actieve laesies in het 
ruggenmerg. Beide celtransplantaties in deze opzet resulteerden in een 
significante reductie van de klinische verschijnselen. Indien we in CREAE 
muizen, de cellen injecteerden bij de allereerste verschijnselen van de eerste 
acute fase bleken NSCs in staat het optreden van een relaps te vertragen, 
terwijl de Olig2-tNSCs het optreden van een relaps zelfs volledig voorkwamen. 
De mogelijke klinische implicaties zijn evident en het spreekt voor zich dat de 
hier aan ten grondslag liggende mechanismen verder onderzocht dienen te 
worden. Pluchino et al. (2003,2005) hebben eerder aangetoond dat 
geïnjecteerde NSCs, en wellicht ook onze Olig2-tNSCs, allerlei anti-
inflammatoire en trofische factoren kunnen produceren die bijdragen tot de 
onderdrukking van klinische symptomen bij EAE. De Olig2-tNSCs, in 
tegenstelling tot de NSCs, in onze experimenten droegen ook bij aan het 
remyelinisatieproces met name in de CREAE muizen indien ze vlak voor de 
relaps werden toegediend; echter vanwege het directe immunomodulerende 
effect van de geïnjecteerde NSCs was de mate van demyelinisatie en daarmee 
de behoefte aan remyeliniserende activiteit sterk verminderd. 
Concluderend, het onderzoek in dit proefschrift heeft zeer belangrijke inzichten 
opgeleverd in de wijze waarop, met name door epigenetische factoren, de 
differentiatie van NSCs tot oligodendrocyten gereguleerd wordt; daarnaast 
hebben de implantatie-experimenten in diermodellen voor MS het opmerkelijke 
restoratieve vermogen van NSCs, en met name de daaruit gedifferentieerde 
OPCs, aangetoond en daarmee hun mogelijke klinische potentie voor MS. NSCs: potentiële toepassingen in demyeliniserende aandoeningen 
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